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ABSTRACT 
Regulatory T cells (Tregs) are a distinct lymphocyte lineage, functionally defined as 
T cells that inhibit an immune response, which is crucial for maintaining peripheral 
tolerance and the prevention of autoimmunity.  Tregs have been implicated in tumour 
immune evasion, suppressing the anti-tumour immune response, resulting in tumour 
progression.  The aim of this PhD was to recognise how Tregs function and 
understand how they are able to modulate tumour immunology.  In order to research 
their proposed role in cancer, it was necessary to be able to phenotype, sort and 
expand functional Tregs.  In preliminary research, strategies were designed to 
phenotype and test the functionality of ex vivo Tregs and commercial isolation kits 
were tested and compared in terms of cost efficiency and effectiveness.  The 
mechanisms of Treg-mediated suppression were investigated, including the necessity 
for cell-to-cell contact and the involvement of key cytokines.  The importance of 
particular cytokines in Treg-mediated suppression was not clear; but cell contact 
appears to be required for optimal suppression. 
 
The project then aimed to address whether or not the importance of Tregs highlighted 
in the literature was reflected in a clinical setting.  The significance of immune cell 
orientation within the tumour microenvironment was researched, investigating the co-
localisation between key immune cell subtypes and their correlation with areas of 
tumour proliferation, apoptosis, hypoxia and vasculature coverage.  In order to 
achieve this successfully, immunohistochemical techniques were optimised and 
image analysis algorithms were constructed to facilitate rigorous and systematic 
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quantification of immune cell infiltrates in primary colorectal and metastatic liver 
cancer patients.  Significant increases in the prevalence of Tregs, CD8 cells, 
macrophages and natural killer (NK) cells were observed within the stroma, 
compared with the tumour.  A metastatic phenotype was alluded to; encompassing 
elevated Tregs and reduced numbers of CD8 cells. 
 
Further to this, the level of Tregs in the peripheral blood and tumour tissue of liver-
metastatic patients were assessed to investigate whether any correlation existed 
between circulating and tumour-infiltrating Tregs.  It was shown that within 
peripheral blood, patients exhibited a Treg
high
CD8
low
NK
low
 phenotype, when 
compared with healthy volunteers.   
 
Finally, the project aimed to build an in vitro human Treg tumour-killing suppression 
model to examine the ability of Tregs to inhibit NK cell-mediated cytotoxicity.  The 
mechanism for this was investigated, evaluating the importance of the NK group 2 
member D (NKG2D) receptor ligand interaction, to mediate cell killing in a 
transforming growth factor-β dependent manner. 
 
This study adds to the ongoing discussion on the role of immune cells in metastatic 
development.  Accumulating evidence points to a critical role of immune infiltrates in 
allowing metastatic development, where Tregs support tumour growth by suppressing 
the host anti-tumour immune response. 
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1.1. LITERATURE REVIEW 
1.1.1. The Immune System 
The immune system evolved to mediate protection from pathogens such as viruses 
and bacteria, primarily functioning to eliminate infectious agents and to minimise the 
damage they cause.  The site of infection and the characteristics of the pathogen 
largely determine the immune response, which involves recognition of the pathogen 
followed by a reaction against it.  The immune response is made up of two systems 
commonly described as innate and adaptive immunity.  The innate response involves 
molecular and cellular components present before the onset of infection and does not 
alter on repeated exposure.  The adaptive response is highly specific to particular 
pathogens and has an aspect of ÔmemoryÕ, improving its function with each 
successive encounter with the same pathogen (Medzhitov, 2007).   
 
1.1.2. Innate Immune Response 
Innate immunity uses primitive non-specific recognition systems to provide what is 
commonly termed Ôthe first line of defenceÕ from infectious disease.  A large 
proportion of the components involved in the innate immune response are employed 
prior to infection.  They consist of molecular and cellular mechanisms, which confer 
disease-resistant properties via recognition of common classes of pathogen 
molecules.  An important innate defence mechanism is phagocytosis.  Here, 
phagocytic cells such as macrophages, dendritic cells (DCs), monocytes, and 
polymorphonuclear neutrophils engulf infectious particles or abnormal cells.  Soluble 
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molecules also play a significant role in innate immunity.  Examples include the 
protein, lysozyme, which is found in mucous secretions and is capable of cleaving 
bacterial cell walls, and the interferon proteins produced by virus-infected cells, 
which induce an anti-viral state in neighbouring cells. 
 
1.1.3. Adaptive Immune Response 
In contrast to the broad recognition ability of the innate immune response, adaptive 
immunity has a high degree of specificity, an element of immunologic memory and 
self non-self recognition (Medzhitov, 2007).  An adaptive immune response occurs 
after the initial exposure and functions in a highly interactive way with the innate 
immune system.  Lymphocytes and the antibodies they produce are central to the 
adaptive response, coordinating specific recognition of individual pathogens.  
Lymphocytes can be subdivided into B lymphocytes (B cells) and T lymphocytes (T 
cells) (Figure 1.1).   
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Figure 1.1 Lymphocyte Lineage 
 
Lymphocytes are subdivided into B cells and T cells.  Maturation of B cells occurs in the bone 
marrow, leading to each B cell expressing a solitary antibody molecule.  Antigen binding 
causes division and differentiation of B cells into memory B cells, which express identical 
antibodies, or effector B cells that secrete the antibody in a soluble form.  T cells mature in 
the thymus and express an exclusive antigen-binding molecule, the T-cell receptor (TCR).  
T cells are subdivided into T helper (TH) cells and cytotoxic T (TC) cells.  TH cells express 
CD4 and recognise antigen associated with Major Histocompatibility Complex (MHC) Class 
II, whereas TC cells express CD8 and recognise antigens bound to MHC Class I.  Natural 
killer (NK) cells are defined as large granular lymphocytes and constitute the third kind of cell 
from the lymphoid progenitor.  They do not have TCRs or surface immunoglobulins but 
commonly express CD16 and CD56, members of the natural killer group 2 (NKG2) family, 
natural cytotoxicity receptors (NCRs) and killer cell immunoglobulin-like receptors (KIRs). 
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B cells mature in the bone marrow and each expresses a unique membrane-bound 
antibody molecule.  The binding of an antigen to a B cell antibody causes rapid 
division of that cell, which then differentiates into a memory B cell the expresses the 
same membrane-bound antibody or an effector B cell (plasma cell) that functions to 
secrete the antibody in a soluble form.   
 
Pluripotent haematological cells in the bone marrow, migrate and mature in the 
thymus, forming T cells.  Mature T cells express an exclusive antigen-binding 
molecule, the T cell receptor (TCR).  T cells can be further subdivided into T helper 
(TH) and cytotoxic T (TC) cells, distinguished by the presence of CD4 (TH) or CD8 
(TC) membrane glycoproteins (Figure 1.1).  T cells recognise antigens that are bound 
to specific antigen-presenting domains of major histocompatibility complex (MHC) 
molecules (Figure 1.2).  There are two types of MHC molecules, class I MHC and 
class II MHC, which can bind a broad spectrum of antigenic peptides.  TH cells 
generally recognise MHC class II bound antigens and TC cells recognise antigens 
bound to MHC class I molecules.   
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Figure 1.2 The Specific Interaction between Antigen-Presenting Cells and T Cells via 
Major Histocompatibility Complex (MHC) Molecules. 
 
A) CD4 T helper cells (pink) recognise antigens bound to class II MHC molecules on antigen-
presenting cells.  B) CD8 T cytotoxic cells (dark blue) recognise only antigens associated 
with class I MHC molecules.  The ovals in the diagrams represent characteristic protein folds.  
Figure adapted from Kuby et al., 2007. 
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Antigen-presenting cells (APCs) are phagocytic cells that present fragments of 
engulfed particles on their surface.  T cells can interact with phagocytic cells to aid in 
the destruction of engulfed particles.  The digested particles are firstly cut into 
oligonucleotides that are 18Ð22 amino acids long and then loaded onto MHC class II 
molecules.  These are then presented to CD4
+
 TH cells, which in turn causes 
activation of B cells to produce antibodies that exclusively recognise the specific 
antigen.  Antibodies produced as a consequence of antigen presentation are released 
into circulation and upon binding result in neutralisation of the infectious particle.  
 
1.1.4. Natural Killer Cells 
First described in 1975 as a lymphocyte subset capable of cytotoxicity against 
leukaemia cells (Kiessling et al., 1975), CD3
-
CD56
+
 Natural killer (NK) cells 
represent 5Ð15% of circulating lymphocytes.  NK cells have distinct morphological 
features of larger granular lymphocytes (LGL) and can be distinguishable from T and 
B lymphocytes by cytokine profile, surface phenotype and their ability to mediate 
cytotoxicity against a broad range of targets including tumour cells (Whiteside and 
Herberman, 1994).  They express characteristic cell-surface receptors, such as NK 
cell receptor protein-1 (termed NK1.1).  Mature, circulating NK cells can be 
distinguished from other peripheral blood mononuclear cells (PBMCs) by a 
combination of CD56, CD16 and CD2, and the absence of markers such as CD3 and 
CD14.  NK cells are important players in the innate immune system; they require no 
priming and so confer early protection against tumour transformation and 
intracellular pathogens.  They are cytotoxic towards tumour cells without prior 
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immunisation, rapidly secreting large amounts of cytokines including interferon-γ 
(IFN-γ), tumour necrosis factor-α (TNF-α) and chemokine ligands (CCLs) such as 
CCL3, CCL4 and CCL5 that influence innate and adaptive immune responses 
(Ghiringhelli et al., 2006; Zimmer et al., 2008).   
 
The mechanisms and molecular basis of NK cell target recognition and interactions 
between NK cells and their targets are topics that have gained increasing interest.  
NK cells trigger apoptosis and target cell death in potentially harmful cells via several 
steps involving intimate contact and the delivery of a lethal dose of granzyme A 
through the perforin/granzyme pathway.  MHC class I molecules are key regulators 
of NK cell activity that are expressed ubiquitously on healthy cells and provide NK 
cells with a means of identifying ÔselfÕ.  Almost all mature NK cells express 
inhibitory receptors specific for autologous MHC class I molecules, described as the 
Ômissing-selfÕ hypothesis.  Several inhibitory receptors for MHC class I molecules 
have since been identified, including the killer cell immunoglobulin-like receptor 
(KIR) family and the lectin-like CD94/NKG2a receptor.  A network of cell-surface 
receptors, including members of the natural killer groups 2 (NKG2) family, KIR 
family and natural cytotoxicity receptors (NCRs), including NKp46, NKp30 and 
NKp44, orchestrate target cell recognition.  These receptors collaborate with cytokine 
receptors, Toll-like receptor 9 and possibly adhesion molecules to coordinate the 
recognition and disposal of dangerous cells, whilst avoiding normal autologous cells.  
The recognition event precedes NK cell binding, involving various cellular adhesion 
molecules (CAMs).  Depending on the repertoire of activating and inhibitory 
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receptors engaged by tumour cell ligands, NK cells are triggered and activation leads 
to the exocytosis of secretory lysosomes and the release of their cytotoxic contents 
(Whiteside and Herberman, 1994).  The major cytotoxic proteins are granzymes and 
perforin.  Perforin facilitates the entry of the granzymes into the target cell cytoplasm, 
which initiates a cascade of intacellular events involving rapid induction of reactive 
oxygen species (ROS), caspase activation, loss of mitochondrial membrane potential 
and DNA fragmentation, all leading to target-cell death (Martinvalet et al., 2005).   
 
NK cells have an indisputable role in cell-mediated cytotoxicity and guarding against 
malignant cells (Wahl et al., 2006).  NK cells also coordinate the transition between 
innate and adaptive immune responses through interactions with DCs and secretion of 
cytokines and chemokines.  Evidence supports the hypothesis that NK cells are 
hindered in eliminating tumour cells and that these innate defenders of the host are 
subject to suppression by regulatory T cells (Tregs) (Wahl et al., 2006).   
 
In humans, the activating receptor NKG2 member D (NKG2D), is a potent 
stimulatory immunoreceptor broadly expressed on most NK cells, CD8 T cells, and 
γδ T cells (Wiemann et al., 2005).  Engagement of NKG2D by its ligand (NKG2DL) 
results in activation of NK-mediated cell killing and cytokine secretion or co-
stimulation of cytotoxic T-lymphocytes (CTLs).  NKG2D is a receptor for the stress-
inducible and tumour-associated MHC class I chain-related proteins A (MICA) and B 
(MICB); and members of the cytomegalovirus UL16 binding proteins (ULBP) family 
ULBP1-4 and REAT1G.  NKG2DLs are up-regulated in tumours, which should 
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render the tumour cells sensitive to NKG2D-dependent cell killing.  MIC molecules 
are expressed in association with cell stress, infection or malignant transformation.  In 
vitro, cell stress-inducible MIC molecules are expressed by many tumour cell lines 
and up-regulated upon infection with human Escherichia coli (Groh et al., 1999).  
Expression of NKG2DL on NK-resistant tumour lines has been shown to mediate 
tumour elimination (Cerwenka et al., 2000) and ectopic expression of NKG2D 
ligands causes rejection of tumour cells by NK and CTL cells in syngeneic mice 
(Parmiani 2009), illustrating the relevance of NKG2D signalling in 
immunosurveillance against tumours.  However, tumours have developed multiple 
ways to evade the NKG2D-mediated immune response (Guerra et al., 2008).  
Literature illustrates that some tumour cells evade NK lysis by releasing soluble MIC 
molecules to adjust NKG2D-mediated tumour immune surveillance (Groh et al., 
1999).  Tumour cells shed NKG2DL, resulting in increased levels in the peripheral 
blood of cancer patients.  This causes reduced cell-surface expression of NKG2D on 
NK cells, CD8
+
 T cells, and γδ T cells and evasion of tumour immunity.  Shedding of 
MICA molecules from tumour cells by metalloproteases results in reduced NKG2DL 
surface density and so further adds to evading NK cell recognition (Groh et al., 
1999).  Observations also show that the NKG2D receptor undergoes ligand-induced 
endocytosis followed by degradation (Groh et al., 2002).  Discrepancies in NKG2DL 
mRNA and protein expression suggest some regulation at the post-transcriptional 
level, possibly controlled by cellular microRNAs (Stern-Ginossar and Mandelboim, 
2009).  Post-
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stress signals, allowing successful expression without the false effect of fluctuations 
of mRNA levels.   
 
NK cells and CTLs perform complementary roles in immune responses directed 
against viruses and tumours (Topham and Hewitt, 2009).  CTLs are antigen specific 
and recognise peptides derived from virus and tumour antigens presented by MHC 
class I molecules.  Down-regulation of MHC class I is often observed in tumours and 
virus-infected cells, allowing escape of CTL killing.  NK cells can continue to 
recognise and kill cells that have reduced surface expression of MHC class I 
molecules.  MHC class I molecules are recognised by NK cell inhibitory receptors 
where engagement inhibits NK cell activation and a lack of interaction can activate 
NK cytotoxicity (Topham and Hewitt, 2009).   
 
Depletion of NK and natural killer T (NKT) cells in mice by administration of the 
anti-NK1.1 monoclonal antibody (mAb) resulted in a two- or three-fold increase in 
susceptibility to methylcholanthrene-induced tumour formation compared to control 
non-NK cell depleted mice (Guerra et al., 2008; Smyth et al., 2001).  In humans, 
patients suffering from Chediak-Higashi syndrome, a disorder that results in 
abnormal NK cell cytotoxic function, have a 200-fold increased risk of developing 
malignancy (Kobayashi, 1985).  In conclusion, human and mouse studies strongly 
suggest an important role for NK cells in tumour immunosurveillance. 
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1.1.5. Regulatory T Cells 
The immune system discriminates between self and non-self antigens, establishing 
and maintaining self-tolerance, while still retaining the ability to initiate appropriate 
immune responses (Bluestone and Abbas, 2003).  Regulation of the immune response 
is a complex process in which Tregs play a central role.  Since their discovery in the 
1960s, the notion of Ôsuppressive T cellsÕ has long been debated (Gershon et al., 
1967; Gershon and Kondo, 1971).  Interest in the concept of T cell-mediated 
suppression resurfaced in the mid 1990s after a sub-population of CD4
+
 T cells that 
co-expressed the α-chain of interleukin-2 receptor (IL-2R), CD25, was found to be 
crucial for the control of auto-reactive T cells in vivo (Sakaguchi et al., 1995).  The 
suppressive function of CD4
+
CD25
+ 
T cells was demonstrated in vitro by inhibiting 
approximately 80 % of CD25
- 
cell proliferation when at a ratio of one CD25
+
 T cell to 
four CD25
-
 T cells (Read et al., 1998; Takahashi et al., 1998; Thornton and Shevach, 
1998). 
 
It is now well established that Tregs are a distinct lymphocyte lineage, functionally 
defined as T cells that inhibit an immune response by influencing the activity of 
another cell type (Colombo and Piconese, 2007; Shevach, 2004).  Tregs are capable 
of regulatory properties that affect a variety of immune cells, including CD4
+
CD25
-
 T 
cells, CD8
+
 T cells, DCs, NK cells, and B cells (Beyer and Schultze, 2006; Piccirillo 
and Shevach, 2001) (Figure 1.3).   
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Figure 1.3 Treg Interaction with Neighbouring T Cells 
 
Tregs that recognise a particular antigen may be responsible for suppression of T cells that 
recognise any other antigen presented by the same antigen-presenting cell.  Tregs specific 
for one antigen can therefore facilitate a tolerance to several antigens. 
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Tregs are crucial for maintaining peripheral tolerance and the prevention of 
autoimmunity (Zimmer et al., 2008).  However, their mechanism of action still 
remains an area of active investigation.  In vitro studies have suggested that Treg-
mediated suppression is cell contact dependent, as suppression was not seen when 
CD25
+
 Tregs and effector T cells were separated by a permeable membrane 
(Nakamura et al., 2004; Tanchot et al., 2004; Thornton and Shevach, 1998).  Several 
mechanisms of action have been described but the topic still remains controversial 
and needs further investigation (van Maren et al., 2008; Vignali et al., 2008; Zimmer 
et al., 2008) (Figure 1.4).   
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Figure 1.4 Diagrammatic Representation of Proposed Treg Suppressive Mechanisms  
 
A summary of the multiple possible suppressive mechanisms employed by naturally 
occurring Tregs.  Cell contact dependent suppression has been shown to involve cytotoxic T-
lymphocyte activation antigen 4 (CTLA-4), membrane bound transforming growth factor β (m-
TGF-β) and secretion of granzyme B (GZB) or perforin.  The aforementioned suppressive 
mechanisms cannot explain Treg suppression entirely and so further mechanisms have since 
been suggested.  Expression of the ectonucleotidase CD39 is seen on Tregs and functions to 
degrade adenosine triphosphate (ATP) into adenosine monophosphates (AMPs) and CD73 
catabolises the conversion of AMPs into adenosine.  Removal of pro-inflammatory ATP and 
subsequent production of immunosuppressive adenosine could function as an additional 
suppressive mechanism of Tregs.  Apoptosis is induced via activation of the tumour necrosis 
factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor 5 (DR5) pathway.  
Activated Tregs up-regulate TRAIL, and DR5 is increasingly expressed on activated effector 
cells.  The cAMP-cleaving enzyme phosphodiesterase 3B (PDE3B) is reduced in Tregs, 
resulting in elevated levels of cAMP.  Intracellular transport of cAMP to a target cell occurs 
via gap junctions and leads to immune suppression from inhibition of cell activation, 
proliferation and cytokine production.  Finally, Interleukin-35 (IL-35) is an inhibitory cytokine 
preferentially expressed in Tregs that may also confer suppression.  Figure adapted from van 
Maren et al., 2008. 
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CD25
+ 
Tregs represent approximately 7Ð10 % of peripheral CD4
+
 T cells (Rudge et 
al., 2006).  These lymphocytes are specialised in suppressing excessive or 
inappropriate immune responses, for example, responses to self-antigens in 
autoimmune disease and environmental substances in allergy.  Autoimmune diseases 
similar to that in humans can be produced in rodent models by depleting the Treg 
population (Shevach, 2002).  However, misplaced Treg responses can impede host 
protective immunity in infectious disease and cancer (Sakaguchi and Powrie, 2007). 
 
Treg precursors are derived from bone marrow cells and then mature in the thymus.  
Thymus developed Tregs are generated in a burst of activity during the early stages of 
foetal and neonatal T cell development (Itoh et al., 1999).  In the thymus 
CD25
+
Foxp3
+
 differentiated Tregs are activated via stimulation of their TCR 
complex.  Stimulation requires recognition of their specific antigen, presented on 
MHC class II molecules, and signals through the cytokine receptor γ-chain, CD132 
(Huang et al., 2005; Maloy and Powrie, 2005).   
 
This stimulation of precursor T cells results in their maturation or deletion depending 
on the ÔstrengthÕ of their interaction between the TCR and MHC via what is known as 
the Goldilocks selection process (Yun and Bevan, 2001).  This determines a cellÕs 
fate by initiating apoptosis when a signal is too weak due to lack of MHC recognition 
or too strong due to recognition of self-antigens.  The thymus-induced regulatory 
cells are CD4
+
 and typically express high levels of IL-2R (CD25) as well as the co-
stimulatory molecule CTL antigen 4 (CTLA4) and the TNF-superfamily member 
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GITR (glucocorticoid-induced TNF receptor family related protein) (Bluestone and 
Abbas, 2003).  The forkhead/winged box helix transcription factor gene, Foxp3, has 
also been shown to be specifically expressed within the Treg population.   
 
CD4
+
CD25
+
Foxp3
+
 Tregs developed in the thymus are frequently termed ÔnaturalÕ 
Tregs (nTregs) because they carry out a regulatory function during normal 
surveillance of self-antigens (Bluestone and Abbas, 2003).  Tregs that develop in the 
periphery are often termed ÔadaptiveÕ or ÔinducedÕ Tregs (iTregs).  iTregs are 
generated in the periphery from nave effector CD4
+
CD25
-
 T cells by stimulation via 
cytokines such as transforming growth factor (TGF)-β, and IL-2, and also by 
immature DCs (Thorstenson and Khoruts, 2001; Valencia and Lipsky, 2007).  TGF-β 
is an immunosuppressive cytokine expressed on the surface of CD4
+
CD25
+ 
T cells.  
TGF-β specific antibodies are able to prevent suppression in vitro and CD25+ Tregs 
are not able to suppress CD8
+
 cells lacking the TGF-β receptor (Chen et al., 2005).  
However, it is still unclear whether CD25
+
 Tregs directly produce TGF-β themselves 
or induce bystander cells to do so.  The presence of IL-2 is seen to be important in 
maintaining the function of Tregs (de la Rosa et al., 2004).  IL-2 appears to be 
dispensable for the development of Tregs in the thymus but essential for their 
maintenance in the periphery.  Activation of nave CD4
+
 T cells drives them to 
produce IL-2 and also to express the IL-2 receptor (CD25) (Maloy and Powrie, 
2005).  Some research suggests that IL-2 is produced by activated effector T cells, 
and not by Tregs, suggesting that effector T cells need to be activated before Tregs 
can be activated (Rudge et al., 2006).  
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Although the concept of thymus- and periphery-generated Tregs is generally accepted 
within the literature, some studies have shown that a small percentage of CD4
+
CD25
-
 
cells express Foxp3, and these cells can gain CD25 expression when transferred into 
a lymphopenic environment (Zelenay et al., 2005). 
 
Natural Tregs are phenotypically in an activated or antigen primed state, which 
makes them difficult to distinguish from activated effector or memory T cells, as 
every T cell expresses CD25, CTLA4 and GITR, for example, once activated.  High 
expression of the subtype of receptor for vitamin folic acid, FR4, can distinguish 
between nave and activated T cells (Yamaguchi et al., 2007).  
 
1.1.6. Regulatory T Cell Markers 
CD25 provides a good marker for Tregs in murine models, as animals can be held 
under pathogen-free conditions.  Humans, however, are constantly exposed to foreign 
antigens, leading to the possibility of elevated levels of activated CD25
+
 effector T 
cells.   
 
CTLA-4 and GITR are also among the possible cell-surface markers associated with 
Treg phenotype and function.  CTLA4 interacts with the CD80 and CD86 ligands and 
has been proposed as a mechanism for mediating contact suppression (Rudge et al., 
2006) (Figure 1.4).  CD25
+
 Tregs express CTLA4 constitutively on their surface, 
while effector T cells up-regulate it upon activation (Takahashi et al., 2000).  Anti-
CTLA4 antibodies abrogate suppression in vitro (Takahashi et al., 1998) and 
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injection of anti-CTLA4 antibody prevents Treg-mediated disease suppression (Liu et 
al., 2001; Read et al., 2000) and allows tumour rejection (Lee et al., 2004b; Sutmuller 
et al., 2001). 
 
Tregs are enriched by, but not homogenous, in the expression of these 
aforementioned markers.  In search for more specific Treg markers, it has been 
proposed that the transcription factor Foxp3 is uniquely expressed by the majority of 
CD4
+
CD25
+
 Tregs, while it remains virtually undetectable in effector T cells 
(Fontenot et al., 2003).  Research suggests that activation of CD4
+
CD25
-
 T cells does 
not cause up-regulation of Foxp3, allowing activated and regulatory CD4
+
 cells to be 
readily distinguished (Rudge et al., 2006).  However, the reliability of Foxp3 as a 
specific Treg marker is still in question due to recent reports on the expression of 
human Foxp3 in activated T cells without a suppressive phenotype (Beyer and 
Schultze, 2006).  Although human CD4
+
CD25
high
 T cells are most enriched for 
Foxp3
+
 T cells, some research has shown Foxp3
+
 cells within the CD4
+
CD25
low
 T 
cell population (Beyer and Schultze, 2006).  Morgan et al revealed Foxp3 mRNA 
expression in both CD25
-
 PBMCs and CD8
+
 cells (Morgan et al., 2005).  The lack of 
more specific Treg markers is a major reason why many functionally relevant aspects 
of Tregs are still unknown (Beyer and Schultze, 2006). 
 
1.1.7. Tumour Immunology 
The basic concepts of tumour immunology are a matter of great debate.  Cancer cells 
are indigenous to the body and are therefore in many respects indistinguishable from 
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the bodyÕs normal cells.  A key question within tumour immunology has been 
whether the immune system can recognise cancer cells as a threat and kill them.  
Over the last decade there has been accumulating evidence suggesting the immune 
system contributes to tumour defence. 
 
Research has shown that cancer cells display certain distinctive antigens on their 
surface that may provoke a specific antibody response.  Tumour-specific CTLs have 
been isolated from patients with melanomas and used to identify genes encoding 
tumour-associated antigens (TAAs).  CD8 CTLs recognise MHC class I restricted 
antigens expressed on the surface of tumour cells.  These TAAs have included genes 
identified as cancer testis antigen (CTA), such as MAGE, BAGE and GAGE, which 
are expressed in many human tumours but not in normal tissue.  Evidence for the 
ability to recognise antigens selectively expressed on autologous tumour cells but 
absent from autologous normal cells is an attractive target for therapeutic 
intervention.  This characteristic feature of TAAs makes them promising for cancer-
specific immunotherapy, opening up new possibilities for immunotherapy of cancer, 
including the induction of a tumour-specific CTL response against defined tumour 
antigens (Mami-Chouaib et al., 2002).  Research has identified a large number of 
tumour antigens from cancer patients; however, loss of TAA expression and secretion 
of immunosuppressive cytokines are some of the main mechanisms in which tumours 
evade CTL recognition (Gilboa, 1999). 
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1.1.8. Regulatory T Cells in Cancer 
An increase in the number of Tregs leads to an imbalance in the immune system, 
which then favours unresponsiveness.  This situation is evident in cancer, to the point 
where tumours are no longer attacked by immune cells (Colombo and Piconese, 
2007).  Cancer-bearing hosts provide a favourable environment for Treg expansion as 
a large panel of cancers overexpress TGF-β, which correlate with advanced stages of 
malignancy and decreased survival (Yamaguchi et al., 2007).  The involvement of 
Tregs in cancer has been described in three separate stages: elimination, representing 
the host-protective actions of immunity; equilibrium, which potentially maintains 
cancer in a dormant state; and escape, where tumours emerge and grow in an 
unrestrained manner.  The involvement of the immune system in detecting, 
eliminating and promoting tumour growth has loosely been termed Ôcancer 
immunoeditingÕ (Bui et al., 2006; Dunn et al., 2002; Schreiber et al., 2011). 
 
Many studies have illustrated an increase in the prevalence of Tregs in cancer 
patients.  Elevated levels of Tregs are seen in the peripheral blood (PB) of breast and 
pancreas cancer patients, where IL-10 and TGF-β secreting Tregs have been found in 
tumour-infiltrating lymphocytes (TILs) and regional lymph nodes infiltrated by 
tumour (Liyanage et al., 2002).  Research has also shown significant increases in the 
proportions of CD4
+
CD25
+ 
T cells in PB, tumours, and ascites of patients with non-
small cell lung cancer (NSCLC) and late-stage ovarian cancer (OVC) (Woo et al., 
2001).  The frequency of CD4
+
CD25
+
Foxp3
+
 Tregs in peripheral blood lymphocytes 
(PBLs) has also been reported as being elevated in gastric and oesophageal cancer 
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patients (Mizukami et al., 2008a).  However, in contrast, no significant increase in 
PBL Treg frequency was observed in patients with gastric cancer compared to normal 
healthy donors (Mizukami et al., 2008b). 
 
Current evidence indicates that failure of endogenous tumour surveillance 
mechanisms can result in tumour progression via escaping immune recognition and 
the anti-tumour immune response (Bui et al., 2006).  Patients with elevated Treg 
levels show reduced survival rates, and the accumulation of Tregs is related to disease 
progression (Mizukami et al., 2008b; Wolf et al., 2005).  Evidence suggests that 
depleting Tregs leads to rejection of transplanted tumours in murine models (Shimizu 
et al., 1999). 
 
Having studied the accumulation of Tregs within cancer, it is also important to 
understand the trafficking behaviour of Tregs and their localisation to and within the 
tumour microenvironment.  Tumour-related factors mediate Treg trafficking to the 
microenvironment of a tumour.  The macrophage-derived chemokine, CCL22, has 
been shown to induce the migration of Tregs through its receptor CCR4 and impair 
anti-tumour immunity in ovarian cancer (Curiel et al., 2004).  Tregs can also migrate 
in response to CCL17 via the same CCR4 receptor (Ishida and Ueda, 2006).  Tregs 
strongly express CCR4 on their surface.  The mechanism for CCL22 and CCL17 up-
regulation has not yet been clarified; however, it has been suggested that the tumour 
microenvironment induces macrophages to secrete these chemokines (Mizukami et 
al., 2008a).  It has also been reported that both CCL17 and CCL22 are produced by 
DCs (Imai et al., 1999; Vulcano et al., 2001) and a correlation has been observed 
Helen Angell   39 
between the level of CCL22 and CCL17 and the frequency of Foxp3
+
 Tregs in 
tumours (Mizukami et al., 2008a).  The involvement of Tregs in cancer is 
summarised in Figure 1.5.   
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Figure 1.5 Tregs in Cancer 
 
A) The macrophage-derived chemokine, CCL22, facilitates the migration of Tregs into the 
tumour microenvironment via the CCR4 receptor.  Tregs also migrate in response to CCL17 
via the same CCR4 receptor.  Once in the tumour microenvironment, Tregs function to 
suppress both the innate and adaptive arms of the immune system.  B) Cytokines, including 
interleukin-10 (IL-10), transforming growth factor-β (TGF-β) and vascular endothelial growth 
factor (VEGF) within the tumour microenvironment lead to dysfunctional dendritic cells (DCs), 
which subsequently induce Tregs.  Additional expansion occurs through C) the proliferation 
of pre-existing Tregs and D) the conversion of nave precursors into Ôde novoÕ induced Tregs.  
Figure is a graphical compilation of the information within the literature. 
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Accumulating evidence points to a critical role for Tregs in blunting the anti-tumour 
immune responses.  It is now widely acknowledged that inhibiting Treg function in 
cancer patients may contribute to the success of new therapies, specifically 
immunotherapies (Colombo and Piconese, 2007).  Although research into Treg 
biology is intensifying, many questions remain unanswered.  
 
1.1.9. Tumour Morphology and Microenvironment 
Weinberg and Hanahan summarised the importance of the tumour microenvironment 
in their in the seminal review ÔHallmarks of CancerÕ (Hanahan and Weinberg, 2000).  
A growing number of studies have subsequently demonstrated the association 
between angiogenesis, infiltrating immune cells and aggressive tumour progression 
with the tumour microenvironment (Pietras and Ostman, 2010). 
 
The tumour microenvironment is made up of a number of entities, including many 
different cell types, such as: pericytes, smooth muscle cells, endothelial cells and 
their precursors, fibroblasts, cancer-associated fibroblasts (CAFs), myofibroblasts, 
neutrophils, eosinphils, basophils, mast cells, T and B lymphocytes, NK cells, APCs 
such as macrophages, and DCs (Coussens and Werb, 2002).  The dynamic and 
reciprocal interactions between neoplastic cells and the aforementioned components 
of the tumour microenvironment orchestrate events involved in tumour development.  
It therefore becomes as essential to understand the workings of the tumour 
microenvironment as it is to understand the transformed cancer cells themselves 
(Lorusso and Ruegg, 2008). 
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Recent research has focused on the tumourÐÔhostÕ interface, investigating the tumour 
microenvironment, with a particular interest in the importance of stromal tissue.  
Malignant cells directly intermingle with components of the stroma and thus stromal 
elements play a pivotal role in tumour progression.  Tumour-associated stroma is a 
complex medium, previously likened to a wound-healing reaction (Dvorak, 1986). 
 
Initially the tumour microenvironment releases a number of growth factors in 
response to tumour hypoxia and areas of necrosis.  These growth factors, for 
example, colony stimulating factor (CSF)-1 and TGF-β, are chemoattractive for 
monocytes and macrophages, which in turn secrete additional growth factors that 
change tumour cell properties and behaviour.  The tumour microenvironment 
becomes saturated with factors, including vascular endothelial growth factor (VEGF)-
A and -C and cyclooxygenase (COX)-2, that stimulate tumour cell proliferation, 
survival, motility and angiogenesis (Coussens and Werb, 2002; Lorusso and Ruegg, 
2008). 
 
Chemokines in the tumour microenvironment recruit cells, rendering the tumour-
associated stroma inundated with various different immune infiltrates, including 
tumour-associated macrophages (TAMs).  Elevated numbers of TAMs have been 
affiliated to tumour initiation and progression (Lin et al., 2007; Lorusso and Ruegg, 
2008).  Macrophages can assume either an M1 or M2 phenotype.  M1 macrophages 
are activated in response to IFN-γ or microbe exposure and have a high capacity to 
present antigens.  A M1 phenotype is associated with high IL-12 and IL-23 
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production and activation of a Type I T cell response.  It has been suggested that M1 
macrophages are cytotoxic towards tumour cells and release high amounts of toxic 
intermediates such as reactive oxygen intermediates (ROI) and TNF (Allavena et al., 
2008).  The M2 phenotype is induced by IL-4, IL-13, IL-10 and immune complexes.  
M2 macrophages have poor antigen presentation and suppress the Type I TH 
response.  Macrophages with a M2 phenotype are affiliated with tissue re-modelling 
and promotion of angiogenesis, key contributors to tumour progression and invasion.   
The tumour microenvironment plays an important role in determining the M1/M2 
fate of TAMs. 
 
CAFs are the most predominant cell within the tumour-infiltrating stroma and are 
found within many cancers (Pietras and Ostman, 2010).  Extensive research has 
highlighted the importance of CAFs and various subtypes of stromal fibroblasts in 
tumour initiation, progression and metastasis (Anderberg et al., 2009; Camps et al., 
1990).  CAFs stimulate tumour cell proliferation via an assortment of growth factors, 
cytokines and hormones.  In addition, the ability of tumours to escape apoptosis has 
been linked to the survival signals they receive from stromal components, including 
insulin-like growth factor-1 and -2 (LeBedis et al., 2002).  CAFs are also providers of 
extra-cellular matrix (ECM) such as collagen, thought to be involved in malignant 
growth and invasion due to its cross-linking properties (Levental et al., 2009).  CAFs 
contribute to the epithelial-to-mesenchymal transition of tumour cells by TGF-β and 
hepatocyte growth factor (HGF) secretion.  This facilitates ECM remodelling and the 
tumour cellsÕ ability to invade surrounding tissue and gain a more metastatic 
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phenotype (Bhowmick et al., 2004).  CAFs also play an important, and well 
researched, role in angiogenesis.  Research has suggested that CAFs produce higher 
amounts of pro-angiogenic factors than that of tumour cells (Thijssen et al., 2004). 
 
Host fibroblasts (also referred to as myofibroblasts) are differentiated fibroblasts that 
express α-smooth muscle actin (α-SMA) and have been linked to tumourigenesis.  In 
a study of 192 colorectal cancer (CRC) patients who had samples assessed for α-
SMA, high α-SMA expression was associated with significantly poorer overall 
survival (OS) and shorter disease free survival (DFS) (Tsujino et al., 2007).  In 
addition, mast cells and neutrophils can also support tumour progression by 
sustaining inflammation and secreting tumour-promoting cytokines (Lorusso and 
Ruegg, 2008) 
 
Changes in the proportions of stroma within primary tumours could reflect disease 
progression (Pietras and Ostman, 2010).  Intra-tumour stroma percentage has been 
reported as a prognostic parameter.  CRC patients with a high percentage of tumour-
associated stroma have been shown to have poorer prognosis, where OS and DFS 
were significantly lower in patients with high stromal-tumour content (Tsujino et al., 
2007; West et al., 2010). 
 
1.1.10. Colorectal Cancer 
Despite significant advances in its treatment CRC is still the third most common 
cause of cancer death in the United Kingdom.  The series of events leading to the 
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development of CRC was first proposed by the Vogelstein group in 1990 and has 
since been well characterised (Fearon and Vogelstein, 1990).  CRC carcinogenesis 
arises from the accumulation of genetic ÔhitsÕ that result in the initiation of neoplastic 
transformation.  The tissue first becomes hyperplastic and then follows a particular 
pattern resulting in disease progression.  Genes in the normal epithelium mutate, 
which leads to the formation of aberrant crypt foci (ACF) and other dysplastic 
lesions, resulting in benign adenomas.  This state of growth can be subdivided into 
early, intermediate and late adenomas.  Disease progression then results in carcinoma 
development and eventually metastatic carcinoma (Weitz et al., 2005) .  In addition to 
the series of events resulting in CRC development, the model also described two key 
concepts: gatekeeper genes and caretaker genes (Fearon and Vogelstein, 1990).  
Gatekeeper genes are tumour suppressing genes that often regulate growth, such as 
the Ras genes and adenomatous polyposis coli genes.  Caretaker genes are involved 
in the maintenance of genetic stability.  The series of events contributing to CRC 
development are summarised in Figure 1.6. 
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Figure 1.6 The Onset and Development of CRC 
 
Example immunohistochemistry images (at x 20 original magnification) highlight the structural 
changes within the tissue during the development of CRC from A) non-neoplastic highly 
organised villi to B) the irregular structures observed in tumour tissue.  C) The adenoma 
carcinoma sequence is often initiated by mutations in gatekeeper genes, which regulate cell 
growth, such as the adenomatous polyposis coli and RAS gene, in addition to other tumour 
suppressor genes.  Repeated ÔhitsÕ (pink arrows) result in the tissue becoming hyperplastic, 
forming dysplastic crypts.  Disease progression facilitates the formation of aberrant crypt foci 
(ACF) and adenoma development, which later develops into a carcinoma. Figure is a 
graphical compilation of the information within the literature. 
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Following tumour resection, anatomic extent of the tumour is pathologically assessed 
and assigned a tumour-node-metastatic (TNM) stage.  TNM stages are used to 
estimate post-operative outcome, where the system relies on the tumour depth and 
absence or presence of nodal and distant metastasis to estimate prognosis and plan 
treatment (Figure 1.7A). 
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Figure 1.7 TNM Staging of CRC and the Importance of Immune Infiltrates in Disease 
Progression 
 
A) The tumour-node-metastasis staging classification (IÐIV) is based on the extent of the 
primary tumour (T1Ð4), and the presence or absence in lymph nodes (N) and distant 
metastasis (M).  The system is far from perfect at predicting clinical outcome, including 
overall survival (OS) disease-free survival (DFS).  B) A strong immune reaction (purple) has 
been shown to correlate with a favourable prognosis, despite the TNM staging, whereas a 
weak immune infiltrate is associated with a poor prognosis.  Figure adapted from (Pages et 
al., 2008) and (Galon et al., 2007). 
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The primary treatment for colon cancer is surgery (TNM I), followed by the addition 
of chemotherapy for TNM IIÐIII.  Adjuvant chemotherapy is recommended for 
patients with distant metastasis and nodal disease (TNM IV).  TNM staging provides 
a system to classify risk according to disease progression, where localised disease has 
better prognosis, compared to distant metastasis, which has the worst.  However, this 
system is often imprecise as 20Ð30 % of TNM I stage patients with localised tumours, 
experience relapse (Pages et al., 2008).  Subsequent research was therefore required 
to determine a strong prognostic marker, regardless of tumour progression.  Galon et 
al have since demonstrated that the prevalence of immune infiltrates and their type, 
density and location has a prognostic significance superior to those of the TNM 
stages IÐIII (Figure 1.7B).  It has been suggested that the prevalence of post-surgical 
immune infiltrates, and not tumour status, is the key indicator for reoccurrence, 
metastasis and therefore clinical outcome (Galon et al., 2007; Pages et al., 2008). 
 
1.2. THE AIMS OF THE CURRENT STUDY 
Despite the fact that activated immune cells exist in cancer patients, the immune 
system often fails to prevent tumour establishment and progression.  Increasing 
evidence supports the essential role of CD4
+
CD25
+
Foxp3
+ 
Tregs in inducing 
tolerance to tumours.  It is now widely acknowledged that inhibiting Treg function in 
cancer patients may contribute to the success of new therapies.  The aim of this PhD 
project was to firstly begin to recognise how Tregs function and understand how they 
are able to suppress such a wide range of cell populations.  This involved addressing 
questions such as: what molecular mechanisms are involved in Treg-mediated 
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suppression?  Is suppression cell contact dependent?  Which cytokines, if any, are 
involved in this suppression?  The project then aimed to address whether or not the 
importance of Tregs highlighted in the literature was reflected in a clinical setting.  
The study aimed to investigate the significance of immune cell orientation within the 
tumour microenvironment, understanding the co-localisation between key immune 
cell subtypes and their correlation with areas of tumour proliferation, apoptosis, 
hypoxia and vasculature coverage.  The comparison of Treg accumulation between 
cancer patients and healthy volunteers was also scrutinised with the aim of addressing 
the involvement of Tregs in actively suppressing the anti-tumour immune response, 
influencing survival rates and disease progression.  The aim was to analyse the level 
of Tregs in the peripheral blood of primary CRC and liver metastatic patients and to 
investigate whether any correlation existed between this and infiltrating Tregs Ôin 
situÕ.  The project then aimed to build an in vitro human Treg suppression model, 
initially investigating the interaction between CD4
+
CD25
+
 and CD4
+
CD25
-
 cell 
populations.  Additional levels of complexity were added, incorporating tumour cells 
and further subdivisions of T-cell populations, including NK cells.  The purpose of 
this model was to gain an insight into the role of Tregs within the tumour 
microenvironment and suppression of anti-tumour immunity.  Initial studies worked 
with healthy volunteers and then progressed into using liver metastatic patient 
samples.  This in vitro model could be employed to screen for Treg targets, initially 
using small interfering ribonucleic acid (siRNA) and then finally via an antibody 
directed therapeutic approach.  This compilation of assays could provide a platform 
to validate lead antibodies produced against a selected Treg target. 
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CHAPTER 2 - WAYS TO WORK WITH TREGS: ISOLATION 
AND EXPANSION 
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Chronological Framework of Thesis Progression  
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CD25
+ 
Tregs represent approximately 7Ð10 % of peripheral CD4
+
 T cells.  The first 
aim of this PhD project was to successfully isolate Tregs for use in subsequent 
assays.  Overcoming problems such as limited cell number and phenotypically 
distinguishing Tregs from activated effector or memory T cells was a fundamental 
requirement.    
 
2.1. METHODOLOGY 
2.1.1. Fluorescence Activated Cell Sorting (FACS) Protocol 
A Beckman Coulter FC 500 flow cytometer allows a sample to be injected into a 
continuous laminar flow.  This formulates a fluid flow system, which draws the 
sample into a single cell stream that is passed through a perpendicular laser beam.  
Individual cells cause light to scatter and fluorescent dyes to emit light at various 
frequencies.  Two common measurements taken for each cell are forward scatter (FS) 
and side scatter (SS).  FS gives an approximate size of the cell, whereas SS (detected 
at 90¡ to the laser) measures the granularity or complexity of the cell.  In a peripheral 
blood sample, lymphoctye, monocyte and neutrophil populations can be segregated 
using FS and SS, with debris and dead cells excluded.  Fluorescence labelling allows 
investigation of specific cellular molecules; where fluorescent emissions are collated 
into corresponding channels. 
 
1 × 106 cells were transferred to fluorescence activated cell sorting (FACS) tubes and 
washed in 1 ml FACS buffer (2 % foetal calf serum [FCS] in phosphate buffered 
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saline [PBS]) by centrifugation at 250 × g for 5 minutes.  A pre-titrated volume of 
surface-staining antibody was added and the tubes agitated, followed by a 20-minute 
incubation step at room temperature, protected from light.  Cells were then fixed by 
adding 1 ml of a commercial fixing buffer (BioLegend) and incubating for 15 
minutes at room temperature, protected from light.  Cells were centrifuged for 5 
minutes at 250 × g and the supernatant removed.  If intracellular staining was 
required, for example for Foxp3, the samples were permeabilised in 1 ml 
permeabilising buffer (0.1 % w/v saponin in PBS) for 15 minutes at room 
temperature protected from light.  Centrifugation at 250 × g for 5 minutes was carried 
out and the supernatant removed prior to the addition of a pre-titrated volume of 
staining antibody in permeabilising buffer for 30 minutes at room temperature, 
protected from light.  Cells were finally washed and re-suspended in 500 µl FACS 
buffer and stored at 4 ûC until required for analysis. 
 
2.1.2. PBMC Isolation 
Histopaque-1077 (Sigma-Aldrich, Cat 1077-1) and isolation buffer (PBS w/o Ca/Mg, 
0.1 % bovine serum albumin [BSA], 2 mM ethylenediaminetetraacetic acid [EDTA]) 
were prepared and brought to room temperature.  Blood was taken by venipuncture 
into a tube containing sodium heparin (250 IU/ml; Heparin Sodium Mucous, CP 
Pharmaceuticals Ltd, Wrexham UK, BN42073).  This was centrifuged at 600 × g for 
8 minutes at room temperature, the plasma removed and isolation buffer added to 
make up to the original volume.  25 ml was then layered over two 20 ml Histopaque-
1077 and centrifuged at 800 × g for 20 minutes at room temperature without braking 
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to form a gradient.  PBMCs were recovered from the interface and combined for each 
donor.  This was made up to 35 ml with isolation buffer and layered onto 15 ml of 
Histopaque-1077 and centrifuged at 160 × g for 20 minutes at room temperature 
without braking.  20 ml of the supernatant was removed to eliminate platelets and 
then further centrifuged at 350 × g for 20 minutes at room temperature without 
braking.  PBMCs were recovered from the interface.  Cells were washed once in 
isolation buffer and then centrifuged at 400 × g for 8 minutes at 4 ¡C.  Two additional 
wash steps in isolation buffer were carried out with two 225 × g for 8 minutes at 4 ¡C 
centrifugation steps.  10 µl was aliquoted and removed for cell counting using a 1:4 
dilution with 0.4 % Trypan Blue Solution (Sigma-Aldrich).  1 × 106 cells were 
removed for FACS analysis. 
 
2.1.3. Regulatory T Cell Isolation 
Treg isolation was achieved using a Dynabeads
¨
 Regulatory CD4
+
CD25
+
 T Cell Kit 
(Invitrogen, Cat 113.63D) and carried out according to the manufacturerÕs 
instructions.  In brief, 500 µl isolation buffer, 200 µl foetal bovine serum (FBS) and 
200 µl Antibody Mix Human CD4 were added per 5 × 107 of isolated PBMCs and 
incubated for 20 minutes at 4 ¡C.  10 ml of cold isolation buffer was added to wash 
cells at 350 × g for 8 minutes.  The supernatant was removed and discarded.  The cell 
pellet was re-suspended in 2 ml of cold isolation buffer.  1 ml of re-suspended 
Depletion MyOne Dynabeads
¨
 were added, mixed well and incubated for 15 minutes 
at room temperature with rolling and tilting.  The bead-bound cells were re-
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suspended by vigorous pipetting, followed by the addition of 3 ml of isolation buffer 
and placed in the magnet stand for 3 minutes.  The supernatant containing the bead-
free CD4
+
 T cells was then transferred to a new tube and replaced on the magnet for a 
further 3 minutes to remove residual Depletion MyOne Dynabeads
¨
.  10 µl was 
removed for cell counting.  The cells were centrifuged for 8 minutes at 350 × g and 
re-suspended in isolation buffer to a concentration of 1.5 × 107 CD4+ cells per ml.  1 
× 106 cells were removed for FACS analysis. 
 
200 µl of Dynabeads
¨
 CD25 was added per 1.5 × 107 of CD4+ cells.  This was mixed 
well and incubated for 25 minutes at 4 ¡C with rolling and tilting.  This was then 
placed in the magnet for a minimum of 1 minute before carefully removing the 
supernatant containing the CD4
+
CD25
-
 (effector) cells.  The tube was removed from 
the magnet and the bead-bound cells were carefully re-suspended in 5 ml isolation 
buffer by gently shaking the tube.  The tube was then returned to the magnet for a 
minimum of 1 minute and the supernatant removed and discarded.  This wash step 
was then repeated.  
 
Roswell Park Memorial Institute (RPMI)-1640 cell culture media (Sigma, Cat 
R0883) was prepared (10 % FBS, 2mM L-glutamine, 0.05 mM sodium pyruvate, 
0.05 mM non-essential amino acids, 25 mM HEPES Buffer, 0.05 mM 2-
mercaptoethanol, 100 IU/ml penicillin, 100 µg/ml streptomycin).  Bead-bound cells 
were re-suspended in 500 µl RPMI (1% FBS).  80 µl of DETACHaBEAD was then 
added and incubated for 45 minutes at room temperature with tilting and rotation.  
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This was then transferred to a 15 ml tube.  Meanwhile, CD4
+
CD25
-
 cells were 
counted by trypan blue exclusion and 1 × 106 cells removed for FACS analysis.  The 
tube was then returned to the magnet for a minimum of 1 minute and the supernatant, 
containing the CD4
+
CD25
+
 cells, carefully removed and transferred to a new tube.  
The Dynabeads
¨ 
were washed twice in 1 ml RPMI (1 % FBS) to obtain the residual 
cells the supernatant collected after separation using the magnet.  10 ml of RPMI 
(1 % FBS) was added to wash the cells, followed by centrifugation for 8 minutes at 
350 × g.  This wash step was then repeated and a 10 µl aliquot removed for cell 
counting.  The supernatant was discarded and cells re-suspended in culture medium. 
 
2.1.4. In vitro Regulatory T Cell Expansion Assay 
Isolated Tregs were re-suspended in X Vivo 15 medium (Lonza, BioWhittaker
¨
 
BE04-418F) with 5 % Human AB serum and plated onto round bottom 96-well plates 
at approximately 1 × 106 cells per ml.  1 × 105 IU/ml of human IL-2 (PeproTech, Cat 
200-02) and 10 µg/ml of purified anti-CD28 super agonist (Ancell, Cat 177-020) 
were added to positive wells (negative controls contained 5 % AB serum only).  Cells 
were maintained at 37 ûC in a humidified atmosphere containing 5 % v/v CO2 for 28 
days, with an additional 5 × 104 IU/ml of IL-2 added every fourth day.  Media was 
changed weekly by centrifuging at 250 × g for 5 minutes and replacing with fresh 5 
% AB serum X vivo media containing 1 × 105 IU/ml of human IL-2 and 10 µg/ml of 
purified anti-CD28 super agonist.  1 × 106 cells were removed for counting and 
FACS analysis.  Cell surface staining was carried out on fixed cells, looking at 
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phycoerythrin Cy5 (PeCy5) anti-CD4, Phycoerythrin-Texas red conjugate energy 
coupled dye (ECD) anti-CD3 and phycoerythrin (PE) anti-CD25, followed by 
internal staining for Alexa 488 anti-Foxp3 as described in section 2.1.3. 
 
2.2. RESULTS AND DISCUSSION 
2.2.1. Human Peripheral Blood Phenotyping 
An overall understanding of phenotyping immune cells and analysing different 
populations via flow cytometric analysis was a fundamental requirement for this 
study.  To facilitate this, healthy volunteers were recruited to donate 50 ml of 
peripheral blood (PB).  PBMCs were isolated over histopaque (section 2.1.2) and 1 × 
10
6
 cells were removed for FACS analysis.  Polymorphonuclear leucocytes (PMNs) 
can be distinguished from mononuclear cells by their lobulated nuclei.  Fluorescein 
isothiocyanate (FITC) anti human-CD14 was then used in combination with 
antibodies against CD4, CD3 and CD25 to distinguish monocytes within the PBMC 
population (Figure 2.1).   
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Figure 2.1 FACS Analysis of Monocytes and B cells from Isolated PBMCs 
 
PBMCs were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added to identify A) 
monocytes; PeCy5 anti-CD4, ECD anti-CD3, PE anti-CD25, FITC anti-CD14, and B) B cells; 
PeCy5 anti-CD4, ECD anti-CD3, FITC anti-CD8, PE anti-CD19.  Cells were fixed and data 
were acquired on a Beckman Coulter FC 500 flow cytometer and analysed using Weasel 
software. 
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CD14 is a 53Ð55 kDa glycoprotein expressed on monocytes, interfollicular 
macrophages and some DCs.  The CD3
-
CD25
-
CD14
+
 monocytic population is 
highlighted in blue (Figure 2.1A) and can be easily identified from the lymphocyte 
population (shown in grey).  In addition, specific staining of B cells can be achieved 
using an anti human-CD19 antibody.  CD19 is a 95 kDa transmembrane glycoprotein 
expressed on B cells during all stages of development, although some follicular DCs 
can also express CD19.  Signalling through CD19 induces tyrosine phosphorylation, 
calcium flux and proliferation of B cells.   
 
Once the lymphocyte population had been detected, further staining was used to 
identify the individual immune cell sub-populations, such as CD8.  CD8 is a 32Ð34 
kDa cell surface receptor expressed on thymocytes and a subpopulation of mature T 
cells and NK cells.  CD8 binds to MHC class I and, through its association with 
protein tyrosine kinase p56lck, plays a role in T cell development and activation of 
mature T cells. 
 
By gating on lymphocytes and then staining with CD4, CD3, CD25 and CD8, various 
CD8 populations can be distinguished (Figure 2.2).  CD8 staining was seen on the 
CD4
-
 population and predominantly CD3
+
, with a smaller fraction of CD3
-
CD8
+
. 
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Figure 2.2 CD8 FACS Analysis of Isolated PBMCs 
 
PBMCs were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added; PeCy5 anti-CD4, 
ECD anti-CD3, PE anti-CD25 and FITC anti-CD8.  Cells were then fixed and data were 
acquired on a Beckman Coulter FC 500 flow cytometer and analysed using Weasel software. 
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Tregs are a key immune cell within this study and therefore it was crucial to be able 
to identify them correctly.  Various Treg markers have previously been suggested 
within the literature.  CD25 provides a good marker for Tregs in murine studies, as 
the animals are often held under pathogen-free conditions and so do not experience 
any CD25 upregulation.  Humans however are constantly exposed to foreign 
antigens, leading to the possibility of elevated levels of activated CD25
+
 effector T 
cells.  As discussed previously, a large amount of research has been invested into 
developing human Treg markers (Beyer and Schultze, 2006; Fontenot et al., 2003; 
Morgan et al., 2005; Rudge et al., 2006). 
 
GITR, L-selectin (CD62L) and CTLA4 are among the possible cell-surface markers 
suggested to be associated with Treg phenotype and function.  CTLA4 interacts with 
the CD80 and CD86 ligands and has been proposed as a mechanism for mediating 
contact suppression (Rudge et al., 2006) (Figure 1.4).  CD25
+
 Tregs express CTLA4 
constitutively on their surface, while effector T cells up-regulate it upon activation 
(Takahashi et al., 2000).  Anti-CTLA4 antibodies abrogate suppression in vitro 
(Takahashi et al., 1998) and injection of anti-CTLA4 antibody prevents Treg 
mediated disease suppression (Liu et al., 2001; Read et al., 2000) and resulted in 
tumour rejection (Lee et al., 2004b; Sutmuller et al., 2001). 
 
Tregs are enriched by, but not homogenous in the expression of these aforementioned 
markers.  In search for more specific Treg markers, it has been proposed that the 
transcription factor Foxp3 is uniquely expressed by the majority of CD4
+
CD25
+
 
Tregs, while it remains virtually undetectable in effector T cells (Fontenot et al., 
Helen Angell   63 
2003).  Research suggests that activation of CD4
+
CD25
-
 T cells does not cause up-
regulation of Foxp3, allowing activated and regulatory CD4
+
 cells to be readily 
distinguished (Rudge et al., 2006).  However, the reliability of Foxp3 as a specific 
Treg marker is still in question due to reports that argue Foxp3 is expressed in human 
activated T cells without a suppressive phenotype (Beyer and Schultze, 2006).  
Although human CD4
+
CD25
high
 T cells are mostly enriched for Foxp3
+
, some 
research has shown Foxp3
+
 cells within the CD4
+
CD25
low
 T cell population (Beyer 
and Schultze, 2006).  Morgan et al revealed Foxp3 mRNA expression in both CD25
-
 
PBMCs and CD8
+
 cells (Morgan et al., 2005).  The lack of more specific Treg 
markers is a major reason that many functionally relevant aspects of Tregs are still 
unknown (Beyer and Schultze, 2006).  This study uses CD4
+
CD25
+
Foxp3
+
 to identify 
Tregs (Figure 2.3).  
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Figure 2.3 Foxp3 FACS Analysis of Isolated PBMCs 
 
PBMCs were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added; PeCy5 anti-CD4, 
ECD anti-CD3 and PE anti-CD25.  Cells were then fixed and permeabilised followed by 
intracellular staining using Alexa 488 anti-Foxp3.  Data were acquired on a Beckman Coulter 
FC 500 flow cytometer and analysed using Weasel software. 
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To further confirm the Treg population used within this study additional 
characterisation was achieved, including their expression of GITR (Figure 2.4) and 
CD62L (Figure 2.5), in agreement with previous literature (Rudge et al., 2006) 
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Figure 2.4 GITR FACS Analysis of Isolated PBMCs 
 
PBMCs were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added: ECD anti-CD4, PE 
anti-CD25, PeCy5 anti-GITR.  Cells were then fixed and permeabilised followed by 
intracellular staining using Alexa 488 anti-Foxp3.  Data were acquired on a Beckman Coulter 
FC 500 flow cytometer and analysed using Weasel software. Glucocorticoid-induced TNF 
receptor family related protein (GITR) analysis was carried out on a Foxp3+ gated plot. 
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Consistent with previous findings, Foxp3 Tregs showed GITR expression.  Here we 
see 17.2 % of Foxp3 gated Tregs expressed GITR (Figure 2.4).   
 
CD62L is expressed on the majority of B cells, nave T cells and a subset of memory 
T and NK cells.  CD62 binds CD34, GlyCam and MAdCAM-1.  CD62L is involved 
in leukocyte homing, rolling and tethering, but it has also been reported that a 
neutralising CD62L antibody will inhibit Treg expansion and functionality.  
Knockdown of Foxp3 has also been shown to reduce the expression of CD62L 
(Antons et al., 2008).  FACS analysis of isolated PBMCs showed an increased 
CD62L mean intensity (MI) of 29.6 expression on Foxp3
+
 cells compared to a MI of 
15.6 on the Foxp3
-
 population (Figure 2.5). 
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Figure 2.5 CD62L FACS Analysis of Isolated PBMCs 
 
PBMCs were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added: ECD anti-CD4, PE 
anti-CD25, PeCy5 anti-CD62L.  Cells were then fixed and permeabilised followed by 
intracellular staining using Alexa 488 anti-Foxp3.  Data were acquired on a Beckman Coulter 
FC 500 flow cytometer and analysed using Weasel software.  CD62L analysis was carried 
out on FOXP3+/- gating and the intensity median is shown. 
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CD127, also known as the IL-7Rα, complexes with CD132 to form the 
multifunctional IL-7R.  CD127 is a type I glycoprotein with a molecular weight of 
75Ð80 kDa and is expressed by immature B cells through the early pre-B stage, by 
thymocytes during several stages of their development and on most mature T cells, 
with transient down-regulation upon activation.  Binding of IL-7 results in signal 
transduction, which occurs through several tyrosine kinase pathways, including the 
Jak/STAT pathway.  IL-7 is indispensable for lymphocyte development and the 
control of homeostatic proliferation of T cells in the periphery.  CD127 expression is 
down-regulated on CD4
+
CD25
+
 Tregs where Foxp3
+
 CD127
low
 are highly enriched 
for the regulatory T cell phenotype (Gobert et al., 2009).  Foxp3
+
 Tregs had a MI of 
15.0 for CD127 compared to Foxp3
-
 cells, which showed a CD127 MI of 43.7, in 
agreement with previous literature (Figure 2.6). 
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Figure 2.6 CD127 FACS Analysis of Isolated PBMCs 
 
PBMCs were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added: ECD anti-CD4, PE 
anti-CD25, PeCy5 anti-CD127.  Cells were then fixed and permeabilised followed by 
intracellular staining using Alexa 488 anti-Foxp3.  Data were acquired on a Beckman Coulter 
FC 500 flow cytometer and analysed using Weasel software.  CD127 analysis was carried 
out on Foxp3+/- gating and the intensity median is shown. 
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CD4 and CD25 have been the main markers used for Treg isolation, resulting in cells 
with potent suppressive properties consistent with the literature (Figueroa-Tentori et 
al., 2008).  The identification of Foxp3 has been a key development in facilitating 
human Treg isolation.  Research using mAbs specific for human Foxp3 via 
intracellular staining has shown that cells expressing the highest levels of intracellular 
Foxp3 protein also represented the population of CD4 T cells expressing the highest 
levels of CD25 (Roncador et al., 2005).  Unfortunately, research has also 
demonstrated that many activated (non-regulatory) human T cells can also express 
Foxp3 (Morgan et al., 2005; Vignali et al., 2008; Wang et al., 2007).  Interestingly, it 
has been shown that Tregs express a high level of folate receptor 4 in comparison to 
activated effector T cells, a possible method to distinguish the populations 
(Yamaguchi et al., 2007).  It is also important to recognise that Tregs could actually 
be more of a heterogeneous population, with two distinct subsets classified by 
expression of MHC class II dimmer human leukocyte antigen (HLA) DR
+/-
 (Baecher-
Allan et al., 2006).  Therefore, a cocktail of surface markers would perhaps be the 
preferred option to facilitate the correct isolation and characterisation of Tregs.  A 
growing number of candidates for human Treg-specific cell surface markers have 
been discussed at length (Vignali et al., 2008; Yi et al., 2006).  For this study the 
following markers were chosen to identify Tregs using FACS analysis: CD3, CD4, 
CD25, and Foxp3. 
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2.2.2. Regulatory T Cell Isolation from Human Peripheral Blood 
Tregs are relatively infrequent in human blood, ranging from only 1Ð5 % of T cells.  
It was therefore integral to this PhD project that efficient protocols for the isolation of 
PB Tregs were established, in order to allow phenotypical and functional analysis of 
ex vivo Treg populations.  The development of a consistent, in-house assay to 
accomplish reliable Treg isolation was thus a fundamental requirement.  There are a 
variety of commercial Treg isolation kits available.  Each kit was tested individually 
and the isolation data compared, critiquing their Treg recovery and efficiency, both in 
terms of cost and laboratory time.   
 
2.2.2.1 The Dynabeads¨ Regulatory CD4+CD25+ T Cell Kit, Invitrogen 
The Dynabeads
¨
 Regulatory CD4
+
CD25
+
 T Cell Kit facilitates Treg isolation from ex 
vivo PBMCs involving a series of steps using magnetic Dynabeads
¨
 and specific 
antibodies to sequentially remove various cell populations (Figure 2.7). 
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Figure 2.7 Diagrammatic Representation of Dynabeads¨ CD4+CD25+ T Cell Isolation 
Kit, Invitrogen 
 
Step 1 involves the use of a magnet to remove non-CD4
+
 cells from peripheral blood 
mononuclear cells (PBMCs) using an Antibody Mix and Depletion Dynabeads
¨
.  CD25 
Dynabeads
¨
 are then added in Step 2 allowing removal of CD25
-
 effector cells in the 
supernatant.  DETACHaBEADs are then added in Step 3 to separate CD4
+
CD25
+
 Tregs from 
the magnetic beads to allow use in subsequent assays.  Figure adapted from 
http://invitrogen.com/content/sfs/posters/Treg%20poster_web.pdf.com. 
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The following cell populations were isolated: CD4
+
 cells, CD4
+
CD25
-
 effector cells 
and CD4
+
CD25
+
 Tregs.  1 × 106 cells from each isolated population was extracted for 
FACS analysis (Figure 2.8).   
 
FACS analysis was achieved by firstly gating on the PBMC population based on 
scatter properties.  37.1 % of the PBMC population was CD3
+
CD4
+
 cells; purity was 
increased to 88.8 % by sorting for CD4
+
 cells.  Within the CD4
+
CD25
-
 effector cell 
population, only 0.91 % of CD4
+
CD25
+
 cells were observed showing very little 
contamination of cell populations.  The kit then allowed sorting of Tregs 
(CD4
+
CD25
high
), where a purity of 71.8 % was achieved, of which 72.1 % were also 
Foxp3
+
.  It has previously been demonstrated in humans that Tregs are best purified if 
only the 2Ð3 % of CD4 cells that express the highest levels of CD25 are isolated 
(Baecher-Allan et al., 2001).  Restricting the isolation to CD25
high
 cells increases the 
homogeneity of the Treg population, as previously indicated by function and by 
surface expression of CD45RO, CD122, and CD62L
high 
(Baecher-Allan et al., 2001).  
Data are consistent with published isolations (Bresatz et al., 2007). 
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Figure 2.8 FACS Analysis of Treg Isolation Using Invitrogen Dynabeads¨ CD4+CD25+ 
T Cell Isolation Kit 
 
Following the manufactureÕs protocol, Tregs were isolated from 50 ml healthy human blood 
using Invitrogens's Dynabeads
¨
 CD4
+
CD25
+
 T Cell Isolation Kit, Invitrogen Treg isolation kit.  
At each cell isolation step 1 x 10
6
 cells were removed for FACS analysis.  A pre-titrated 
volume of the following surface antibodies was added: PeCy5 anti-CD4, ECD anti-CD3 and 
PE anti-CD25.  Cells were then fixed and permeabilised followed by intracellular staining 
using Alexa 488 anti-Foxp3.  Data were acquired on a Beckman Coulter FC 500 flow 
cytometer and analysed using Weasel software. 
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2.2.2.2. The MACS¨ CD4+CD25+ Regulatory T Cell Kit, Miltenyi Biotec 
A second isolation kit was then investigated: MACS
¨
 CD4
+
CD25
+ 
Regulatory T Cell 
Isolation Kit from Miltenyi Biotec.  The kit was developed for the isolation of 
CD4
+
CD25
+
 cells from PBMCs and includes a cocktail of biotinylated antibodies and 
Anti-Biotin MicroBeads for depletion of non-CD4
+
 T cells and CD25 MicroBeads for 
subsequent positive selection of the CD4
+
CD25
+
 cells, all carried out on specific 
columns (Figure 2.9). 
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Figure 2.9 Diagrammatic Representation of MACS
¨
 CD4+CD25+ Treg Isolation Kit, 
Miltenyi Biotec 
 
The kit consists of a cocktail of biotinylated antibodies and anti-biotin MicroBeads for 
depletion of non-CD4
+
 T cells and CD25 MicroBeads for subsequent positive selection of 
CD4
+
CD25
+
 cells.  Step 1 involves adding peripheral blood mononuclear cells (PBMCs) with 
Biotin Antibody Cocktail and Anti-Biotin MicroBeads to isolated CD4
+
 cells on an LD Column.  
These are then added with CD25 MicroBeads in Step 2 and subjected to an MS Column to 
isolate CD4
+
CD25
-
.  The column is then flushed with buffer to elute CD4
+
CD25
+
 cells. 
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As a comparison to the previous kit, the same cell populations were isolated and 
1 × 106 cells were analysed by FACS (Figure 2.10). 
 
Once again the FACS data were gated on the PBMC population and then analysed for 
CD4 and CD3 expression.  46.1 % of the PBMC population were CD3
+
CD4
+
 and this 
increased to 97.1 % following the CD4 sort.  Only 0.08 % of cells were CD25
+
 within 
the CD4
+
CD25
-
 effector cell population.  70.6 % of cells were CD4
+
CD25
+
Foxp3
+
; 
however, the corresponding CD4
+
CD25
+
 population, within the Treg sort, did not 
correlate, at only 3.24 %.  
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Figure 2.10 FACS Analysis of Treg Isolation Using MACS
¨
 CD4+CD25+ Regulatory 
T Cell Isolation Kit, Miltenyi Biotec 
 
Following the manufactureÕs protocol, Tregs were isolated from 50 ml healthy human blood 
using MACS
¨
 CD4
+
CD25
+
 Regulatory T Cell Isolation Kit.  At each cell isolation step 1 x 10
6
 
cells were removed for FACS analysis.  A pre-titrated volume of the following surface 
antibodies was added: PeCy5 anti-CD4, ECD anti-CD3 and PE anti-CD25.  Cells were then 
fixed and permeabilised followed by intracellular staining using Alexa 488 anti-Foxp3.  Data 
were acquired on a Beckman Coulter FC 500 flow cytometer and analysed using Weasel 
software. 
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It was not possible to do a direct comparison between these two kits, looking at the 
same patient on the same day, due to the intensity of the work and time restrictions.  
It is therefore necessary to take into account any discrepancies between samples that 
may affect the results.  However, these data are representative of three individual 
isolations using both kits. 
 
Conventionally, mouse Tregs have been characterised as CD4
+
CD25
+
 and can be 
effectively isolated based on staining for expression of these.  Trouble arises, 
however, when isolating human Tregs because activated T cells up-regulate CD25 
expression and therefore this affects the purity of the Treg isolation.  Consequently, 
seasonal differences must be taken into account; for example, during influenza or 
allergy seasons a substantial proportion of human CD4
+
 T cells may express CD25 
(Vignali et al., 2008).  Therefore, this must be accounted for when assessing Treg 
isolations from donors throughout the year. 
 
As CD25
+
 Tregs only represent approximately 7Ð10 % of peripheral CD4
+
 T cells 
(Rudge et al., 2006), a fundamental difficulty when working with Tregs is the issue of 
low cell number.  Cell numbers from 8 different isolations can be seen in Figure 2.11, 
highlighting the inter-assay differences and limited Treg numbers. 
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Figure 2.11 Differences in Donor Cell Isolation Numbers Using Invitrogen Dynabeads
¨
 
CD4
+
CD25
+
 T Cell Isolation Kit 
 
Following the manufacturerÕs protocol, Tregs were isolated from 50 ml healthy human blood 
using Invitrogens's Dynabeads
¨
 CD4
+
CD25
+
 T Cell Isolation Kit, Invitrogen Treg isolation kit.  
At each cell isolation step 1 x 10
6
 cells were removed for cell counting. 
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Additional limitations also apply, including the amount of blood you can take from a 
volunteer and how frequently you can take blood from the same donor.  All these 
restraints result in limited Treg numbers and so hinder the number and size of assays 
possible post-isolation. 
 
2.2.3. Expansion of Human Isolated Regulatory T Cells 
The constraint of limited Treg numbers from healthy donors has led to the 
development of Treg expansion protocols (Maloy and Powrie, 2005; Sakaguchi et al., 
1995).  Maintenance of an undifferentiated cell line of this type would reduce the 
problem of limited Treg numbers and facilitate cell-based assays to further 
understand Treg mechanisms.  Research has shown that Tregs can be expanded in 
vitro for cell-based therapies, either alone or in combination with DCs (Bresatz et al., 
2007).   
 
Tregs are anergic in vitro and do not proliferate or produce IL-2 in response to 
conventional T-cell stimuli (TCR stimulation).  This anergy can be broken by the 
addition of high doses of exogenous IL-2 and anti-CD28 or the use of mature DCs as 
APCs.   
 
Following the methodology described in 2.1.3, Tregs were isolated and then cultured 
and expanded over a 3-week period.  Treg numbers were calculated at weekly 
intervals and FACS analysis carried out to assess phenotype (Figure 2.12A). 
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Figure 2.12 Expanded Treg Numbers and FACS Analysis Comparing Populations 
 
A) Tregs were isolated from 50 ml healthy human blood, and re-suspended in X Vivo media 
(5 % Human AB serum).  Cells were split equally into expanded and none expanded 
populations and plated at approximately 1 x 10
6
 cells per well with 1 x 10
6
 U/ml of human IL-2 
and 10 g/ml of purified anti-CD28 super agonist (expanded cells only).  Cells were 
maintained at 37 ¡C in a humidified atmosphere containing 5 % v/v CO2 for 28 days, with an 
additional 5 x 10
6
 IU/ml of IL-2 added every fourth day.  Cells were counted and re-seeded 
with fresh media weekly and 1 x 10
6
 cells removed for FACS.  Data are representative of n = 
1 experiments.  B) Surface staining was carried out on fixed cells, looking at PeCy5 anti-CD4, 
ECD anti-CD3 and PE anti-CD25, followed by internal staining for Alexa 488 anti-Foxp3.   
Data were acquired on a Beckman Coulter FC 500 flow cytometer and analysed using 
Weasel software, comparing initial isolation Tregs to those expanded for 3 weeks. 
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As seen in Figure 2.12A, Tregs expand in culture from 6.25 × 104 to 1.26 × 107 over 3 
weeks.  The success of this expansion protocol is reflected in the FACS data (Figure 
2.12B), where the Treg phenotype shows little change and purity remains at 94.8 %.   
 
Treg proliferation is not readily observed in vitro; therefore questions arise regarding 
the use of expanded cells to represent a true Treg population.   
 
Research has shown an alternative approach to Treg expansion whereby CD4
+
CD25
+
 
T cells are cultured in conditioned medium derived from tumour cells RENCA or 
TRAMP-C2, which have similar characteristics as those of naturally occurring Tregs 
such as Foxp3, IL-2 production, high IL-10 and TGF-β.   
 
2.3. CONCLUSIONS AND FUTURE WORK  
Although there are conflicting data in the literature with regards to Treg markers, the 
author is confident that Treg selection based on a CD4
+
CD25
+
Foxp3
+
 phenotype was 
the best choice within the constraints of the current study.  Expression of Foxp3 in 
CD4
+
 T cells has been shown to correlate with their suppressive ability (Walker et al., 
2003).  It is the authorÕs opinion that Tregs represent a population of cells that exhibit 
varying plasticity, perhaps changing their cell-surface expression fingerprint with 
great fluidity.  In an ideal world, a large cohort of markers would be implemented to 
further distinguish different subtypes of Tregs.  Unfortunately, this was beyond the 
scope of the current study.  A decision was required to select the most appropriate 
markers that would facilitate Treg identification throughout the entire study. 
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The difficulty in obtaining enough Tregs for experimental work was an underlying 
problem throughout this study.  The number of Tregs was successfully expanded ex 
vivo over a 4-week period.  Despite validating the expanded Treg phenotype, the 
author was apprehensive to solely rely on these cells.  By pushing Tregs into a 
proliferate phenotype, their role in subsequent assays could greatly differ to that of in 
vivo Tregs.  For this reason it was decided to use freshly isolated Tregs for all 
subsequent experiments.   
 
In addition, research has demonstrated the use of Rapamycin to expand both murine 
and human CD4
+
CD25
+
Foxp3
+
 functional Tregs (Battaglia et al., 2006).  Suppression 
most often involved polyclonal stimulation methods that range from undefined 
allogeneic responses to mitogenic lectins (phytohemaglutinin [PHA], Concavalin A 
[ConA]) or to the use of different mAbs against CD3 in the presence or absence of 
anti-CD28 co-stimulation.  Moreover, stimulation with anti-CD3 or anti-CD28 in 
different physical forms, such as immobilised versus soluble, or at different 
concentrations provides different strengths of signal to the target cells, influencing the 
suppressive ability of the effector cells. 
 
The conversion of CD4
+
CD25
-
 into CD4
+
CD25
+
 cells may provide an additional 
method to acquire the required numbers of Tregs.  Research has shown that 
CD4
+
CD25
+
 T cells generated as a result of stimulation of CD4
+
CD25
-
 T cells, 
express Foxp3 and acquire Treg function (Apostolou and von Boehmer, 2004).  Anti-
CD3 stimulation in the presence of TGF-β in vitro has been shown to result in the 
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stimulation of CD25
+
 Foxp3-expressing suppressor T cells (Apostolou and von 
Boehmer, 2004).  TGF-β plays a critical role in the conversion of CD4+CD25- into 
CD4
+
CD25
+
, demonstrated by using a neutralising TGF-β antibody (Zheng et al., 
2004), where mAb TGF-β treatment reduced the conversion of CD4+CD25- into 
Tregs and subsequently Treg mediated suppression of anti-tumour immunity (Zheng 
et al., 2004). However, similar problems as those faced with expanding Tregs would 
arise if the conversion, via chronic antigenic stimulation, gave rise to regulatory T 
cell subsets that appeared to be distinct from natural CD25
+
 suppressor cells. 
 
Due to the restraints of obtaining large repeated volumes of healthy PB, future work 
could include investigation into the use of cord blood.  Cord blood is a good source of 
Tregs because it is available in large quantities, most of which is generally disposed 
of.  The proportion of Tregs in this tissue has been shown to be approximately the 
same as that observed in adult blood (Bresatz et al., 2007).  Further to this, Treg work 
has been carried out using buffy coat supplied from the National Blood Service, 
which could be an additional option to overcome any problems with isolation of 
Tregs from healthy volunteers.   
 
Summary:  Identification of Tregs and the ability to distinguish them from other cell 
types was essential and completed successfully.  Regular isolation of Tregs from 
peripheral blood was a fundamental requirement of this PhD.  The development of a 
consistent, in-house assay to accomplish reliable Treg isolation was therefore a 
principal requirement.  The Dynabeads
¨
 Regulatory CD4
+
CD25
+
 T Cell Kit provided 
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consistently reliable isolation of Tregs to a high level of purity and showed little 
contamination of other cell types.  Successful in vitro expansion of isolated Tregs was 
achieved using IL-2 and purified anti-CD28 super agonist.  Expanded Tregs retained 
their phenotype, as evaluated by FACS. 
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CHAPTER 3 Ð MECHANISMS OF SUPPRESSION AND TREG 
FUNCTIONALITY 
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Chronological Framework of Thesis Progression  
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A failure of endogenous tumour surveillance can result in tumour progression via 
active suppression of the anti-tumour immune response.  To recognise how Tregs 
function and understand how they are able to suppress such a wide range of cell 
populations is vital.  This chapter focused on beginning to understand which 
molecular mechanisms are involved in Treg mediated suppression.  Research 
investigated the importance of cell contact dependency and the involvement of 
particular cytokines in Treg-mediated effector cell suppression. 
 
3.1. METHODOLOGY 
3.1.1. Regulatory T Cell Suppression Assay 
The suppressive ability of CD4
+
CD25
+
 Tregs when co-cultured with effector cells is 
a key requirement to show Treg-mediated suppression activity.  Isolated effector cells 
(section 2.1.1.) were seeded at 5 × 104 cells per well in 100 µl suppression media 
(RPMI, 10 % FBS, 0.5 mM Sodium pyruvate, 0.05 mM NeAA, 25 mM HEPES) in a 
96-well round bottom Nunc Tissue Culture Plate (NuclonTM Surface, Cat 163320).  
Isolated Tregs were then added (50 µl) at 0:2, 0:1, 1:0 1:5, 1:10, and 1:20 
Treg:effector cell ratios.  Effector cells were stimulated with 50 µl of Lectin from 
Phaseolus vulgaris (red kidney bean) PHA (Sigma, L1668-5MG) and Prostate mucin 
antigen (PMA) or ConA at 10 µg/ml in a final well volume of 200 µl.  Triplicates of 
stimulated and non-stimulated wells were carried out for all cell ratios.  0:1 and 0:2 
ratios are control wells to illustrate effector cell proliferation, with 0:2 representing 
the highest number of cells seen in any well to examine any restriction in 
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proliferation due to elevated cell number and reduced nutrients.  Cells were cultured 
at 37 ¡C in a humidified atmosphere containing 5 % v/v CO2 for 96 hours.  The 
suppressive ability of Tregs was then determined via various proliferation assays as 
described below. 
 
3.1.1.1. Cell Titer 96®  Aqueous One Solution Cell Proliferation (MTS) 
Assay 
This assay uses a reagent composed of a tetrazolium compound; 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt (commonly called MTS) and an electron-coupling reagent, 
phenazine ethosulfate.  The reagent consists of 1.9 mg/ml MTS and 300 µM PES in 
DulbeccoÕs PBS.  Cells chemically reduce MTS into soluble formazan in tissue 
culture media at 492 nm.  MTS measures dehydrogenase enzyme activity found in 
metabolically active cells and therefore the production of formazan is proportional to 
cell number and intensity is an indication of cell viability.  MTS reagent was added to 
the cell suspension at a 1:5 dilution and incubated for 3 hours.  Cells were quantified 
using spectrometry at 492 nm against a known standard curve of cell number of the 
same cell type.  Prior to the proliferation assay, 100 µl of the supernatant was 
carefully removed from each well and stored at − 80 ¡C until used for enzyme-linked 
immunosorbent assay (ELISA) analysis. 
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3.1.1.2. 3H-Thymidine Radioactive Assay 
[Methyl-
3
H]-thymidine (TRA120 aqueous solutions 37 mBq, 1 mCi, B499 185 
Gbq/mmol 5 Ci/mmol, Amersham) at 0.5 µCi per well was added for the final 18 
hours of a day 5 assay.  Plates were harvested on day 5 and, following the addition of 
scintillation fluid (MicroscintTM PerkinElmer, Cat 6013611), were left to dry at 37 ¡C 
in a humidified atmosphere containing 5 % v/v CO2 for 2 hours prior to being read on 
a Microplate Scintillation & Luminutesescence Counter (TopCount NXTTM, Packard). 
 
3.1.2. Enzyme Linked Immunosorbant Assay (ELISA) 
ELISA assays were carried out to investigate the cytokines present in the supernatants 
of the aforementioned suppression assays.  Prior to the addition of [Methyl-
3
H]-
thymidine, 100 µl of the culture media was carefully extracted from each well.  This 
was then stored at − 80 ¡C until required.  ELISA plates were pre-coated with 
2 µg/ml purified anti-human IL-10 (BioLegend, Clone JES3-12GB, Cat 501501) or 
IFN-γ (BioLegend, Clone NIB42, cat 502401) in coating buffer (0.5 M Tris-HCl, 
pH 8.9) at 50 µl per well and left overnight at 4 ¡C.  Plates were then washed three 
times in PBS Tween (0.05 % v/v Tween 20) followed by a blocking step in 5 % v/v 
Marvel for 30 minutes at 37 ¡C.  Three more wash steps were then carried out before 
plating out a titration of corresponding standard of Recombinant Human IL-10 
(Peprotech, Cat 200-10) and IFN-γ (Peprotech, Cat 300-02) at a top concentration of 
10 ng/ml and a dilution of × 0.5.  50 µl per well of defrosted supernatant was then 
added to the plate and incubated for 1 hour 45 minutes at room temperature.  Four 
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wash steps were then carried out preceding the addition 50 µl per well biotin 
antibodies at 2 µg/ml IFN-γ (BioLegend, Clone 4S.B3, Cat 502504) and 1 µg/ml IL-
10 (BioLegend, Clone JES3-12GB, Cat 501502) and incubated for 1 hour and 30 
minutes at room temperature.  Plates were washed again six times and then 50 µl per 
well Streptavadin HRP (PharMinutesgen, Cat 554066) was added for 30 minutes at 
room temperature.  A further 10 wash steps were carried out prior to the addition of 
50 µl per well HP Solution (1:30 sodium acetate buffer, 1:5 hydrogen peroxide and 1 
mg/ml 3,3),5,5)-tetra methylbenzidine dihydrochloride, in H20) for 5Ð30 minutes.  
The reaction was stopped with 50 µl 2M H2SO4 then read on a MRX plate reader 
(Dynex Technologies) at 450 nm.   
 
3.1.3. Transwell Assay 
Isolated effector cells (see parts 2.1.1. of Treg isolation procedure) were seeded at 
5 × 104 cells per well in 100 µl media in a 96-well Flat Bottom Costar Tissue Culture 
Plate (3513).  Tregs or Karpas-299 cells were then seeded onto membrane inserts 
with a pore size of 0.4 µm (Corning® Transwell
TM
 Permeable Supports) at 1:5, 1:10 
and 1:20 ratios in 50 µl of media.  Effector cells were stimulated with a combination 
of 10 µg/ml PHA in a final well volume of 200 µl.  Triplicates of stimulated and non-
stimulated wells were carried out for all cell ratios.  Plates were then incubated for 96 
hours at 37 ¡C, 5 % v/v CO2.  The suppressive ability of Tregs or Karpas-299 cells 
was then determined via methyl-
3
H-thymidine incorporation as described previously.   
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3.1.4. Method of Statistical Analysis 
Data points were in triplicate and graphically expressed as the mean, where error bars 
depicted standard deviation (SD).  Further analysis was then carried out to quantify 
any trends in the data, using Prism® 5 software.  To analyse the repeat measured data 
within this chapter, a one way analysis of variance (ANOVA) was firstly 
implemented to determine any significant differences.  A TukeyÕs multiple 
comparison post test was then implemented to further distinguish p values between 
data groups. 
 
3.1.5. Ethics Approval 
All samples were acquired with written informed consent and given ethical approval 
by Nottingham Research Ethics Committee, REC reference BT/04/2005, first granted 
in 2005.  
 
3.2. RESULTS AND DISCUSSION 
Tregs are involved in suppressive control of a broad spectrum of immune responses, 
encompassing those against autologous tumour cells, allergens, pathogenic microbes, 
allogeneic organ transplants and the foetus during pregnancy (Miyara and Sakaguchi, 
2007).  CD4
+
CD25
+
 Tregs are potent immuno-suppressors that are critical in the 
maintenance of self-tolerance (Bresatz et al., 2007). 
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The ability of CD4
+
CD25
+
 Tregs to suppress activated T cells has been demonstrated 
clearly in both murine (Sakaguchi et al., 1995) and human (Levings et al., 2001; 
Stephens et al., 2001) studies.  Identification of Foxp3 established a link between the 
CD4
+
CD25
+
 Treg suppression of auto-reactive T cells.  This correlation between 
Foxp3 expression and suppressor function has been well established in murine 
models (Fontenot et al., 2003; Kasprowicz et al., 2003) and to a lesser degree in 
humans (Kuniyasu et al., 2000; Peng et al., 2004). 
 
3.2.1. Suppression Assay Protocol Optimisation 
Human T cell suppressor function may be assayed using isolated human PB Tregs 
and stimulated T effector cells.  Tregs inhibit the proliferation of CD4
+
CD25
-
 effector 
cells, providing an in vitro culture assays model to potentially assess their in vivo 
suppressive ability.  A variety of assay methods have previously been utilised and 
various techniques used to quantify suppression.  Protocol optimisation was therefore 
essential, investigating assay technique, cell populations and effector cell stimulants. 
 
Initially, the Cell Titer 96® Aqueous One Solution Cell Proliferation Assay, utilising 
MTS, was investigated (as described in section 3.1.1.1).  Preliminary experiments 
studied the suppressive effects of CD4
+
CD25
+
 Tregs on stimulated PBMCs (Figure 
3.1).   
 
The MTS experiment required a preliminary cell titration assay in order to extrapolate 
cell number.  The assay investigated 1.5, 2, 3 and 20 hour incubation periods of MTS 
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reagent, in order to determine optimal conditions for subsequent suppression assays 
(data not shown).  It was decided that 3 hours gave optimal results, providing a 
compromise between assay time and reliability.  Suppression assays were then carried 
out to investigate the effects of isolated CD4
+
CD25
+
 Tregs co-cultured stimulated 
PBMCs with ConA (Figure 3.1A) or a combination of PHA and PMA (Figure 3.1B). 
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Figure 3.1 Treg Suppression of ConA or PHA/PMA Stimulated PBMCs, MTS 
 
CD4
+
CD25
+
 Tregs and peripheral blood mononuclear cells (PBMCs) were isolated from 
50 ml blood from a healthy volunteer, as previously described.  PBMCs, stimulated with 
either A) Concavalin A (ConA) or B) a combination of Phytohemaglutinin (PHA) and Prostate 
mucin antigen (PMA), were plated at 5 x 10
4
 cells per well.  CD4
+
CD25
+
 cells were then 
added at 0:2, 0:1, 1:0, 1:5, 1:10 and 1:20 Treg:PBMC cell ratios.  Cells were cultured at 37 ¡C 
in a humidified atmosphere containing 5 % v/v CO2 for 96 hours.  A 1:5 dilution of MTS 
reagent was added for 3 hours and suppression quantified using a spectrometry at 492 nm 
against a known standard curve of PBMC cell number.  Results were evaluated using Prism 
5.  Data are a mean of triplicates from a single plate (± SD), statistically analysed using a one 
way ANOVA and Tukey's multiple comparison post-test (ns). 
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Results indicated a lack of significant Treg suppressive activity against stimulated 
PBMCs with both ConA and PHA/PMA.  The MTS read out was very low and made 
extrapolation of cell number difficult.  It was therefore decided to use isolated 
CD4
+
CD25
-
 effector cells to increase suppression susceptibility (Figure 3.2). 
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Figure 3.2 Treg Suppression of ConA or PHA/PMA Stimulated Effector Cells, MTS 
 
CD4
+
CD25
+
 Tregs and CD4
+
CD25
-
 effector cells were isolated from 50 ml blood from a 
healthy volunteer as previously described.  CD4
+
CD25
-
 cells, stimulated with either A) 
Concavalin A (ConA) or B) a combination of Phytohemaglutinin (PHA) and Prostate mucin 
antigen (PMA), were plated at 5 x 10
4
 cells per well.  CD4
+
CD25
+
 cells were then added at 
0:2, 0:1, 1:0, 1:5, 1:10 and 1:20 Treg:effector cell ratios.  Cells were cultured at 37 ¡C in a 
humidified atmosphere containing 5 % v/v CO2 for 96 hours.  A 1:5 dilution of MTS reagent 
was added for 3 hours and suppression quantified using a spectrometry at 492 nm against a 
known standard curve of effector cell number.  Results were evaluated using Prism 5.  Data 
are a mean of triplicates from a single plate (± SD), statistically analysed using a one way 
ANOVA and Tukey's multiple comparison post-test (ns). 
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Again results were disappointing, showing no effect when stimulated with ConA and 
only general trends of suppression against PHA/PMA stimulated effector cells but no 
significant results.  It was thus decided to continue with PHA alone as a stimulant and 
change the technique used to quantify cell proliferation and suppression.  A 
3
H-
thymidine incorporation assay was therefore used, where co-cultures were pulsed 
with 0.5 µCi of [Methyl-
3
H]-thymidine for the final 18 hours of the assay.  
3
H-
thymidine is incorporated into replicating cells, providing a readout of proliferation 
and therefore allows measurement of suppression (Figure 3.3). 
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Figure 3.3 Treg Suppression of PHA Stimulated Effector Cells, via 3H-Thymidine 
Incorporation 
 
CD4
+
CD25
+
 Tregs and CD4
+
CD25
-
 effector cells were isolated from 50 ml blood from a 
healthy volunteer as previously described.  CD4
+
CD25
-
 cells were plated at 5 x 10
4
 cells per 
well with CD4
+
CD25
+
 cells at 0:2, 0:1, 1:0, 1:5, 1:10 and 1:20 (Treg:effector cell ratios) and 
stimulated with 10 µg/ml Phytohemaglutinin (PHA).  Cells were cultured at 37 ¡C in a 
humidified atmosphere containing 5 % v/v CO2 for 96 hours.  Wells were pulsed with 0.5 µCi 
of [Methyl-3H]-thymidine for the final 18 hours of the assay before harvesting and thymidine 
incorporation quantified on a Microplate beta Scintillation Counter.  Data are a mean of 
triplicates from a single plate (± SD), statistically analysed using a one way ANOVA and 
Tukey's multiple comparison post test (** p < 0.01, *** p < 0.001).  Data are representative of 
three different experiments, where A), B) and C) show variation between donors.   
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When cultured, CD4
+
CD25
-
 cells responded with robust proliferation in the presence 
of PHA, whereas the CD4
+
CD25
+
 cells did not.  Co-culture of the two populations 
resulted in a significant reduction in the level of proliferation, as measured by 
[Methyl-
3
H]-thymidine incorporation.  The level of suppression correlated with the 
ratio of CD4
+
CD25
-
:CD4
+
CD25
+
 cells in the culture, with more CD25
+
 cells resulting 
in increased levels of suppression of CD25
-
 cell proliferation.  Suppression was not 
due to exhaustion of nutrients within the well as addition of the same amount of 
CD25
-
 cells instead of CD25
+
 cells did not cause suppression (! 2 CD25
- 
control).  
These results are robust and representative of three experiments, comparing the same 
and different cell donors, and findings are in agreement with previous literature 
(Apostolou and von Boehmer, 2004).  The suppressive function of CD4
+
CD25
+ 
T 
cells was demonstrated in vitro by inhibiting approximately 80 % of CD25
- 
cell 
proliferation when at a ratio of one CD25
+
 T cell to four CD25
-
 T cells (Read et al., 
1998; Takahashi et al., 1998; Thornton and Shevach, 1998). 
 
3.2.2. Suppression by Inhibitory Cytokines  
Various molecular and cellular events have been described to explain the 
mechanism(s) of Treg mediated suppression.  However, none of the proposed 
mechanisms can explain all aspects of suppressive activity.  It is possible that various 
combinations of several mechanisms are operating, depending on the milieu and the 
type of immune responses. 
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To further understand how CD4
+
CD25
+ 
Tregs function to inhibit effector T cells, 
ELISA assays were carried out on the supernatants of suppression cultures.  100 µl of 
supernatant was carefully extracted from the suppression assay cultures prior to 
[Methyl-
3
H]-thymidine incorporation and assayed for relevant cytokines. 
 
Inhibitory cytokines such as IL-10 have been the focus of considerable attention as 
mediators of Treg-induced suppression.  Although the general importance of IL-10 as 
a suppressive mediator is undisputed, its contribution to the function of naturally 
occurring Tregs is still a matter of debate.  An ELISA was carried out to investigate 
the amount of IL-10 present in the supernatant of suppression assay wells (Figure 
3.4). 
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Figure 3.4 IL-10 ELISA of Supernatants from Treg Suppression of PHA Stimulated 
Effector Cells 
 
100 µl of supernatant was carefully removed from the wells of the CD4
+
CD25
+
 Treg 
suppression assay.  ELISA plates were pre-coated with purified anti-human IL-10 antibody 
overnight, followed by a blocking step in 5 % Marvel.  50 µl per well of supernatants were 
added, along with a titration of recombinant human IL-10 standard for 120 minutes.  Biotin 
anti-human IL-10 antibody was then added (90 minutes) followed by a Streptavadin HRP 
incubation step for 30 minutes.  Plates were developed using HP Solution for 5Ð30 minutes 
and stopped with 2M H2SO4 prior to reading on a MRX plate reader at 450 nm. Results were 
evaluated using Prism 5.  Data are a mean of triplicates from a single plate (± SD), 
statistically analysed using a one way ANOVA and Tukey's multiple comparison post-test 
(* p < 0.05, ** p < 0.01, *** p < 0.001).  Data are representative of three different experiments, 
where A), B) and C) show variation between donors.   
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An interesting trend was observed, showing elevated levels of IL-10 in CD4
+
CD25
- 
effector cell only wells (CD4
+
CD25
- 
! 1, CD4
+
CD25
- 
! 2) and reduced levels of IL-
10 in CD4
+
CD25
+ 
Treg wells.  Levels of IL-10 increased when Treg numbers were 
reduced (Figure 3.4).  This trend was observed in three experiments and does not 
support the idea that IL-10 is involved in Treg-mediated suppression.  There are 
discrepancies within the literature with regards to whether or not Tregs secrete IL-10.  
In contrast to what is normally reported on IL-10 secretion by Tregs, but in 
agreement with the current study, Baecher-Allan and Hafler (2006) found that 
effector cells, stimulated with strong TCR activation, primarily produced IL-10.  In 
addition, IL-10 was found to be higher in the supernatant from effector cells 
compared to that observed from effector-Treg cocultures and was absent from wells 
containing only Tregs.  The authors concluded that Tregs were inhibiting IL-10 
production or utilising the IL-10 within the supernatant (Baecher-Allan and Hafler, 
2006). 
 
In vitro studies using neutralising antibodies or T cells unable to produce or respond 
to IL-10 have suggested that IL-10 may not be essential for Treg function, and IL-10 
deficient Tregs were still capable of suppression.  However, this is in contrast to data 
from in vivo studies, that indicated Treg mediated suppression is IL-10 dependent 
(Roncarolo et al., 2006).  
 
Collectively, the picture that appears to be emerging is that IL-10 production by 
Tregs is still debated and contradicting data has been published on the relative 
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importance of IL-10 as a mechanism of Treg-mediated suppression.  It is however 
agreed that IL-10 is not the only Treg mechanism of suppression and it can be 
speculated that its role may be dependent on the target organism or disease. 
 
In addition to IL-10, the classical pro-inflammatory cytokine, IFN-γ, was 
investigated.  IFN-γ is secreted by Th1 cells, NK cells, and by CD4 and CD8 CTL 
effector cells following immune activation.  IFN-γ produces a variety of 
physiological and cellular response via transcription regulation, resulting in 
immunoregulatory and anti-tumour properties (Schroder et al., 2004).    
 
A significant increase of IFN-γ was observed in the presence of Tregs and subsequent 
suppression (Figure 3.5).  This was unexpected as IFN-γ production is associated 
with proliferation of stimulated effector cells (Byeon et al., 2009), and it is thought 
that Tregs inhibit its production (Ghiringhelli et al., 2006). 
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Figure 3.5 IFN-gamma ELISA of Supernatants from Treg Suppression of PHA 
Stimulated Effector Cells 
 
100 µl of supernatant was carefully removed from the wells of the CD4
+
CD25
+
 Treg 
suppression assay.  ELISA plates were pre-coated with purified anti-human interferon-γ (IFN-
γ) antibody overnight, followed by a blocking step in 5 % Marvel.  50 µl per well of 
supernatants were added, along with a titration of recombinant human IFN-γ standard for 120 
minutes.  Biotin anti-human IFN-γ antibody was then added (90 minutes) followed by a 
Streptavadin HRP incubation step for 30 minutes.  Plates were developed using HP Solution 
for 5Ð30 minutes and stopped with 2M H2SO4 prior to reading on a MRX plate reader at 
450 nm.  Data are a mean of triplicates from a single plate (± SD), statistically analysed using 
a one way ANOVA and Tukey's multiple comparison post test (*** p < 0.001, * p < 0.05).  
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Data are representative of three different experiments, where A), B) and C) show variation 
between donors.   
The author would like to suggest that perhaps the reason behind this unexpected IFN-
γ profile is due to the use of PHA as a stimulant.  Antigenic TCR engagement results 
in no subsequent Treg activation; however, mitogenic PHA stimulation could by-pass 
normal cell signalling activation pathways and result in activation of downstream 
components, such as nuclear factor kappa B (NFκB) (Long et al., 2009; Niederman et 
al., 1992). 
 
Research has highlighted discrepancies in the involvement of various cytokines in 
Treg suppression.  It then begs the question, if cytokines only play a partial role in 
Treg mediated suppression, are additional cell-to-cell contact-dependent mechanisms 
playing a more significant role? 
 
3.2.3. Cell-Cell Contact Dependent or Independent? 
The unusual cytokine profile and inconsistencies in cytokine involvement described 
previously led to the investigation of additional suppressive mechanisms, specifically 
focusing on the concept of cell-contact mediated suppression.  In order to investigate 
whether cell-to-cell contact is a requirement for Treg suppression, a transwell system 
was designed (Figure 3.6). 
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Figure 3.6 Diagrammatic Representation of the Transwell System 
 
Stimulated effector cells were seeded at 3 x 10
4
 cells per well in 1.5 ml of media into the 
lower chamber.  CD4
+
CD25
+
 Tregs were then added onto the 0.4 µm membrane insert 
(Corning Transwell
TM
) in 500 µl media at various Treg:effector cell ratios. 
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A direct comparison between the two assay systems was investigated using isolated 
effector cells and Tregs, from the same donor, on the same day.  The co-cultured 
environment of the suppression assay (described previously) was removed in the 
second assay, eliminating cell-to-cell contact between effector and Tregs via the 
transwell system.  The suppression activity was measured using 
3
H-thymidine 
incorporation and levels of cytokines investigated using ELISAs (Figure 3.7). 
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Figure 3.7 Transwell Suppression Activity of Tregs  
 
Isolated effector cells stimulated with 10 µg/ml PHA were seeded at 5 x 10
4
 cells per well in 
100 µl of media into the lower chamber of the transwell system.  CD4
+
CD25
+
 Tregs were 
then added onto the 0.4 µm membrane insert (Corning Transwell
TM
) in 50 µl media seeded at 
1:5, 1:10 and 1:20 Treg:effector cell ratios.  A) Transwell and B) normal suppression was 
accessed via 
3
H-Thymidine incorporation.  C) The presence of IL-10 and D) IFN-γ was 
determined using an ELISA on well supernatants.  Data are a mean of triplicates from a 
single plate (± SD) and is representative of n = 3 experiments, statistically analysed using a 
one way ANOVA and Tukey's multiple comparison post test (* p < 0.05, ** p < 0.01). 
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Results show a lack of significant Treg-mediated suppression when cultured in a 
transwell system, compared to the suppression observed when co-cultured with 
effector cells.  The levels of IL-10 and IFN-γ present within the supernatants were 
very low and showed no general trends.  The transwell system removes both cell-to-
cell contact and also close cell proximity.  These studies have demonstrated that in 
vitro CD4
+
CD25
+
 cells suppress co-cultured effector cells via a mechanism involving 
cell contact or close proximity.  These results are in agreement with previous 
literature indicating that Treg-mediated suppression is cell contact dependent, as 
suppression was not seen when CD25
+
 Treg and CD25
-
 effector cells were separated 
by a permeable membrane (Nakamura et al., 2004; Tanchot et al., 2004; Thornton 
and Shevach, 1998).  Several mechanisms responsible for suppression have been 
proposed but the topic still remains controversial and requires further work (Zimmer 
et al., 2008). 
 
3.2.4. A Surrogate Cell Line? 
Due to the limited numbers of Tregs and difficulties with isolation, a replacement cell 
line would be favourable for use in preliminary studies and optimisation.  A cell line, 
designated Karpas-299, was established from blast cells from the peripheral blood of 
a 25-year-old male with T cell non-Hodgkin lymphoma.  Research has suggested that 
the Karpas-299 are able to suppress PHA/PMA stimulated effector cells and express 
Treg markers such as CD25, Foxp3, CD62L and TGF-β (Wolke et al., 2006).  
Therefore, it is possible that this cell line could act as a surrogate Treg for in vitro 
experiments. 
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The suppressive ability of the Karpas-299 cell line when co-cultured with effector 
cells is a key requirement to show Treg-like properties.  Due to the allogeneic effect a 
co-culture would cause, the transwell system was implemented.  Corning® 
Transwell
TM
 Permeable Supports enabled the two different cell types to be cultured 
within the same well without direct cell-to-cell contact. 
 
Unlike Tregs, Karpas-299 cells are not anergic in vitro and so proliferate excessively 
by themselves (Figure 3.8A).  In a co-culture situation this would greatly affect the 
suppression assay readout as no distinction is made between the two cell populations; 
however, in a transwell system only the lower chamber containing the effector cells 
undergo 
3
H-thymidine incorporation for suppression measurement.  However, even 
with elevated Karpas-299 cell numbers, no significant suppression of PHA-stimulated 
effector cells was observed.  FACS analysis of the Karpas-229 cells showed positive 
staining for CD4 and CD25; however, Foxp3 remained negative (Figure 3.8B).   
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Figure 3.8 Transwell Suppression Activity of Karpas-299 Cell Line with FACS Analysis 
 
A) Isolated effector cells stimulated with 10 µg/ml PHA were seeded at 5 x 10
4
 cells per well 
in 100 µl of media into the lower chamber of the transwell system.  Karpas-299 cells were 
then added onto the 0.4 µm membrane insert (Corning Transwell
TM
) in 50 µl media seeded at 
1:5, 1:10 and 1:20 Karpas:effector cell ratios.  Suppression was accessed via 
3
H-Thymidine 
incorporation.  Data are a mean of triplicates from a single plate (± SD) and is representative 
of n = 3 experiments.  B) 1 x 10
6 
Karpas cells were removed for FACS analysis.  A pre-
titrated volume of the following surface antibodies was added; PeCy5 anti-CD4, ECD anti-
CD3 and PE anti-CD25.  Cells were then fixed and permeabilised followed by intracellular 
staining using Alexa 488 anti-Foxp3.  Data were acquired on a Beckman Coulter FC 500 flow 
cytometer and analysed using Weasel software. 
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In addition, previous transwell suppression work showed that this system was not 
suitable for measurement of Treg suppression and therefore concerns would arise if 
using the Karpas-299 cell line as a Treg replacement.  Different mechanisms must be 
involved in order to have a suppressive effect, which leads to the question: would it 
be a representative surrogate cell line? 
 
3.3. CONCLUSIONS AND FUTURE WORK 
Despite some safety concerns and a popular trend to move away from the use of 
radiation techniques, tritiated thymidine incorporation provided the most sensitive 
and reproducible assay to determine Treg-mediated suppression of immune cell 
proliferation.  To investigate the suppressive ability of Tregs, a reciprocal immune 
cell population was required.  Utilising a mixed PBMC population for this role was 
not successful; however, isolation of a CD25
-
 population worked well, when 
stimulated with PHA. 
 
The current study highlighted discrepancies in the involvement of pro-inflammatory 
and suppressive cytokines in Treg-mediated suppression.  The use of antigenic 
instead of mitogenic stimulation could provide further understanding in this area and 
therefore scope for future research.  However, when further investigating Treg 
suppression in a transwell system, results suggest that in vitro CD4
+
CD25
+
 Tregs 
suppress effector cells via a mechanism involving cell contact or close proximity.  
Research is in agreement with previous literature but the topic still remains 
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controversial and could require additional investigation (Nakamura et al., 2004; 
Tanchot et al., 2004; Thornton and Shevach, 1998). 
 
A surrogate cell line to replace difficulties in Treg isolation and limited numbers 
would be desirable.  Unfortunately, the Karpas-299 cell line did not show a 
significant trend in Treg-like suppression of stimulated effector cells and lacked 
Foxp3 expression.  In addition, the Karpas-299 cell line would need to be utilised in a 
transwell system; an assay already determined not appropriate in the understanding of 
Treg-mediated suppression mechanisms. 
 
Summary:  Protocol optimisation demonstrated that Ôin vitroÕ CD4
+
CD25
+
 cells 
suppression of PHA stimulated effector cells was favourable and [Methyl-
3
H]-
thymidine incorporation was the most sensitive technique.  The current study has 
shown that the role of cytokines in Treg-mediated suppression is still unclear and 
requires further investigation.  However, classical CD4
+
CD25
+
 Tregs are thought to 
suppress via a cell contact-mediated mechanism.  Despite what previous literature 
suggests, the Karpas-299 cell line does not suppress CD4
+
CD25
-
 effector cells, a key 
requirement for a surrogate Treg cell line.   
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CHAPTER 4 Ð IMMUNE INFILTRATES AND TUMOUR 
PROGRESSION 
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Chronological Framework of Thesis Progression  
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At this stage in the PhD a foundation of knowledge, understanding the importance of 
Tregs in tumour immunology, was achieved.  Tregs were selected as the prime 
candidate for modulating tumour immunology.  The successful isolation and ways to 
work with Tregs was accomplished.  In addition, hypothesised Treg-mediated 
mechanisms of suppression were tested.  It was then necessary to determine whether 
or not the importance of Tregs highlighted in the literature was reflected in a clinical 
setting.  The tumour microenvironment is thought to provide a favourable milieu for 
Treg expansion, where elevated numbers of Tregs result in an imbalance within the 
immune system.  Research has advocated that this imbalance favours 
unresponsiveness and facilitates tumour escape of immune recognition.  Questions 
remain unanswered with regards to the importance of immune cell location at the 
tumour site.  This chapter aimed to investigate the significance of immune cell 
orientation within distinct tumour and non-neoplastic regions.  Additionally, the 
implication of co-localisation between key immune cell subtypes was scrutinised.  
Immune cell infiltrates were then correlated with areas of tumour proliferation, 
apoptosis, hypoxia and vasculature coverage. 
 
4.1. METHODOLOGY 
4.1.1. Cell Pellet Preparation 
The cells of interest, for example Tregs, were isolated from 50 ml healthy blood as 
previously described.  Cells were then fixed in 4 % formaldehyde for 24 hours and 
centrifuged at 350 ! g for 5 minutes.  Cells were then washed in PBS followed by a 
second wash in 80 % ethanol.  Cells were finally centrifuged at 350 ! g for 5 minutes 
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and the cell pellet re-suspended in molten histogel (HG 4000-012, Thermo 
Scientific).  This uniform mixture was transferred to an eppendorf lid and allowed to 
set.  The cell pellet was then loosened with a clean probe and stored in 80 % ethanol 
until processing.   
 
4.1.2. Histology Specimen Processing and Embedding 
Tissue or cell pellets were processed on a Shandon Excelsior Tissue Processor 
(Thermo Electron Corporation), following the manufacturerÕs instructions.  In brief, 
specimens were fixed in 4 % formaldehyde for 24 hours and then placed into RA 
Lamb Embedding Cassettes (Thermo Scientific, 83500).  Cassettes were then loaded 
into the processor and underwent the following program (Table 4.1). 
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Table 4.1 A Summary of the Tissue Processing Programme Used 
 
 
 
Helen Angell   122 
On completion of the processing program, specimens were embedded on a Shandon 
Histocentre 3 (Thermo Electron Corporation).  Low melting point and polymer-free 
paraffin cell wax (Cell Path Plc., GCA-0302-00A) was used in embedding moulds.  
When dry, blocks were trimmed of excess wax using a Shandon PARA TRIMMER
¨
 
and left overnight to solidify.   
 
4.1.3. Section Cutting  
Prior to cutting, specimen blocks were placed on ice for 30 minutes.  Superfrost® Plus 
slides (VWR International, 081610-9, 25 × 75 × 1.0 mm) were printed on a Leica IP5.  
4.0 µm thick sections were cut using a Leica RM2255 Microtome with a Shandon 
MB35 Premier Microtome Blade (35¡/80 mm, Thermo Electron Corporation).  
Sections were then placed in a Leica HI1210 water bath to spread before being 
transferred onto the corresponding slide and moved to a heat block to dry.  Sections 
were then left overnight at 37 ¡C to fix to the slide.   
 
4.1.4. Haematoxylin and Eosin (H&E) 
Slides were dewaxed and rehydrated using a Leica Autostainer XL.  In brief, this 
involved a series of wash steps firstly in two xylene (Sigma-Aldrich, 33817) baths 
followed by two 100 % ethanol (UK IDA standard, Sigma-Aldrich, 458600) baths, 
one 70 % ethanol bath and finally a water bath.  Sections were stained with CarazziÕs 
Haematoxylin Gill III (Surgipath, 01540BBE), followed by a wash step in Shandon 
Bluing Reagent (Thermo Scientific, 6769002).  Finally, the slides were introduced to 
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Eosin (alcoholic solution, Leica Microsystems, 01600BBE) before being dehydrated 
in ethanol and cleared using xylene on a Leica Autostainer XL.  Slides were mounted 
using Premier Cover Glass slips (24 mm ! 50 mm, Surgipath
¨
) with Histomountª 
(National Diagnostics, HS-103) on a Leica CV5030 and left to dry prior to viewing 
on a Leica DM4000B microscope. 
 
4.1.5. Immunohistochemistry 
Slides were dewaxed and rehydrated using a Leica Autostainer XL.  Following this, 
where appropriate, antigen retrieval was performed using a pressure vessel in a RHS2 
Microwave Rapid Histoprocessor (Milestone).  The appropriate target retrieval 
solution was added, pH6 (Dako, S1699), pH8 EDTA or pH9 (Dako, S2367).  Slides 
were heated to 110 ¡C for 5 minutes and then cooled under running water for 15 
minutes.  The Autostainer 720 (Lab Vision) was then used to perform all antibody 
stains, washes and block steps, where antibodies were made up in tris-buffered saline-
tween (0.05 %, TBS-T).  On completion of the pre-treatment process, sections were 
marked with an upper and lower boundary, using a waterproof pen (Dako, S2002) 
and pre-rinsed in TBS-T.  3 % H2O2 was applied for 10-20 minutes at room 
temperature to block endogenous peroxidase activity.  Slides were washed twice in 
TBS-T.  Avidin block (Vector Labs, SP-2001) was applied for 20 minutes followed 
by a TBS-T wash.  Biotin Block (Vector Labs, SP-2001) was applied for 20 minutes 
followed by an additional TBS-T wash.  Slides were incubated for 20 minutes with 
serum-free protein block (Dako, X0909), which was then blown off the slides (a wash 
step was not performed at this stage).  Sections were incubated with primary antibody 
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for 60 minutes.  The current study used the following antibodies at the corresponding 
optimised concentrations: mouse anti-human Foxp3 IgG1 (5 µg/ml, Clone 236A/E7, 
Abcam 20034), mouse anti-human CD8 IgG2b (0.5 µg/ml, Clone 4B11, Leica NCL-
CD8-4B11), mouse anti-human CD56 IgG1 (0.5 µg/ml, Clone 1B6, Leica NCL-L-
CD56-1B6), mouse anti-human Ki67 IgG1 (0.35 µg/ml, Clone MIB-1, Dako M7240), 
mouse anti-human CD68 IgG1 (0.2 µg/ml, Clone PG-M1, Dako M0876), rabbit anti-
human CD31 (0.27 µg/ml, CHG-CD31-PI, AstraZeneca in house), rabbit anti-human 
cleaved caspase-3 (5 µg/ml, Clone D175, Cell Signalling Technology 9661), mouse 
anti-human α-SMA IgG2a (2 µg/ml, Clone 1A4, Sigma A2547) and mouse anti-
human  HIF-1α, IgG1 (5 µg/ml, Clone 54, Becton Dickinson 610950).  Following the 
primary antibody incubation, slides were washed twice in TBS-T.  Slides were 
incubated with the optimised detection methods: Vector Elite ABC kit (PK6101) or 
Mouse/Rabbit Envision HRP-linked polymer (Dako, K4001), for 30 minutes.  When 
using the Envision HRP-linked detection method, previous avidin and biotin blocking 
steps were not required.  Slides were washed twice in TBS-T and then incubated in 
3,3-Diaminutesobenzidine (DAB, D/K3468) solution for 10 minutes.  Slides were 
rinsed twice in distilled water and removed from the autostainer.  Sections were 
counterstained with CarazziÕs Haematoxylin Gill III (Surgipath, 01540BBE), 
dehydrated in ethanol and cleared using xylene, all carried out on the Leica 
Autostainer XL.  Slides were then mounted using Premier Cover Glass slips (24 mm 
× 50 mm, Surgipath
¨
) with Histomountª (National Diagnostics, HS-103) on a Leica 
CV5030 and left to dry before viewing on a Leica DM4000B microscope.   
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4.1.6. Image Analysis 
Analysis of IHC images was achieved using a ScanScope digital scanner (Aperios 
Technologies Ltd.) and images were taken at x 20 original magnification.  Images 
were viewed and organised using ImageScope viewer and Spectrum operating 
system.  Each scanned image was annotated for analysis to exclude areas of glass, 
dark background staining or poor sample quality.  Genieª pattern recognition 
software was used for the automated quantitative assessment of immune infiltrates 
within specific regions of tissue.  Genieª classifiers were generated for the 
separation of areas of tumour, stroma, lymphatic aggregates, non-neoplastic tissue 
and glass (as described in section 4.2.3).  
 
4.1.7. Ethics Approval 
All samples used were sourced from the AstraZeneca Alderley Park Biobank, which 
is a licenced premises under the Human Tissue Act (2004) (HTA number 12109) and 
has NRES ethical approval as a tissue bank (07/MRE08/29).  All third party providers 
to the Alderley Park Biobank have passed an approval process at AstraZeneca and all 
samples were acquired by those providers with written informed consent. 
 
4.1.8. Method of Statistical Analysis 
Data were collated into certain groups and graphically expressed as the mean, where 
error bars depicted SD.  Further analysis was then carried out to quantify any trends 
in the data, using Prism® 5 software and Spotfire® programmes.  Paired data 
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underwent a t-test to determine any significant differences.  If the data assumed a 
normal distribution pattern, a paired or unpaired t-test was carried out.  If the data did 
not assume a normal distribution pattern, a ranked method was selected.  For paired 
rank testing a Wilcoxon test was carried out.  For unpaired rank testing a Mann-
Whitney analysis was used.   
 
4.2. RESULTS AND DISCUSSION 
It is becoming increasingly apparent that tumours contain various cells from the 
immune system, including inflammatory infiltrates of innate immunity (macrophages, 
neutrophils, NK cells and DCs) and also infiltrates of the adaptive immune response 
(B lymphocytes, cytotoxic T cells and Tregs) (Pages et al., 2008).  GalonÕs group 
were one of the first to characterise tumour-infiltrating immune cells, specifically 
CD45RO memory T cells, in large cohorts of human CRCs and solidified the 
association between tumour progression and inflammation (Pages et al., 2005).  
These tumour infiltrating immune cells live in a milieu of chemokines and cytokines 
produced by the tumour cells and stromal cells, as well as the immune cells 
themselves.  Interactions between tumour cells and immune infiltrates are complex 
and result in a balance between tumour promotion and tumour suppression.  
Increasing evidence supports the idea that immune infiltration into the tumour 
microenvironment could result in a strong parameter influencing clinical outcome, 
regardless of the tumour stage (Pages et al., 2008).   
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The involvement of the immune system in the early stages of metastasis has been 
studied histologically using tissue microarrays to investigate the in situ adaptive 
response in the centre and margin of 415 CRC tumours.  Early stages of the 
metastatic process, including vascular emboli, lymphatic invasion and perineural 
invasion, have been collectively termed ÒVELIPIÓ.  Negative VELIPI were seen to be 
associated with strong immune infiltrates that gave longer DFS and OS in patients 
(Pages et al., 2005).  The type, density and location of immune cells was also studied 
in CRC.  When CD3, CD8, CD45RO and granzyme B (GZB) were looked at in the 
centre of the tumour (CT) and at the invasive margin (IM), patients without 
recurrence of disease had higher immune cell densities (Galon et al., 2006; Pages et 
al., 2008).  Potential implications of these findings have been reviewed (Galon et al., 
2007) and their prognostic significance investigated (Pages et al., 2008).   
 
The immune sytems association with areas of tumour proliferation (Ki67) and 
apoptosis (M30) in 435 samples of primary CRC was assessed by 
immunohistochemical staining (Camus et al., 2009).  CD8/CD3 T cell density ratio 
was investigated in relation to clinical outcome and high proportions of CD8 
cytotoxic T cells within the primary tumour was associated with reduced risk of 
relapse (Camus et al., 2009).  A comparison between patients presenting no 
metastases (MET- stages IÐII), patients with invaded lymph nodes (MET+ stage III) 
and/or distant organ metastases (stage IV) was achieved.  Patients were classified 
according to the mean percentage of CD3
+
CD5
+
 cells among total cells within 
tumours (CD3
+
CD5
+
Hi or CD3
+
CD5
+
 Lo).  Large-scale FACS analysis showed no 
difference in the distribution of TAMs, NK cells, NKT cells, or B cells between 
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MET
-
Lo and MET
+
Lo patients.  However, MET
+
Hi patients showed significantly 
lower levels of TAMs, cytotoxic T cells (CD3
+
CD8
+
) and NKT cells density 
compared with MET
-
Hi patients.  No significant difference was seen between TH 
cells (CD3
+
CD4
+
) or Tregs (CD4
+
CD25
hi
).  CD8
+
/CD4
+
 and CD8
+
/CD3
+
 cell ratios 
were significantly higher in MET-Hi patients compared with MET
+
 Hi and MET
+
 Lo 
patients (Camus et al., 2009).   
 
The extent of the immune reaction at the tumour site also correlates with clinical 
outcome in stages I and II of CRC (Pages et al., 2009).  An excellent review, 
summarising the work over the last decade, has recently been published and 
highlights the key questions that still remain (Pages et al., 2010).  The question of the 
prognostic role of Tregs in human CRC appears to be complex and ambiguous.  
Curiel et al., (2004) reported that the increase in Tregs correlated with tumour staging 
and reduced survival in ovarian carcinoma (Curiel et al., 2004).  Subsequent data are 
in agreement with this in other solid tumours such as NSCLC (Woo et al., 2001), 
gastric (Mizukami et al., 2008b) and hepatocellular carcinoma (HCC) (Fu et al., 
2007).  In contrast to this, data has accumulated suggesting that elevated Tregs may 
not always be associated with poor prognosis.  For example Salama et al., (2009) 
reported an increase in Foxp3 density within the tumour associated with better OS 
(Salama et al., 2009).  Galons group found no association between Foxp3, CTLA-4, 
GITR, IL-10, TGF-β and the presence of intratumoural or distant metastasis (Pages et 
al., 2008).     
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The clinicopathologic significance of Tregs and CD8 cells during 
hepatocarcinogenesis has also been studied and the prevalence of Tregs was 
suggested as an unfavourable prognostic marker (Kobayashi et al., 2007).  The 
infiltration of Tregs and CD8 cells between HCC and primary hepatic 
adenocarcinoma, intrahepatic cholangiocarcinoma (ICC) as well as between primary 
and metastatic liver tumours was studied.  In addition, 59 patients with metastatic 
liver tumours from primary CRC were evaluated for Treg prevalence.  Analysis of the 
antitumour response (Tregs and CD8 T cells) in primary HCC (n = 235), intrahepatic 
metastatic foci (n = 27) and liver metastasis from primary CRC (n = 59) was 
evaluated.  The prevalence of Tregs was higher in primary tumours than metastatic.  
Tregs were elevated in HCC compared to non-tumour tissue or healthy liver samples, 
where low-Treg groups showed improved OS and DFS compared to high-Treg 
groups (Kobayashi et al., 2007).  Analysis of additional immune infiltrates such as 
CD3, CD8, CD45RO, GZE, CD57 (cytotoxic T cells and NK cells), CD1a (immature 
DCs), cytokeratin-8, T-Bet (TH1 cells) and CD68 (macrophages) has been assessed 
and associated with survival in CRC (Mlecnik et al., 2010a).  Extensive work was 
achieved using a platform of techniques (gene expression, phenome mapping, 
immunohistochemistry (IHC) of TMAs and T cell TCR repertoire) to identify 
immune-related genes associated with patient prognosis and absence of tumour 
recurrence.  The phenotypes and locations of intratumoral immune cells were 
assessed for correlations with DFS.  The evaluation of Tregs, however, was absent 
from the study.   
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Ratios of immune cells have also been studied, such as CXCR3/Foxp3 ratio (Ohtani 
and Yoshie, 2010) and CD8/Foxp3 cell ratio as a predictive marker for survival in 
CRC (Suzuki et al., 2010). 
 
In CRC, T cells are distributed in different tumoral areas; in the CT within the stroma 
and tumour glands, at the IM, and in lymphoid structures resembling germinal centres 
at the tumour periphery.  More precise analysis of Tregs within the tumour 
microenvironment is required, including investigation of their location in the CT and 
IM of the tumour, the proportions of Tregs versus helper and cytotoxic T cells and 
their role in metastatic development.  Tumour-infiltrating immune cells have been 
analysed in detail by gene-expression profiling and flow cytometry; however, gaps in 
the literature are apparent when looking at in situ co-localisation of CD8 cells, NK 
cells, Tregs and macrophages by IHC. 
 
The current study aimed to determine in a large cohort of CRC patients whether the 
functional orientation, density, and co-localisation of immune cell populations within 
distinct tumour territories (CT, IM, stroma) change with areas of tumour 
proliferation, apoptosis or hypoxia and to evaluate any changes between primary 
CRC and metastatic liver patients. 
 
4.2.1. Immunohistochemistry Antibody Optimisation 
Initially, staining protocol optimisation was a fundamental requirement.  To aid in 
this process, various cell pellet plugs were made to provide positive and negative 
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controls.  Immune cells were isolated from human PB as previously described and 
then prepared to form a paraffin embedded pellet (Figure 4.1). 
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Figure 4.1 Cell Pellet Procedure for Optimisation of IHC Staining  
 
Immune cells were isolated from 50 ml blood from a healthy volunteer, as previously 
described, or cultured cell lines were harvested.  Cells were counted and 1 x 10
6
 removed for 
FACS analysis.  The remaining cells were resuspended in agarose and allowed to set, 
forming a pellet.  This pellet was then embedded into a paraffin block for IHC staining 
protocol optimisation.  Sections were then used for staining optimisation.  Example images 
(at x 20 original magnification) showing K562 cells stained with A) H & E, B) anti-human Ki67 
antibody and C) isotype control. 
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This process was carried out for CD4
+
CD25
+
 Tregs, CD25
- 
cells, CD8
+
 cells, CD56
+
 
cells and CD8
-
CD56
-
 cells.  In addition, an unrelated cell line, K562, was also used to 
provide a true negative control. 
 
Example staining images of the CD4
+
CD25
+
 Treg pellet and CD25
-
 Effector control 
pellet are shown in Figure 4.2, stained for Foxp3 and also the proliferation marker, 
Ki67.  Foxp3 positive staining was seen in the CD4
+
CD25
+
 plug (Figure 4.2J) but 
was absent from the CD25
-
 effector cell control (Figure 4.2F).  In addition, 
proliferation was observed in the CD25
-
 effector cells (Figure 4.2G) but was absent 
from the non-proliferating Tregs (Figure 4.2K). 
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Figure 4.2 IHC Foxp3 Antibody Protocol Validation on Cell Pellets 
 
Sections of K562 (A, B, C, D), CD25
-
 effector (E, F, G, H) and CD25
+
 Treg (I, J, K, L) cell 
pellets were de-waxed and re-hydrated followed by a pH 6 citrate antigen retrieval step.  
Sections were blocked in 3 % H2O2 followed by a serum-free protein block.  Mouse anti-
human Foxp3 (5 µg/ml) antibody (B, F, J), mouse anti-human Ki67 (0.35 µg/ml) antibody (C, 
G, K) or corresponding isotype controls (D, H, L) were incubated for 1 hour.  Sections were 
incubated for 30 minutes in Mouse Envision HRP-linked polymer followed by two TBS-T 
wash steps.  Liquid DAB was then added for 10 minutes before the sections were rinsed with 
water and counter-stained with Haematoxylin Gill III.  Following dehydration in ethanol and 
clearing in xylene, sections were mounted with cover slips and left to air dry prior to 
visualisation.  (Arrow, example remaining red blood cell from isolation procedure). 
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Development of these cell pellets enabled confidence in the presence of Tregs and 
subsequent successful staining protocol optimisation.  Unfortunately, the optimal 
staining conditions differed for cell pellets and sections of tissue.  For this reason, it 
was decided to move into human tissue.  Further validation was achieved by running 
the antibodies of interest across different human tissues known to either be positive or 
negative for the different immune cells.  Altered staining conditions greatly affect the 
specificity and quality of the staining, which are unique for individual antibodies, and 
therefore each stage of the protocol required optimisation.  Due to the fixation of the 
tissue and embedding procedure, an antigen retrieval step was frequently required, in 
which the tissue was heated in a pressurised vessel using an optimal buffer to ÔfreeÕ 
the target for antibody binding.  Blocking steps to prevent non-specific binding were 
critical to minimise background staining.  Endogenous peroxidase within the tissue 
can result in false positive staining as it reacts with the visualisation methods used.  
Any endogenous peroxidase activity was therefore quenched by incubating the 
specimen with an appropriate endogenous peroxidase blocking reagent, such as 
hydrogen peroxide.  Different tissue and cells contain different levels of peroxidase 
and so optimisation of this step was required.  A serum block or serum-free protein 
block was also necessary and required optimisation to prevent the ÔfcÕ portion of the 
antibody sticking non-specifically to the tissue.  The final protocol step that needed 
optimisation was the detection method used.  The two methods tested within this 
study were Envision (Dako, K4001) and Vector Elite.  Alongside optimising these 
staining steps, antibody concentration was also titrated.  A summary of the 
optimisation carried out for this work is detailed in table 4.2.  
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Table 4.2 The Multiple Combinations of Optimisation Assays Carried Out 
 
 
 
 
 
 
 
 
 
(S, serum; SF, serum-free; ABC, Vector Elite ABC kit; EDTA, Ethylenediaminetetraacetic 
acid). 
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This validation and optimisation work was run across human lymph node and tonsil 
control tissue.  Lymphoid tissue provides a good source of immune cells and so acts 
as a reliable positive control tissue.  Lymphoid tissue contains spherical aggregates of 
lymphocytes called lymphoid follicles.  Follicles responding to antigen have less 
densely stained germinal centres (GCs) and are described as secondary follicles 
(Figure 4.4D).  The lymphocyte population of the GCs consists predominately of B 
cells in various stages of maturation, and possibly some macrophages.  It is for this 
reason that lymphoid tissue provides such an excellent control for CD4, CD8 and 
Foxp3 T cell markers, as these should be absent from the GC, as seen in Figure 4.4, 
4.5 and 4.7.  
Helen Angell   138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 IHC CD4 Antibody Protocol Validation across Human Lymph Node and 
Tonsil Tissue 
 
Human lymph node (LN) and tonsil (TN) tissue was de-waxed and re-hydrated followed by a 
pH6 citrate antigen retrieval step.  Sections were blocked in 3 % H2O2 followed by a serum 
free protein block.  Mouse anti-human CD4 IgG1 (5 µg/ml) antibody (A, D) or IgG1 isotype 
control (B, E) was then incubated for 1 hour.  Sections were incubated for 30 minutes in 
Mouse Envision HRP-linked polymer followed by two TBS-T wash steps.  Liquid DAB was 
then added for 10 minutes before the sections were rinsed with water and counter-stained 
with Haematoxylin Gill III.  Following dehydration in ethanol and clearing in xylene, sections 
were mounted with cover slips and left to air dry prior to visualisation.  Haematoxylin and 
Eosin (H & E) staining was also carried on each tissue type (C, F) as previously described.  
CD4 T cells are mainly present in the paracortex (P) and the mantle zone (M) but absent 
from the germinal centres (GC) containing small naive B cells.  Images at x 20 original 
magnification. 
Helen Angell   139 
Small nave B cells and some T cells form in the dark mantle (M) zone; however, the 
paracortex (P) is predominately composed of T cells (Figure 4.4F).  A similar pattern 
was observed for both CD4 and CD8 cells (Figure 4.5). 
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Figure 4.5 IHC CD8 Antibody Protocol Validation across Human Lymph Node and 
Tonsil Tissue 
 
Human lymph node (LN) and tonsil (TN) tissue was de-waxed and re-hydrated followed by a 
pH6 citrate antigen retrieval step.  Sections were blocked in 3 % H2O2 followed by a serum-
free protein block.  Mouse anti-human CD8 IgG2b (0.5 µg/ml) antibody (A, D) or IgG2b 
isotype control (B, E) was then incubated for 1 hour.  Sections were incubated for 30 minutes 
in Mouse Envision HRP-linked polymer followed by two TBS-T wash steps.  Liquid DAB was 
then added for 10 minutes before the sections were rinsed with water and counter-stained 
with Haematoxylin Gill III.  Following dehydration in ethanol and clearing in xylene, sections 
were mounted with cover slips and left to air dry prior to visualisation.  Haematoxylin and 
Eosin (H & E) staining was also carried on each tissue type (C, F), as previously described. 
Images at x 20 original magnification. 
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For NK cell staining, CD56-NCAM antibody was selected.  CD56 provides good 
staining for NK cells; however, it is a neural cellular adhesion molecule and so also 
stains neuronal cells.  Due to this potential cross-reactivity, cerebellum (brain) tissue 
was introduced as an additional positive control, and placenta as a negative control 
(Figure 4.6).   
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Figure 4.6 IHC CD56 Antibody Protocol Validation across a Selection of Human Tissue 
with Matched H & E Staining 
 
Lymph node (LN), tonsil (TN), brain (BN) and placenta (PL) sections were de-waxed and re-
hydrated followed by a pH6 citrate antigen retrieval step.  Sections were blocked in 3 % H2O2 
followed by a serum-free protein block.  Mouse anti-human CD56 IgG1 (0.5 µg/ml) antibody 
(A, D, G, J) or IgG1 isotype control (B, E, H, K) was then incubated for 1 hour.  Sections were 
incubated for 30 minutes in Mouse Envision HRP-linked polymer followed by two TBS-T 
wash steps.  Liquid DAB was then added for 10 minutes before the sections were rinsed with 
water and counter-stained with Haematoxylin Gill III.  Following dehydration in ethanol and 
clearing in xylene, sections were mounted with cover slips and left to air dry prior to 
visualisation.  Haematoxylin and Eosin (H & E) staining was also carried on each tissue type 
(C, F, I, L), as previously described. Images at x 20 original magnification. 
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Figure 4.6 shows good specific staining of CD56
+
 NK cells within lymph node and 
tonsil tissue.  In agreement with previous literature there is an absence of NK cells 
from the GCs.  Strong positive staining was observed within brain tissue as expected, 
highlighting the cross-reactivity of the antibody for nerve cells.  This was not a 
problem for the current study, as even small twig-like nerves, present in colorectal 
tissue, were easily distinguished from NK cells both by eye and also using analytical 
algorithms. 
   
Foxp3 antibody validation was also carried out across human tonsil and lymph node 
tissue (Figure 4.7).  Following protocol optimisation, good specific staining was 
achieved at 5 µg/ml.  As T cells, they are absent from the germinal centres and found 
predominately throughout the paracortex area.   
Helen Angell   144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 IHC Foxp3 Antibody Protocol Validation across Human Lymph Node and 
Tonsil Tissue 
 
Lymph node (LN) and tonsil (TN) tissue was de-waxed and re-hydrated followed by a pH6 
citrate antigen retrieval step.  Sections were blocked in 3 % H2O2 followed by a serum-free 
protein block.  Mouse anti-human Foxp3 IgG1 (5 µg/ml) antibody (A, D) or IgG1 isotype 
control (B, E) was then incubated for 1 hour.   Sections were incubated for 30 minutes in 
Mouse Envision HRP-linked polymer followed by two TBS-T wash steps.  Liquid DAB was 
then added for 10 minutes before the sections were rinsed with water and counter-stained 
with Haematoxylin Gill III.  Following dehydration in ethanol and clearing in xylene, sections 
were mounted with cover slips and left to air dry prior to visualisation.  Haematoxylin and 
Eosin (H & E) staining was also carried on each tissue type (C, F), as previously described. 
Images at x 20 original magnification. 
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During this optimisation work, a validated antibody was included as an internal 
positive control.  Here the proliferation marker, Ki67 was used (Figure 4.8).   
 
The lymphatic structures are further highlighted when staining for proliferation.  
Using Ki67 the highly proliferating B cells were very apparent within the germinal 
centres (Figure 4.8D).   
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Figure 4.8 IHC Ki67 Staining across a Selection of Human Tissue with Matched H & E 
Staining 
 
Lymph node (LN), tonsil (TN), brain (BN) and placenta (PL) tissue was de-waxed and re-
hydrated followed by a pH6 citrate antigen retrieval step.  Sections were blocked in 3 % H2O2 
followed by a serum-free protein block.  Mouse anti-human Ki67 IgG1 (0.35 µg/ml) antibody 
(A, D, G, J) or IgG1 isotype control (B, E, H, K) was then incubated for 1 hour.  Sections were 
incubated for 30 minutes in Mouse Envision HRP-linked polymer followed by two TBS-T 
wash steps.  Liquid DAB was then added for 10 minutes before the sections were rinsed with 
water and counter-stained with Haematoxylin Gill III.  Following dehydration in ethanol and 
clearing in xylene, sections were mounted with cover slips and left to air dry prior to 
visualisation.  Haematoxylin and Eosin (H & E) staining was also carried on each tissue type 
(C, F, I, L), as previously described. Images at x 20 original magnification. 
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Following full antibody validation and staining optimisation, markers with matched 
isotype controls were run across a sample of primary CRC tumour tissue (Figure 4.9). 
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Figure 4.9 Key Immune Cell IHC Staining Across Human CRC Primary Tissue 
 
Tissue was de-waxed and re-hydrated followed by a pH 6 citrate antigen retrieval step.  
Sections were blocked in 3 % H2O2 followed by a serum-free protein block.  Mouse anti-
human CD4 (A), CD8 (C), CD56 (E) or Foxp3 (G) antibodies or corresponding isotype 
controls (B, D, F, H) were then incubated for 1 hour.  Sections were incubated for 30 minutes 
in Mouse Envision HRP-linked polymer followed by two TBS-T wash steps.  Liquid DAB was 
then added for 10 minutes before the sections were rinsed with water and counter-stained 
with Haematoxylin Gill III.  Following dehydration in ethanol and clearing in xylene, sections 
were mounted with cover slips and left to air dry prior to visualisation. Images at x 20 original 
magnification. 
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Optimal staining protocols can vary across different tissue.  It was therefore 
necessary to test the methodology across the tissues of interest: colorectal and liver.  
Liver tissue contains a very high level of endogenous peroxidase.  It was therefore 
necessary to increase the hydrogen peroxidases blocking incubation from 10 to 20 
minutes to ensure the quenching reaction was fully complete.   
 
In addition to immune infiltrates, a selection of markers were chosen to be 
incorporated into the study, with the aim of understanding more about the localisation 
of immune infiltrates with different aspects of the tumour microenvironment.  These 
markers and a summary of the rationale for choosing them are depicted in Table 4.3.   
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Table 4.3 A Summary of Markers 
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Linking the type, density and location of immune cell infiltrates with areas of 
proliferation, apoptosis, hypoxia and vasculature was key to help understand the 
tumour microenvironment and the impact the immune system had on tumour 
progression.   
 
Caspase-3 is one of the key executioners of apoptosis, as it is responsible for the 
proteolytic cleavage of many key proteins such as the nuclear enzyme poly ADP-
ribose polymerase (PARP).  Activation of caspase-3 requires proteolytic processing 
of its inactive form into activated cleaved caspase-3 (CC-3) p17 and p12 fragments.  
CC-3 therefore provided a reliable marker for apoptosis.   
 
Alongside apoptosis, cell proliferation was also assessed using Ki67.  Ki67 is a large 
395 kDa protein that undergoes phosphorylation and dephosphorylation during 
mitosis, which is vital for cell proliferation (Brown and Gatter, 2002).  Ki67 is 
routinely used as a marker of proliferation as it is a cell cycle related nuclear protein, 
expressed by proliferating cells in all phases of the active cell cycle (G1, S, G2 and M 
phase) but absent in resting (G0) cells.  The anti-Ki67 antibody used in this study was 
the molecular immunology Borstel-1 (MIB-1) clone.  Ki67 has a very specific 
localisation pattern within the nucleus, which changes during the cell cycle.  It has an 
estimated half-life of 60Ð90 minutes, highly regulated by precise synthesis and 
degradation systems (Brown and Gatter, 2002).   
 
In addition, the current study measured the levels of hypoxia.  Hypoxia in tumours is 
caused by an imbalance in oxygen supply and demand, where regions of tumour are 
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beyond the diffusion distance of oxygen (Dewhirst, 2009; Vaupel and Mayer, 2007).  
Numerous studies have demonstrated the link between hypoxia and tumour treatment 
resistance.  Intratumoral hypoxia causes increased expression and activity of hypoxia-
inducible transcription factor-1α (HIF-1α) and thus provides a good marker of 
hypoxic tissue.  HIF-1 is a heterodimeric transcription factor that consists of two 
subunits, HIF-1α and HIF-1β, which both belong to the helix-loop-helix proteins of 
the Per-ARNT-Sim family.  HIF-1 regulates the transcription of a broad range of 
genes that facilitate responses to a hypoxic environment, including regulation of 
angiogenesis, erythropoiesis, the cell cycle, metabolism and apoptosis.  HIF-1α is 
widely expressed but normally rapidly degraded in normoxic cells by the 
ubiquitin/proteasomal pathway.  HIF-1α plays an important role in tumour 
progression, angiogenesis, metastasis and treatment resistance (Dewhirst et al., 2008).  
 
There appears to be an agreement within the literature of an association between areas 
of hypoxia and poorly organised vasculature system.  It was therefore decided to 
investigate the prevalence of blood vessels within the tumour, using CD31 as a 
marker.  CD31, also known as platelet endothelial cell adhesion molecule-1 
(PECAM-1), is a 130 kDa integral membrane glycoprotein expressed on the surface 
of endothelial cells.   
 
Blood vessels consist of endothelial cells and pericytes.  Pericytes are seen as 
important regulators of vessel function and angiogenesis.  They are enveloped by 
basement membrane and are closely associated with endothelial cells in the 
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microvasculature.  Pericytes express α-SMA and are thought to have a contractile 
function.  α-SMA will therefore stain the supporting cells of the vascular system and 
co-localise with CD31.  α-SMA is also used as an indicator for stromal elements 
(Smith et al., 2010).  In addition, as a marker for smooth muscle, α-SMA staining is 
observed in the muscular regions of colorectal tissue.    
 
In addition to the immune infiltrates described previously, the prevalence of 
infiltrating macrophages was also investigated.  Here CD68 was used as a human 
macrophage cell marker (Mlecnik et al., 2010b). 
 
Again, staining optimisation was required to run these markers across CRC and liver 
metastatic tissue.  Example staining images are illustrated in Figure 4.10, where clean 
isotype controls demonstrating antibody specificity can be observed.   
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Figure 4.10 IHC Staining of Key Markers Taken Across Human CRC Primary Tissue 
 
Tissue was de-waxed and re-hydrated followed by a pH 6 citrate antigen retrieval step.  
Sections were blocked in 3 % H2O2 followed by a serum-free protein block.  Mouse anti-
human alpha smooth muscle (α-SMA, A), cleaved caspase-3 (CC-3, C), hypoxia induced 
factor-1 alpha (HIF-1α, E), CD68 (G) or CD31 (I) antibodies or corresponding isotype controls 
(B, D, F, H, J) were then incubated for 1 hour.  Sections were incubated for 30 minutes in 
Mouse Envision HRP-linked polymer followed by two TBS-T wash steps.  Liquid DAB was 
then added for 10 minutes before the sections were rinsed with water and counter-stained 
with Haematoxylin Gill III.  Following dehydration in ethanol and clearing in xylene, sections 
were mounted with cover slips and left to air dry prior to visualisation. Images at x 20 original 
magnification. 
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Specific staining of CC-3 and HIF-1α can be seen in areas of hypoxia.  α-SMA and 
CD31 co-localise around blood vessels and α-SMA stains the stromal elements 
successfully.  Staining for macrophages using CD68 was successfully optimised, 
where specific macrophages can be seen in Figure 4.10G.  Species-specific isotype 
controls remained clean for all antibodies used (Figure 4.10B, D, F, H, and J).   
 
4.2.2. Tissue of Interest and Ethics 
The aim of this study was to evaluate a large cohort of patients for the orientation, 
density, and co-localisation of immune cells and to evaluate any differences between 
primary CRC and metastatic liver patients.  Tissue selection was therefore very 
important to ensure the answers to these questions could be obtained.  Three different 
sample groups were used, summarised in Table 4.4.  All samples used were sourced 
from the AstraZeneca Alderley Park Biobank, which is a licenced premises under the 
Human Tissue Act (2004) (HTA number 12109) and has NRES ethical approval as a 
tissue bank (07/MRE08/29).  All third party providers to the Alderley Park Biobank 
have passed an approval process at AstraZeneca and all samples are acquired by those 
providers with written informed consent. 
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Table 4.4 A Summary of the Tissue Used 
 
 
 
(INA, information not available; MCRC, Manchester Cancer Research Centre). 
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4.2.3. Image Analysis 
Analysis of IHC images is often time consuming and subject to large variability.  
Digitally acquired images were achieved using a ScanScope digital scanner (Aperio 
Technologies Ltd.).  Images were viewed and organised using ImageScope viewer 
and Spectrum operating system.  Genieª pattern recognition software (Aperio 
Technologies Ltd.) was used for the automated quantitative assessment of immune 
infiltrates within specific regions of tissue.  Genieª classifiers were generated for the 
separation of areas of tumour, stroma, lymphatic aggregates, non-neoplastic tissue 
and glass (Figure 4.11).  
Helen Angell   158 
 
Figure 4.11 Genieª Classifier Mark Up 
 
Genieª pattern recognition software (Aperio Technologies Ltd.) was implemented to 
distinguish different areas of tissue.  Genieª Classifiers were trained to recognise these 
patterns by manually marking up example areas.  Areas identified included tumour (red), 
stroma (yellow), lymphatic (green) and background glass (blue).  
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Mark-up images were implemented to train the Genieª classifiers to recognise the 
appropriate regions.  Genieª classifiers were then combined with appropriately 
tuned image analysis algorithms for the quantification of different markers.  A 
nuclear algorithm was modified to quantify the number of immune cells, expressed as 
a percentage of the total number of cells within the area of interest (percentage 
positive cells %).  The areas of stroma and lymphatic aggregate were combined and 
are herein termed ÔstromaÕ, resulting in three analysis outputs (Figure 4.12). 
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Figure 4.12 Example Genieª Analysis Output 
 
Genieª Classifiers under-went pattern recognition training to identify areas of tissue.  These 
then provided data analysis outputs, for example; ÔHA_ImmuneCell_CRC_with_LV_TumourÕ 
(colorectal or liver tumour tissue), ÔHA_ImmuneCell_CRC_with_LV_Stroma&LymphaticÕ 
(colorectal or liver stroma and lymphoid tissue) and ÔHA_ImmuneCell_CRC_with_LV_NnPÕ 
(Non-neoplastic colorectal and liver tissue).  Classifiers were then combined with a nuclear 
algorithm for each output and expressed as the number of percentage positive cells within 
that area. 
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Digitally acquired images were then marked up for analysis, highlighting the area of 
interest to reduce the background white space (Figure 4.13).  Analysis was carried out 
and data exported into Microsoft Excelª.   
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Figure 4.13 Genieª Analysis of Stroma and Tumour 
 
The area of interest was manually marked (green line) to reduce the amount of background 
white space.  Genieª Classifiers under went pattern recognition training to identify areas of 
tissue and were then combined with a nuclear algorithm for each output, for example A) 
tissue alone B) stroma and C) colorectal liver metastatic tumour. 
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The distinct morphology of CRC tumour necessitated the generation of only a few 
variations of Genieª classifiers for different sets of tumour samples.  AstraZeneca 
are one of the few places in the United Kingdom to pilot this image analysis platform.  
The development of classifiers to distinguish human tumour, stroma and non-
neoplastic tissue, is a novel achievement.  Refined image analysis, coupled with this 
ability to characterise distinct human tissue components, could refine current 
pathological techniques.  The classifiers were able to separate the designated regions 
with a high degree of accuracy.  Example images of separating tumour from stroma 
can be seen in Figure 4.14.   
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Figure 4.14 Genieª Analysis of Foxp3 Algorithm in Stroma and Tumour 
 
A) Digital images were acquired.  Genieª Classifiers were then used to distinguish the areas 
of B) tumour and C) stroma, combined with a nuclear algorithm to quantify the percentage 
positive number of immune cells (brown). 
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4.2.4. Immune Infiltrates in Colorectal Metastatic Liver Samples  
It is becoming increasingly apparent that tumours contain various cells from the 
immune system, including Tregs, cytotoxic T cells, NK cells, macrophages, 
neutrophils, B lymphocytes, and DCs (Pages et al., 2008). 
 
It was necessary to solidify the association between tumour progression and 
inflammation and to understand the interactions between tumour cells and immune 
infiltrates, that result in a balance between tumour promotion and tumour 
suppression.  An increasing amount of evidence supports the idea that immune 
infiltration into the tumour microenvironment could influence clinical outcome and 
disease progression, regardless of the tumour stage. 
 
4.2.4.1. Adaptive Immunity 
4.2.4.1.1. CD8 Positive Cytotoxic T Cells 
The prevalence of cytotoxic T cells was analysed immunohistochemically using a 
CD8 antibody.  Initially, seven primary CRC tissue samples with patient matched 
metastatic liver samples were evaluated (Figure 4.15).  
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Figure 4.15 CD8 Cell Infiltrates in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue was examined for CD8 cell infiltration using 
IHC techniques (mouse anti-human CD8 IgG2b, 0.5 µg/ml).  Digital images were acquired 
and Genieª Classifiers were then used to distinguish the areas of tumour and stroma, 
combined with a nuclear algorithm to quantify the percentage positive number of CD8 cells.  
A) An overall assessment of the percentage positive CD8 cells in primary and metastatic 
disease was carried out.  A direct comparison between the number of CD8 cells in the 
tumour and stroma for both B) primary and C) metastatic (met) tissue.  (Paired t-test, normal 
distribution, * p < 0.05). 
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The percent of positive CD8 cells within the tumour and stroma of primary and 
secondary diseased tissue was compared.  There was a significant (p < 0.05) elevation 
of CD8 CTLs within the stroma of both primary CRC and metastatic liver samples.   
 
Previous studies have examined the CD8/CD3 T cell density ratio in relation to 
clinical outcome, where high proportions of CD8 cytotoxic T cells within the primary 
tumour was seen to be associated with reduced risk of relapse (Camus et al., 2009). 
 
The primary (MET+) samples from Figure 4.15 were then compared to primary CRC 
samples that showed no metastatic development (MET-) (n = 18).  This correlation 
was necessary to assess any differences in the prevalence of cytotoxic CD8 cells 
between a MET+ and MET- primary tissue phenotype (Figure 4.16). 
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Figure 4.16 Comparison of CD8 Cells in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were compared for CD8 cell infiltration using IHC 
techniques (mouse anti-human CD8 IgG2b, 0.5 µg/ml).  Digital images were acquired and 
Genieª Classifiers were then used to distinguish the areas of tumour and stroma.  This was 
combined with a nuclear algorithm to quantify the percentage positive number of CD8 cells in 
the A) tumour and B) stroma.  (Unpaired t-test, normal distribution, * p < 0.05). 
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MET+ and MET- primary samples were evaluated for the percent of positive CD8 
cells within the tumour (Figure 4.16A) and stroma (Figure 4.16B).  Similar trends 
were observed for both tumour and stroma regions, where MET+ primary samples 
showed significantly lower levels of CD8 cell infiltration. 
 
Data are in agreement with previous literature where MET
+
 patients showed 
significantly lower levels of CD3
+
CD8
+
 cells compared with MET
-
 patients (Camus 
et al., 2009).  CD8
+
/CD4
+
 and CD8
+
/CD3
+
 cell ratios were also significantly higher in 
MET
-
 compared with MET
+
 patients (Camus et al., 2009).   
 
Research suggests that primary CRC tissue with fewer CD8 infiltrates results in 
metastatic development.  This is in accordance with previous research that 
highlighted that patients without recurrence had higher overall CD8 cell densities in 
primary tumours (Galon et al., 2006; Pages et al., 2008).   
 
CRC liver metastatic samples with matched distant normal liver samples were then 
selected (n = 40) to enable a comparison between tumour, tumour adjacent non-
neoplastic tissue and distant non-neoplastic samples (Figure 4.17) 
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Figure 4.17 CD8 Cells in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
The prevalence of CD8 cells was analysed immunohistochemically (mouse anti-human CD8 
IgG2b, 0.5 µg/ml).  Digital images were acquired and Genieª Classifiers were combined with 
a nuclear algorithm to quantify the percentage positive number of cells.  A) Tumour (Tumour 
Tumour), tumour-associated stroma (Tumour Stroma) and tumour adjacent non-neoplastic 
(Tumour NonNeo) tissue was compared to matched distant normal stroma (Normal Stroma) 
and non-neoplastic (Normal NonNeo).  B) A comparison between tumour adjacent non-
neoplastic (NonNeo Tumour) and distant non-neoplastic (NonNeo Normal) tissue was 
achieved (Paired t-test, normal distribution, *** p < 0.001). 
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When investigating the location of CD8 cells, it became apparent that there was a 
significant increase in the number of CTLs within the non-neoplastic tissue at the 
tumour edge compared to distant non-neoplastic tissue or within the tumour itself 
(p < 0.001, Figure 4.17B).  An example image of this is illustrated in Figure 4.18.  In 
addition, the frequency of CD8 cells at the adjacent non-neoplastic area was higher 
(p < 0.01) than those observed within the stroma infiltrating the tumour.  When 
comparing normal non-neoplastic tissue with tumour tissue the frequency of CD8 
cells drops significantly (p > 0.001), perhaps indicating the inability of CD8 cells to 
penetrate into the CT. 
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Figure 4.18 Example Image of CD8 Immune Cells in Liver Metastatic CRC  
 
Liver metastatic CRC tissue was de-waxed and re-hydrated followed by a pH 6 citrate 
antigen retrieval step.  Sections were blocked in 3 % H2O2 followed by a serum-free protein 
block.  Mouse anti-human CD8 IgG2b (0.5 µg/ml) antibody was then incubated for 1 hour.  
Sections were incubated for 30 minutes in Mouse Envision HRP-linked polymer followed by 
two TBS-T wash steps.  Liquid DAB was then added for 10 minutes before the sections were 
rinsed with water and counter-stained with Haematoxylin Gill III.  Following dehydration in 
ethanol and clearing in xylene, sections were mounted with cover slips and left to air dry prior 
to visualisation. Image at x 20 original magnification.  (CT, tumour centre; S, stroma; IM, 
invasive margin; NNLV, non-neoplastic liver; green arrow, CD8 within the stroma; black 
arrow, CD8 within the NNLV).  
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Numerous CD8 cells were observed in the non-neoplastic liver (NNLV) tissue at the 
tumour edge (Figure 4.18, black arrow).  The number of CD8 cells at this invasive IM 
was significantly higher than those found at the CT, both within the tumour-
associated stroma (Figure 4.18, green arrow) and in the tumour itself. 
 
Previous studies have also examined the location of CD8 cells in the CT and at the 
IM of CRC patients.  These studies have shown that patients without recurrence had 
higher overall CD8 cell densities (Galon et al., 2006; Pages et al., 2008).   
 
The rationale for the elevation of CTLs at the tumour edge becomes an interesting 
debate.  The author would like to propose two hypotheses.  Firstly, the increased 
number of CD8 cells at the tumour edge may be providing a protective ÔblanketÕ for 
the surrounding non-neoplastic tissue.  Here the CTLs could be holding back the 
progression of tumour growth.  This would tie in well with studies that show an 
elevation of CD8 cells results in reduced recurrence and a MET- phenotype.  
However, it could also be argued that the tumour may be producing a cocktail of 
chemokines and cytokines, preventing CD8 penetration into the CT and therefore 
resulting in reduced levels of tumour cytotoxicity.  Perhaps what we are seeing is the 
result of a cytokine/chemokine chemical gradient extending from the tumours edge?  
Understanding ways to perforate this hypothesised impenetrable Ôbuffer zoneÕ could 
lead to the development of a therapeutic solution.   
 
Finally, primary and metastatic CRC samples were pooled to examine the occurrence 
of CD8 cells specifically between the tumour and stroma (Figure 4.19). 
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Figure 4.19 Overall Evaluation of CD8 Cells in Tumour and Stroma 
 
A) Primary CRC and CRC metastatic liver samples were pooled to compare the percentage 
positive CD8 cells between tumour and stroma. (paired t-test, *** p < 0.001).  B) A 
corresponding example image of liver metastatic CRC tissue stained with anti-human CD8 
IgG2b (0.5 µg/ml).  Image at x 20 original magnification.  (T, tumour; S, stroma; green arrow, 
CD8 within the stroma; black arrow, CD8 within the tumour).  
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The frequency of CTLs was significantly higher in the stroma (Figure 4.19B, green 
arrow) compared to those infiltrating the tumour (Figure 4.19B, black arrow) 
(p < 0.0001).   
 
4.2.4.1.2. Foxp3 Positive Tregs 
Alongside the level of infiltrating CTLs, the pervasiveness of Tregs was also 
investigated, through staining for Foxp3.  Foxp3-positive staining was observed in 
colorectal tumour sections of various stages and differentiation.  Initially, as with 
CD8 staining, seven primary CRC tissue samples with patient matched metastatic 
liver samples were evaluated to investigate the role of Tregs in CRC tumour 
progression (Figure 4.20). 
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Figure 4.20 Foxp3 Cell Infiltrates in Primary CRC vs Matched Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue was examined for Treg infiltration into the 
tumour and stroma using IHC techniques (mouse anti-human Foxp3 IgG1, 5 µg/ml).  Digital 
images were acquired and Genieª Classifiers were then used to distinguish the areas of 
tumour and stroma.  This was combined with a nuclear algorithm to quantify the percentage 
positive number of Foxp3 Tregs.  A) An overall assessment of the percentage positive Tregs 
in primary and metastatic disease was carried out.  A direct comparison was made between 
the number of Tregs in the tumour and stroma for both B) primary and C) metastatic (met) 
tissue.  (Paired t-test, * p < 0.05).  
Helen Angell   177 
No significant differences were found when evaluating the frequency of Tregs 
between primary CRC and secondary liver disease (Figure 4.20A).  However, as with 
CD8 analysis, Tregs were significantly elevated within the stromal areas compared to 
infiltrating the tumour itself (Figure 4.20B).  This was true for both primary and 
secondary disease. 
 
To further examine this correlation, primary MET+ and primary MET- samples were 
compared for Treg frequency (Figure 4.21). 
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Figure 4.21 Comparison of Foxp3 Cells in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were evaluated immunohistochemically (mouse anti-
human Foxp3 IgG1, 5 µg/ml).  Digital images were acquired and Genieª Classifiers were 
then used to distinguish the areas of tumour and stroma.  This was combined with a nuclear 
algorithm to quantify the percentage positive number of Foxp3 Tregs infiltration into the A) 
tumour and B) stroma.  (Unpaired Mann-Whitney test, * p < 0.05). 
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Results demonstrated an inverse relationship between Tregs in the stroma and tumour 
of MET+ tissue.  A decrease in the incidence of Tregs within tumour cell-rich regions 
was affiliated with a MET+ phenotype, whereas an increase Tregs within stromal-rich 
regions was associated with a MET+ phenotype. 
 
The general consensus is that increased numbers of Tregs are associated with poor 
prognosis and tumour progression.  However, here we showed that Tregs infiltrating 
the tumour are less frequent in patients who go on to develop metastatic disease 
(MET+).  Some literature has suggested that Tregs may not always be associated with 
poor prognosis.  For example, Salama et al., reported an increase in Foxp3 density 
within the tumour was linked with better OS (Salama et al., 2009).  In contrast, 
additional research has shown that patients with elevated Treg numbers showed 
reduced survival rates and the accumulation of Tregs was related to disease 
progression (Mizukami et al., 2008b; Wolf et al., 2005). 
 
The current data are in conflict with some previous literature showing no significant 
difference in the number of Tregs (CD4
+
CD25
hi
) between MET+ and MET- when 
analysed using large scale flow cytometry (Camus et al., 2009).   
 
It is the authorÕs opinion that analysis using large-scale flow cytometry loses the 
detail of location that has been demonstrated in this study and this is why a lack of 
significance was previously observed.  By using IHC techniques, the precise location 
of Tregs can be compared, to a greater degree of accuracy.  The current data also 
perhaps supports the previously conflicting publications on the prognostic 
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significance of Tregs.  Are Tregs within the tumour associated with better prognosis, 
whilst Tregs within the stroma associated with a poor prognosis?  
 
The question of the prognostic role of Tregs in human CRC appears to be complex 
and ambiguous.  Curiel et al., (2004) reported that the increase in Tregs correlated 
with tumour staging and reduced survival in ovarian carcinoma.  Subsequent data are 
in agreement with this, in other solid tumours, such as NSCLC (Woo et al., 2001), 
gastric (Mizukami et al., 2008b) and hepatocellular carcinoma (Fu et al., 2007).  In 
contrast to this, data have accumulated suggesting that elevated Tregs may not always 
be linked with poor prognosis (Ladoire et al., 2011a; Salama et al., 2009).  A recent 
study has proposed that tumour infiltrating Tregs are associated with favourable 
prognosis in patients with CRC, and Tregs are acting against a microbial driven 
response rather than by tumour antigens (Ladoire et al., 2011a). 
 
GalonÕs group found no association between Foxp3, CTLA-4, GITR, IL-10, TGF-β 
and the presence of intratumoural or distant metastasis (Pages et al., 2008).     
 
As with the CD8 cell analysis, metastatic CRC samples with matched distant non-
neoplastic tissue were analysed for Treg infiltration (Figure 4.22). 
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Figure 4.22 Foxp3 Cells in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
The number of Tregs in metastatic CRC liver samples was analysed immunohistochemically 
(mouse anti-human Foxp3 IgG1, 5 µg/ml).  Digital images were acquired and Genieª 
Classifiers were then used to distinguish the areas of tumour, stroma and tumour adjacent 
non-neoplastic (Tumour NonNeo) tissue, compared matched distant normal stroma and non-
neoplastic (Normal NonNeo).  B) A comparison between tumour adjacent non-neoplastic 
(NonNeo Tumour) and distant non-neoplastic (NonNeo Normal) tissue was achieved. (Paired 
t-test, *** p < 0.001).   
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Interestingly, the highest level of infiltrating Tregs was observed in the tumour 
adjacent non-neoplastic tissue.  The frequency of Tregs here was significantly 
(p > 0.001) higher than those observed at the matched distant non-neoplastic samples 
(Figure 4.22B).  Results are in agreement with previous literature showing elevated 
Tregs in tumour sections compared to normal tissue (Mizukami et al., 2008b).   
 
In addition, this level of Treg infiltration at the tumour edge is very similar to that 
seen for CD8 cells.  Amplified numbers of Tregs were found within the tumour 
adjacent non-neoplastic tissue, compared to those that had infiltrated the tumour 
(p > 0.001).  An increase in Treg number could be responsible for an imbalance in the 
immune system, which would then favour unresponsiveness.  This situation could 
lead to tumour cells escaping immune cell recognition (Colombo and Piconese, 
2007).  Tumour progression could therefore result from Treg-mediated suppression of 
the anti-tumour immune response, such as CTLs (Bui et al., 2006).   
 
Interestingly, the numbers of Tregs within tumour stroma were higher (p > 0.01) than 
those observed within distant non-neoplastic stromal tissue (Figure 4.22A).  It could 
be speculated that the level of Tregs is elevated because Tregs might be attracted to 
the tumour microenvironment and could be patrolling the tumour stromal ÔstreetsÕ, 
suppressing any immune cell that has accomplished tumour infiltration. 
 
The similarities and co-localisation of Tregs and CD8 CTLs at the IM is 
demonstrated in Figure 4.23. 
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Figure 4.23 Example Image of CD8 and Foxp3 Cell Co-localisation at the Tumour Edge  
 
Example images of liver metastatic CRC tissue stained with A) anti-human CD8 IgG2b (0.5 
µg/ml) or B) anti-human Foxp3 IgG1 (5 µg/ml).  Images at x 20 original magnification.  (CT, 
tumour centre; IM, invasive margin; NNLV, non-neoplastic liver; black arrow, example CD8 
cell; green arrow, example co-localising Treg). 
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Sequential cutting of sections enabled a more detailed analysis of immune cell 
locations within subsequent sections.  CD8 cells (Figure 4.23A, black arrow) were 
seen in very close proximity to Tregs (Figure 4.23A, green arrow). 
 
Studies suggest that tumour-related factors mediate Treg trafficking into the tumour 
microenvironment, which could explain the elevated Tregs observed at the tumour 
edge.  Chemotaxis experiments have demonstrated the ability of the macrophage-
derived chemokine, CCL22, to induce Treg migration through its receptor CCR4 and 
impair anti-tumour immunity (Curiel et al., 2004).  Tregs strongly express CCR4 on 
their surface and have been shown to also migrate in response to CCL17 via the same 
CCR4 receptor (Ishida and Ueda, 2006).  The mechanism for CCL22 and CCL17 up-
regulation has not yet been clarified, however, it has been suggested that the tumour 
microenvironment induces macrophages to secrete these chemokines (Mizukami et 
al., 2008a).  Further to this, the tumour microenvironment could provide a favourable 
setting for Treg expansion due to the cocktail of chemokines, such as TGF-β, it 
produces (Yamaguchi et al., 2007). 
 
Patients with elevated Treg levels show reduced survival rates and the accumulation 
of Tregs is debatably related to disease progression (Mizukami et al., 2008b; Wolf et 
al., 2005).  Evidence suggests that depleting Tregs leads to rejection of transplanted 
tumours in mice models (Shimizu et al., 1999). 
 
A direct comparison between Tregs within the tumour and those found in the stroma 
was achieved (Figure 4.24). 
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Figure 4.24 Overall Evaluation of Foxp3 Cells in Tumour and Stroma 
 
The number of Tregs was analysed immunohistochemically (mouse anti-human Foxp3 IgG1, 
5 µg/ml).  Digital images were acquired and Genieª Classifiers were then used to distinguish 
areas of tumour and stroma.  This was combined with a nuclear algorithm to quantify the 
percent positive Tregs.  A) Primary CRC and CRC metastatic liver samples were pooled to 
compare the percentage positive Tregs between tumour and stroma. (Unpaired t-test, 
*** p < 0.001).  B) A corresponding example image (at x 20 original magnification) of liver 
metastatic CRC tissue stained with anti-human Foxp3 (T, tumour; S, stroma). 
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As with CD8 cells, Tregs were seen to be significantly higher within the stroma than 
within the tumour itself (p < 0.001).  An example image depicting this can be seen in 
Figure 4.24B, where Tregs reside predominantly within the stroma (S) and to a much 
lesser extent within regions of tumour (T). 
 
The clinicopathologic significance of Tregs and CD8 cells during 
hepatocarcinogenesis has also been studied, where the prevalence of Tregs was 
suggested to be an unfavourable prognostic marker (Kobayashi et al., 2007).  The 
infiltration of Tregs and CD8 cells in patients with metastatic liver tumours from 
primary CRC were evaluated.  Analysis of the anti-tumour response (Tregs and CD8 
T cells) in primary HCC (n = 235), intrahepatic metastatic foci (n = 27) and liver 
metastasis from primary CRC (n = 59) was evaluated.  The frequency of Tregs was 
higher in primary tumours than metastatic.  Tregs were elevated in HCC compared to 
non-tumour tissue or healthy liver samples, where low-Treg groups showed improved 
OS and DFS compared to high-Treg groups (Kobayashi et al., 2007).  
 
4.2.4.2. Innate Immunity 
4.2.4.2.1 CD68 Positive Macrophages 
The current study then moved on to look at the occurrence of macrophages, using 
CD68 staining.  The frequency of macrophages within primary and metastatic tissue 
was investigated (Figure 4.25).  
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Figure 4.25 CD68 Macrophage Infiltrates in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue was examined for CD68 cell infiltration into 
the tumour and stroma using IHC techniques (anti-human CD68 IgG1, 0.2 µg/ml).  Digital 
images were acquired and Genieª Classifiers were then used to distinguish areas of tumour 
and stroma and combined with a nuclear algorithm to quantify the percent positive CD68 
cells.  A) An overall assessment of the percentage positive CD68 cells in primary and 
metastatic disease was carried out.  A direct comparison between the number of CD68 cells 
in the tumour and stroma for both B) primary and C) metastatic (met) tissue.  (Paired t-test, 
** p < 0.01). 
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When evaluating CD68, similar trends were observed for macrophages as those seen 
for CTLs and, to some extent, Tregs.  An elevation in macrophage number was noted 
in the metastatic versus primary samples.  This was true for numbers within tumour 
(p < 0.01) and stroma (p < 0.05) of metastatic tissue opposed to primary tissue 
(Figure 4.25A).  In addition, macrophage infiltration was highest in stromal areas, in 
contrast to those seen within the tumour tissue, for both primary (p < 0.01) and 
metastatic (p < 0.01) disease (Figure 4.25B).  
 
TAMs have been identified as regulators of tumour progression, via their ability to 
promote angiogenesis and metastatic development (Qian and Pollard, 2010).  TAMs 
are derived from monocytes that are recruited largely by monocyte chemotactic 
protein (MCP) chemokines.  TAMs have a dual function: IL-2 and IL-12 mediated 
neoplastic cell death, but also the production of angiogenic and lymphangiogenic 
growth factors renders them mediators of neoplastic progression (Coussens and 
Werb, 2002).  Along with tumour cells, TAMs also produce IL-10, which dampens 
the anti-tumour response. 
 
Further research explored the macrophage infiltration in primary MET+ and MET- 
tissue (Figure 4.26). 
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Figure 4.26 Comparison of CD68 Cells in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were analysed using IHC techniques (anti-human CD68 
IgG1, 0.2 µg/ml).  Digital images were acquired and Genieª Classifiers were used, 
combined with a nuclear algorithm to determine the number of percent positive CD68 cells in 
the A) tumour and B) stroma.  (Unpaired t-test). 
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Interestingly, there was no statistical significance between macrophages in the 
tumour or stroma of MET+ versus MET- primary CRC tissue.  This is in agreement 
with recently published data demonstrating that CD68
+
 cell density alone resulted in 
no correlation to survival or metastatic development (DeNardo et al., 2011).  
However, when combined with CD8 CTL analysis, it was shown that an inverse 
relationship occurred between macrophages and CTLs within the stroma of breast 
cancer tissue.  Results alluded to a CD68
high
/CD4
high
/CD8
low
 pro-tumour phenotype, 
associated with reduced OS and relapse-free survival (RFS) (DeNardo et al., 2011). 
 
Differences in the prognostic significance of TAMs could, in part, be explained by 
the fact that TAMs result in either pro-tumour or anti-tumour activities, depending on 
the cytokines to which they are exposed to (Ruffell et al., 2010).  Cytokines, such as 
IFN-γ or TNF-α, result in TAM cytotoxicity, antigen presentation and the release of 
pro-inflammatory cytokines, whereas TAMs exposed to immunosuppressive 
cytokines promote angiogenesis and block CTL activity (Ruffell et al., 2010).   
 
Within the current study, TAMs were examined in comparison to the frequency of 
macrophages observed at distant sites of non-neoplastic tissue (Figure 4.27).    
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Figure 4.27 CD68 Cells in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
CRC metastatic liver samples were analysed for CD68 cells immunohistochemically (anti-
human CD68 IgG1, 0.2 µg/ml). Digital images were acquired and Genieª Classifiers were 
combined with a nuclear algorithm to quantify CD68 cells, looking at the difference between 
tumour, stroma and tumour adjacent non-neoplastic (Tumour NonNeo) tissue, compared to 
matched distant normal stroma and non-neoplastic (Normal NonNeo).  B) A comparison 
between tumour adjacent non-neoplastic (NonNeo Tumour) and distant non-neoplastic 
(NonNeo Normal) tissue was achieved. (Paired t-test, *** p < 0.001). 
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A significant elevation of macrophage numbers was observed at the tumour IM and 
adjacent non-neoplastic tissue, when compared to distant non-neoplastic samples 
(Figure 4.27B).  Previous research has revealed that the cytokine, CSF-1, plays a key 
role in recruitment and activation of macrophages (Tang et al., 1992).  In addition, the 
number of macrophages at this IM site was also higher than those seen within the 
tumour (p < 0.001) and stroma (p < 0.01), very similar to the trends observed for 
CTLs and Tregs. 
 
An example image illustrating the numbers of macrophages found at the tumour IM 
and adjacent non-neoplastic tissue is depicted in Figure 4.28.   
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Figure 4.28 Example Image of Infiltrating CD68 Cells at the Tumour Edge  
 
An example image of a CRC metastatic liver section stained with anti-human CD68 IgG1 (0.2 
µg/ml). Black arrow, CD68 cell at the IM, green arrow, CD68 cell within adjacent NNLV tissue 
(CT, tumour centre; IM, invasive margin; NNLV, non-neoplastic liver).  Image at x 20 original 
magnification. 
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The influx of macrophages to the tumour IM is very similar to that of Tregs and CD8 
cells.  This could be explained, in part, by the ability of macrophages to produce the 
chemokine CCL22.  Cellular trafficking has been shown to occur between CCL22 
and CCL17 and cells expressing the CCR4 receptor.  Tregs strongly express CCR4 
on their surface and so could migrate to the tumour microenvironment, influenced by 
this macrophage-derived chemokine (Curiel et al., 2004); (Mizukami et al., 2008a).   
 
The frequency of macrophages within the tumour and stroma of primary and 
metastatic CRC tumour tissue was then scrutinised (Figure 4.29). 
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Figure 4.29 Overall Evaluation of CD68 Cells in Tumour and Stroma 
 
Primary CRC and metastatic liver samples were pooled and analysed for CD68 cells 
immunohistochemically (anti-human CD68 IgG1, 0.2 µg/ml).  Digital images were acquired 
and Genieª Classifiers were combined with a nuclear algorithm to quantify the number of 
positive CD68 cells.  A) The percentage of positive CD68 cells was compared between 
tumour and stroma. (Unpaired t-test, *** p < 0.001).  B) A corresponding example image of 
liver metastatic CRC tissue stained with anti-human CD68 IgG1 (0.2 µg/ml).  Image at x 20 
original magnification (T, tumour; S, stroma). 
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Elevation of macrophages within the stroma was observed and is in agreement with 
previous literature, showing the stromal macrophages had the most significant impact 
on prognostic factors. 
 
4.2.4.2.2. CD56 Positive NK Cells 
To complete the set of immune markers studied, the frequency of CD56-positive NK 
cells was determined within primary CRC and matched liver metastatic samples 
(Figure 4.30). 
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Figure 4.30 CD56 NK Cell Infiltrates in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue were examined for NK cell infiltration using 
IHC techniques (anti-human CD56 IgG1, 0.5 µg/ml).  Digital images were acquired and 
Genieª Classifiers were combined with a nuclear algorithm to quantify the percentage of 
CD56 positive cells.  A) An overall assessment of the percentage positive CD56 cells in 
primary and metastatic disease.  A comparison between the number of NKs in the tumour 
and stroma of B) primary and C) metastatic (met) tissue.  (Paired t-test, * p < 0.05).  
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As with previous immune infiltrates, the highest occurrence of NK cells was 
observed within the stroma of both primary and metastatic disease (Figure 4.30B).  
However, the author would like to draw the readerÕs attention to the scale bars used 
within this study.  Although similar trends were observed for the location of NK cells, 
the percentage of positive CD56 cells was significantly lower than that of other 
immune infiltrates, such as CD8s, Tregs and macrophages. 
 
A comparison between the number of NK cells within primary MET- and MET+ 
tissue was then accomplished (Figure 4.31).  
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Figure 4.31 Comparison of CD56 Cells in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were examined for NK cell infiltration using IHC 
techniques (anti-human CD56 IgG1, 0.5 µg/ml).  Digital images were acquired and Genieª 
Classifiers were used to distinguish areas of tumour and stroma.  This was combined with a 
nuclear algorithm to quantify the percentage of CD56 positive cells.  A) tumour and B) stroma 
were compared for CD56 cell infiltration. 
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A trend was observed within the stroma between MET- and MET+ CD56 cells, 
where primary tissue, which went on to develop metastatic disease, showed fewer NK 
cells (Figure 4.31B).  Fewer NK cells would suggest a reduced level of tumour cell 
cytotoxicity and therefore favour disease progression and metastasis.  However, no 
statistically significant difference was observed, possibly due to the low numbers. 
 
Within the literature analysis of CD57 as an NK cell marker was associated with 
survival in CRC (Mlecnik et al., 2010a).  Extensive work was achieved using a 
platform of techniques including gene expression, to identify immune-related genes 
associated with patient prognosis and absence of tumour recurrence.  The phenotypes 
and locations of intratumoral immune cells were assessed for correlations with DFS. 
 
CD56 NK cells were subsequently analysed within the tumour and compared to 
matched, distant, non-neoplastic samples (Figure 4.32). 
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Figure 4.32 CD56 Cells in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
Liver metastatic CRC samples were analysed immunohistochemically for CD56-positive cell 
infiltrates (anti-human CD56 IgG1, 0.5 µg/ml).  Digital images were acquired and Genieª 
Classifiers were combined with a nuclear algorithm to quantify the percentage of CD56 
positive cells, looking at the difference between tumour, stroma and tumour adjacent non-
neoplastic (Tumour NonNeo) tissue, compared to matched distant normal stroma and non-
neoplastic (Normal NonNeo) tissue.  B) A comparison between tumour and tumour adjacent 
non-neoplastic (NonNeo Tumour) tissue was achieved. (Mann-Whitney test, *** p< 0.001). 
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The numbers of CD56-positive NK cells were compared between tumour adjacent 
non-neoplastic tissue and matched distant non-neoplastic samples (Figure 4.32B).  A 
significant (p < 0.001) decrease in the prevalence of NK cells was observed at the 
tumour edge.  This was also true when comparing distant stroma NK numbers to 
those seen in the stroma within the tumour (p < 0.05).  This drop in NK cell numbers 
may result in limited NK-mediated tumour cell killing.  No difference in numbers of 
NK cells was seen between the tumour edge and those infiltrating the tumour, 
possibly indicating a lack of anti-tumour NK cell activity. 
 
The prevalence of NKs was then compared between the tumour and stroma of all 
CRC patients within the study (Figure 4.33). 
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Figure 4.33 Overall Evaluation of CD56 Cells in Tumour and Stroma 
 
Primary CRC and liver metastatic samples were pooled and examined for NK cell infiltration 
using IHC techniques (anti-human CD56 IgG1, 0.5 µg/ml).  Digital images were acquired and 
Genieª Classifiers were combined with a nuclear algorithm to quantify the percentage of 
CD56-positive cells.  A) The number of percentage positive CD56 cells was compared 
between tumour and stroma. (Unpaired t-test, *** p < 0.001).   
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In agreement with the trend seen for previous immune infiltrates, there was a 
significant increase in the amount of NK cells within the stroma compared to those 
seen within the tumour itself (Figure 4.33). 
 
4.2.4.3. Tumour Environment 
4.2.4.3.1. CD31 Positive Vasculature Staining 
Alongside immune infiltrates, various aspects of the tumour microenvironment were 
also analysed in this study.  
 
Decades of research have been invested into studying the ability of tumours to induce 
the formation of new blood vessels, a key requirement to sustain solid tumour 
growth.  Fundamental to that research was the discovery and subsequent 
understanding of the VEGF and its contribution to driving tumour angiogenesis 
(Ferrara, 2002).   
 
Within this study, CD31 was used to analyse the distribution of blood vessels within 
and around the tumour and stroma, first comparing primary and metastatic tissue 
(Figure 4.34). 
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Figure 4.34 CD31 MVD in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue was examined for microvessel density 
(MVD) by examining the number of vessels per unit area (mm
2
) within the tumour and stroma 
using IHC techniques (anti-hum CD31 IgG1, 0.27 µg/ml).  Digital images were acquired and 
Genieª Classifiers were combined with a nuclear algorithm to quantify the MVD.  A) An 
overall assessment of the MVD in primary and metastatic disease was carried out.  A direct 
comparison between the MVD in the tumour and stroma for both B) primary and C) 
metastatic (met) tissue was achieved (Mann-Whitney test, * p < 0.05, ** p < 0.01). 
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Anti-human CD31 was used to stain the vasculature within tissue samples.  Image 
analysis was achieved as previously described, utilising the Genie pattern recognition 
software in association with a microvessel density (MVD) algorithm. MVD was 
calculated by examining the number of vessels per unit area (mm
2
).  There was no 
significant difference in the MVD between primary and metastatic disease, both 
within the tumour and stroma (Figure 4.34A).  However, elevation in the number of 
vessels was observed infiltrating the stroma in primary (p < 0.01) and metastatic 
(p < 0.05) tissue (Figure 4.34B), compared with the tumour. 
 
The vessel density was compared between MET+ and MET- primary CRC tissue 
(Figure 4.35). 
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Figure 4.35 Comparison of CD31 MVD in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were examined for the number of vessels per unit area 
(mm
2
) within the tumour and stroma using IHC techniques (anti-hum CD31 IgG1, 0.27 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the microvessel density (MVD).  MVD was compared in the A) tumour 
and B) stroma.  (Mann-Whitney test, * p < 0.05). 
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The microvessel density was significantly higher in the stroma of MET+ primary 
tissue (Figure 4.35B).  This reiterates previous data showing the importance of the 
vasculature system and angiogenesis in tumour progression.  The formation of new 
blood vessels from pre-existing vasculature is key to tumour progression and 
metastasis of solid tumours (Yancopoulos et al., 2000).  Angiogenesis is needed to 
supply nutrients and oxygen to the central tumour, and without adequate vascular 
supply solid tumours rarely grow beyond 1Ð2 mm (Lin et al., 2007). 
 
CD31 was subsequently analysed in the tumour and surrounding non-neoplastic 
tissue and compared to distant non-neoplastic samples (Figure 4.36). 
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Figure 4.36 CD31 MVD in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
Liver metastatic CRC samples were examined for the number of vessels per unit area (mm
2
) 
within the tumour and stroma using IHC techniques (anti-hum CD31 IgG1, 0.27 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the microvessel density (MVD).  The number of vessels per unit area 
was analysed in metastatic CRC samples, looking at the difference between tumour, stroma 
and tumour adjacent non-neoplastic (Tumour NonNeo) tissue, compared to the MVD in 
matched distant normal stroma and non-neoplastic (Normal NonNeo) tissue.  B) A 
comparison between stroma within the tumour (Tumour Stroma) and tumour adjacent non-
neoplastic (Tumour NonNeo) tissue was achieved.  (Paired t test, *** p < 0.001). 
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The MVD was compared between tumour tissue and matched distant normal samples 
(Figure 4.36).  The stroma within the tumour had significantly higher levels of 
vessels than those seen infiltrating the tumour (p < 0.001) or in the non-neoplastic 
adjacent tissue (p < 0.001).  However, when comparing this number of tumour 
stromal vessels to stroma in distant no-neoplastic normal tissue, there were higher 
number of vessels in the non-neoplastic samples (p < 0.05, Figure 4.36B).  This could 
simply be explained by the fact that the liver is a very well vascularised organ.   
 
CD31 was used to establish the differences in MVD within the tumour and 
surrounding stroma of both primary and metastatic CRC (Figure 4.37). 
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Figure 4.37 Overall Evaluation of MVD in Tumour and Stroma 
 
Primary CRC and metastatic liver samples were pooled and examined for the number of 
vessels per unit area (mm
2
) within the tumour and stroma using IHC techniques (anti-human 
CD31 IgG1, 0.27 µg/ml).  Digital images were acquired and Genieª Classifiers were 
combined with a nuclear algorithm to quantify the microvessel density (MVD).  A) The MVD 
was compared between tumour and stroma. (Unpaired t test, *** p < 0.001).  B) A 
corresponding example image of liver metastatic CRC tissue stained with anti-human CD31 
IgG1 (0.27 µg/ml).  Image at x 20 original magnification (T, tumour; S, stroma). 
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The vasculature in and around the tumour was predominately within the stroma 
(Figure 4.37A).  This is in agreement with previous data, indicating that 
intratumoural vessels are scarce in CRC.  An example image of the elevated levels of 
stromal infiltrating vessels is seen in Figure 4.37B.  This vascular localisation pattern, 
combined with corresponding α-SMA analysis (Section 4.2.3.9.) contributes to 
recognising CRC as having a stromal phenotype (Smith et al., 2010). 
 
4.2.4.3.2. HIF-1α Positive Hypoxia Staining 
The formation of new blood vessels is essential to supply solid tumours with nutrients 
and oxygen to facilitate tumour growth.  It is therefore sensible to suggest a 
relationship between the lack of adequate vascular supply and the levels of hypoxia 
(Dewhirst, 2009; Matsumoto et al., 2010; Vaupel and Mayer, 2007).   
 
Hypoxia in tumours is caused by an imbalance in oxygen supply and demand, where 
regions of tumour are beyond the diffusion distance of oxygen.  The level of hypoxia 
was evaluated using HIF-1α in primary and matched secondary CRC diseased tissue 
(Figure 4.38). 
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Figure 4.38 HIF-1α  in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue was examined for hypoxia-inducible 
transcription factor-1α (HIF-1α) within the tumour and stroma using IHC techniques (anti-
human HIF-1α IgG1, 5 µg/ml).  Digital images were acquired and Genieª Classifiers were 
combined with a nuclear algorithm to quantify the number of HIF-1α-positive cells.  A) An 
overall assessment of HIF-1α in primary and metastatic disease was carried out.  A direct 
comparison between hypoxia in the tumour and stroma for both B) primary and C) metastatic 
(met) tissue was achieved.  (Mann-Whitney test, * p < 0.05). 
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Intratumoural hypoxia causes increased expression and activity of HIF-1α and thus 
provides a good marker of hypoxic tissue.  Overall, the percentage of positive HIF-1α 
cells was relatively low, perhaps reflecting a stromal phenotype and well vascularised 
system.  Surprisingly, an increase was observed in the primary stromal tissue 
compared to primary tumour (Figure 4.38B).  This was unexpected as it was the 
authorÕs opinion that the hypoxic cells would predominate throughout the tumour. 
HIF-1α is widely expressed in normoxic cells but is normally rapidly degraded by the 
ubiquitin/proteasomal pathway (Semenza, 1999; Zhong et al., 2004).  HIF-1 regulates 
the transcription of a broad range of genes that facilitate responses to a hypoxic 
environment, including regulation of angiogenesis, erythropoiesis, the cell cycle, 
metabolism and apoptosis.  
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Figure 4.39 Comparison of HIF-1α  in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were analysed for hypoxia-inducible transcription factor-
1α (HIF-1α) using IHC techniques (anti-human HIF-1α IgG1, 5 µg/ml).  Digital images were 
acquired and Genieª Classifiers were combined with a nuclear algorithm to quantify the 
number of HIF-1α positive cells in the A) tumour and B) stroma.  
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Although no statistical significance was observed between MET- and MET+ primary 
samples, a general trend was seen that MET+ tissue showed an elevation of tumoural 
and stromal HIF-1α positive cells.  Data are in agreement with the well published 
idea that hypoxia plays an important role in tumour progression, angiogenesis and 
metastasis (Dewhirst et al., 2008). 
 
The frequency of HIF-1α was then compared between tumour and adjacent non-
neoplastic matched tissue (Figure 4.40). 
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Figure 4.40 HIF-1α  in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
The level of hypoxia-inducible transcription factor-1α (HIF-1α) was analysed 
immunohistochemically in liver metastatic CRC samples (anti-human HIF-1α IgG1, 5 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the number of HIF-1α-positive cells.  A) The difference between tumour, 
stroma and tumour adjacent non-neoplastic (Tumour NonNeo) was examined.  B) A 
comparison between the tumour (Tumour Stroma) and tumour adjacent non-neoplastic 
(Tumour NonNeo) tissue was achieved. (Paired t test, ** p < 0.01). 
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Levels of hypoxia were established and compared within the tumour infiltrating 
stroma and tumour adjacent non-neoplastic samples (Figure 4.40B).  A significant 
increase was seen in the tumour-associated stroma (p < 0.01).  The adjacent non-
neoplastic tissue should show relatively low levels of hypoxia as the vasculature 
structures here should be intact.   
 
Interestingly, hypoxic levels appeared elevated in the tumour infiltrating stroma 
compared to the tumour tissue itself (p < 0.05).  This unexpected result was further 
investigated by comparing the difference between tumour and stroma levels of 
hypoxia in primary and metastatic tissue (Figure 4.41). 
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Figure 4.41 Overall Evaluation of Hypoxia in Tumour and Stroma 
 
Primary CRC and CRC metastatic liver samples were pooled and examined for hypoxia-
inducible transcription factor-1α (HIF-1α) within the tumour and stroma using IHC techniques 
(anti-human HIF-1α IgG1, 5 µg/ml).  Digital images were acquired and Genieª Classifiers 
were combined with a nuclear algorithm to quantify the number of HIF-1α positive cells.  A) 
The percentage of HIF-1α positive cells was compared between tumour and stroma. (Mann-
Whitney test, *** p < 0.001).  B) A corresponding example image of liver metastatic CRC 
tissue stained with anti-human HIF-1α IgG1 (5 µg/ml).  Image at x 20 original magnification 
(T, tumour; S, stroma; N, necrotic; black arrow, example hypoxic cell within the tumour; green 
arrow, example hypoxic cell within the stroma). 
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Data reiterates the trend previously observed that an increase in hypoxia was 
observed within the stroma versus tumour cells (Figure 4.41A).  An example image 
shows HIF-1α positive cells within the stroma (S) and tumour (T) (Figure 4.41B).  In 
addition, an observation was made that the greatest levels of tumour cell hypoxia was 
observed adjacent to necrotic (N) regions (also illustrated in Figure 4.46).  It is also 
noted that the intensity of the staining differs.  The lower levels of HIF-1α staining 
seen within the stroma could therefore be a result of HIF-1α expression not yet 
degraded by the ubiquitin/proteasomal pathway (Semenza, 1999; Zhong et al., 2004).  
 
4.2.4.3.3. CC-3 Positive Apoptotic Staining 
Defects in apoptosis mechanisms have key roles in tumour progression, allowing 
neoplastic cells to survive beyond normal limitations, for example, hypoxia, oxidative 
stress and cell-to-cell contact restrictions.  Protecting tumour cells by escaping 
apoptosis facilitates the accumulation of genetic alterations that result in deregulation 
of cell proliferation, differentiation and motility, favouring invasiveness and tumour 
progression (Reed, 2003).   
 
The level of apoptosis was determined by CC-3 staining and assessed in primary and 
metastatic CRC samples (Figure 4.42).  
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Figure 4.42 CC-3 in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched metastatic liver samples were examined for cleaved caspase-3 
(CC-3) within the tumour and stroma using IHC techniques (anti-human CC-3 IgG1, 5 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the number of CC-3 positive cells.  A) An overall assessment of CC-3 in 
primary and metastatic disease was carried out.  A direct comparison between the levels of 
apoptosis in the tumour and stroma for both B) primary and C) metastatic (met) tissue was 
achieved. 
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Similar levels of CC-3-positive apoptotic cells were observed throughout both 
primary and metastatic CRC tumours.  Apoptosis and inflammation via tumour-
released cytokines have been proposed to play a key role in CRC progression.  TNF-
α is a cytokine extensively researched for its ability to induce apoptosis.  TNF-α 
expression in tumour cells is thought to facilitate immunological escape by 
inflammation-enhanced metastasis (Grimm et al., 2010b).  In addition, it is thought 
that tumour cells expressing TNF-α can induce apoptosis in tumour infiltrating CD8 
CTLs (Grimm et al., 2010a; Koyama et al., 2002).   
 
The current study is a blanket screen of apoptosis within all cells throughout the 
tumour microenvironment, segregated via regions, but not necessarily cell type.  This 
is perhaps a limitation of the current work as it becomes difficult to hypothesise the 
prognostic significance of apoptosis in combined cell populations.  Based on the 
prevalence of immune cells within the stroma, one could speculate that apoptosis 
seen within this region could be indicative of immune cell death.  Likewise, one 
could suggest that the level of apoptosis seen within the tumour region is most likely 
to reflect tumour cell death, as opposed to infiltrating immune cells. 
 
The levels of apoptotic positive cells within the tumour and stroma were compared in 
MET+ and MET- primary tissues (Figure 4.43). 
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Figure 4.43 Comparison of CC-3 in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were examined for cleaved caspase-3 (CC-3) within the 
tumour and stroma using IHC techniques (anti-human CC-3 IgG1, 5 µg/ml).  Digital images 
were acquired and Genieª Classifiers were combined with a nuclear algorithm to quantify 
the number of CC-3-positive cells in the A) tumour and B) stroma. 
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Significant differences were not seen between MET+ and MET- primary tissue 
samples (Figure 4.43).  Based on the previously suggested assumptions that apoptotic 
cells within the tumour region were predominantly tumour cells, one would expect 
reduced tumour cell death to be associated with a MET+ phenotype.  Defects in 
tumour cell apoptosis, and the ability to escape the restraints of normally controlled 
cell death, could facilitate metastasis by allowing epithelial cells to survive without 
attachment to the ECM (Frisch and Screaton, 2001). 
 
In addition, defects in tumour apoptotic machinery could hinder the ability of 
immune infiltrates to undergo tumour cell killing. 
 
The level of apoptosis seen in and around the tumour was then compared to that 
found at distant matched tissue (Figure 4.44). 
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Figure 4.44 CC-3 in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
The percentage of cleaved caspase-3 (CC-3) positive apoptotic cells was analysed 
immunohistochemically in liver metastatic CRC samples (anti-human CC-3 IgG1, 5 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the number of CC-3-positive cells, investigating A) the difference 
between tumour, stroma and tumour adjacent non-neoplastic (Tumour NonNeo) tissue, 
compared to matched distant normal stroma and non-neoplastic (Normal NonNeo).  B) A 
comparison between tumour (Tumour Tumour) and tumour adjacent non-neoplastic (NonNeo 
Tumour) tissue was achieved. (Paired t-test, *** p < 0.001). 
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Tumour adjacent non-neoplastic tissue showed significantly higher levels of 
apoptosis than that seen within the tumour (Figure 4.44B).  Previously in the current 
study, the accumulation of immune cells, such as CTLs (Figure 4.23A), at the IM and 
tumour adjacent non-neoplastic tissue, has been highlighted.  The same region 
subsequently showed the highest levels of apoptosis, greater than those observed 
within the tumour-associated stroma (p < 0.01) and the tumour itself (p < 0.001).  
These results possibly suggest that adjacent non-neoplastic tissue, and the immune 
cells within it, is undergoing high levels of cell death.  This is in accordance with 
research indicating that tumour cells expressing TNF-α can induce apoptosis in 
tumour-infiltrating CD8 CTLs (Grimm et al., 2010a).       
 
Analysis of apoptosis was then achieved in tumour versus stroma regions (Figure 
4.45). 
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Figure 4.45 Overall Evaluation of Apoptosis in Tumour and Stroma 
 
Primary CRC and liver metastatic samples were pooled and examined for cleaved caspase-3 
(CC-3) positive apoptotic cells using IHC techniques (anti-human CC-3 IgG1, 5 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the number of CC-3-positive cells, A) investigating CC-3 expression 
between tumour and stroma (unpaired t-test, *** p < 0.001).  B) A corresponding example 
image of liver metastatic CRC tissue stained with anti-human CC-3 IgG1 (5 µg/ml).  Image at 
x 20 original magnification (T, tumour; S, stroma). 
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A higher level of apoptosis activity was observed within the stromal regions when 
compared to tumour (Figure 4.45A).  It is well established that the cellular and non-
cellular stromal components of the tumour microenvironment, such as myofibroblasts 
and ECM proteins, contribute to the anti-apoptotic protection of tumour cells (Sebens 
and Schafer, 2011). 
 
The prevalence of apoptotic cells within the tumour microenvironment was compared 
and contrasted to areas of hypoxia and necrosis.  It was hypothesised that areas of 
hypoxia would see subsequent elevated levels of apoptosis and necrotic regions.  
Example images are illustrated in Figure 4.46. 
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Figure 4.46 Example Images of Hypoxic and Apoptotic Areas of Necrosis 
 
Example images of liver metastatic CRC samples analysed immunohistochemically for 
apoptosis using cleaved caspase-3 (anti-human CC-3 IgG1, 5 µg/ml) and hypoxia by 
hypoxia-inducible transcription factor-1α (anti-human HIF-1α IgG1, 5 µg/ml).  Digital images 
were acquired and Genieª Classifiers were combined with a nuclear algorithm to quantify 
the number of A) CC-3- and B) HIF-1α-positive cells.  Images at x 20 original magnification 
(T, tumour; S, stroma; N, necrotic). 
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Levels of apoptosis within the tumour region were strongly affiliated to the central, 
necrotic (N) areas (Figure 4.46A).  In addition, it was noticed that these necrotic areas 
were associated with adjacent hypoxic cells (Figure 4.46B, black arrow).   
 
4.2.4.3.4 Ki67 Positive Proliferation Staining 
Ki67 was used to assess the level of proliferation within the tumour and stroma of 
primary and metastatic CRC samples (Figure 4.47). 
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Figure 4.47 Ki67 in Primary CRC vs Metastatic Liver  
 
Primary CRC and matched liver metastatic tissue were examined for the proliferation marker, 
Ki67 using IHC techniques (anti-human Ki67 IgG1, 0.35 µg/ml).  Digital images were 
acquired and Genieª Classifiers were combined with a nuclear algorithm to quantify the 
number of Ki67-positive cells.  A) An overall assessment of percentage positive proliferating 
cell in primary and metastatic disease was carried out.  A direct comparison between 
proliferation in the tumour and stroma for both B) primary and C) metastatic (met) tissue was 
achieved. (Paired t test, ** p < 0.01, *** p < 0.001). 
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The level of proliferation was significantly higher in the tumour compared to that 
seen in the stroma of both primary and metastatic samples.  No difference in 
proliferation was observed within these regions when comparing primary and 
metastatic disease (Figure 4.47A).  The percentage of Ki67-positive proliferating 
cells reached near 80 % within the tumour of both primary and met samples.   
 
The level of proliferation was investigated in primary CRC tissue of a MET+ or 
MET- phenotype (Figure 4.48). 
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Figure 4.48 Comparison of Proliferation in MET+ and MET- Primary CRC Tissue 
 
Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that has since 
developed liver metastasis (MET+) were examined for the proliferation marker, Ki67 using 
IHC techniques (anti-human Ki67 IgG1, 0.35 µg/ml).  Digital images were acquired and 
Genieª Classifiers were combined with a nuclear algorithm to quantify the number of Ki67-
positive cells in A) tumour and B) stroma.  (Mann-Whitney test, * p < 0.01). 
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Although an increase in tumour proliferation was observed in MET+ CRC primary 
tissue, no significant correlation was determined (Figure 4.48A).  When researching 
the differences in proliferating stromal cells, a significant (p < 0.05) increase was 
seen in tissue that went on to develop metastatic disease (Figure 4.48B).   
 
The level of proliferation was compared in and around the tumour and adjacent non-
neoplastic tissue (Figure 4.49). 
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Figure 4.49 Ki67 in Liver Metastatic CRC and Matched Non-Neoplastic Tissue 
 
Liver metastatic CRC samples were examined for the proliferation marker, Ki67 using IHC 
techniques (anti-human Ki67 IgG1, 0.35 µg/ml).  Digital images were acquired and Genieª 
Classifiers were combined with a nuclear algorithm to quantify the number of Ki67-positive 
cells, looking at the difference between tumour and tumour stroma tissue, compared to 
matched distant normal stroma and non-neoplastic (Normal NonNeo).  B) A comparison 
between distant non-neoplastic and stroma tissue was achieved.  (Wilcoxon test, 
*** p < 0.001). 
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The number of Ki67-positive cells in the tumour was significantly higher (p < 0.001) 
compared to that seen in distant non-neoplastic tissue (Figure 4.49A).  This shows the 
highly proliferative phenotype of the neoplastic tissue.  Interestingly, the proliferation 
seen in normal stroma showed no significant difference compared to that seen 
infiltrating the tumour (Figure 4.49).  Under normal, non-neoplastic conditions the 
cells within the stroma show significantly higher (p < 0.001) levels of proliferation 
than observed in non-neoplastic tissue (Figure 4.49B).  This relationship is 
completely inverted in a neoplastic setting, where the tumour cell replication was 
significantly more frequent than observed in the tumour associated stroma 
( p< 0.001).   
 
This tumour-stroma relationship is further illustrated in Figure 4.50. 
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Figure 4.50 Overall Evaluation of Proliferation in Tumour and Stroma 
 
Primary CRC and liver metastatic samples were pooled and examined 
immunohistochemically for the proliferation marker, Ki67 (anti-human Ki67 IgG1, 0.35 µg/ml).  
Digital images were acquired and Genieª Classifiers were combined with a nuclear 
algorithm to quantify the number of Ki67-positive cells between A) tumour and stroma (Mann-
Whitney test, *** p < 0.001).  B) A corresponding example image of liver metastatic CRC 
tissue stained with anti-human Ki67 IgG1 (0.35 µg/ml).  Image at x 20 original magnification 
(T, tumour; S, stroma). 
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The significant elevation in proliferation observed in tumour cells is illustrated in the 
pooled primary and metastatic patient cohort (Figure 4.50A).  In addition, an example 
image is exemplified in Figure 4.50B.  The image selected is the same area as that 
shown in Figure 4.45B stained with the apoptotic marker CC-3.  The correlation 
between evading tumour cell death and uncontrolled proliferation is well documented 
within the literature to be a key contributor to tumour progression.  These two images 
represent the tipping of this normally well-regulated and balanced environment.   
 
4.2.4.3.5. α-SMA Stromal Staining 
Irrespective of their origin, tumours are heterogeneous cellular entities; whose growth 
depends on reciprocal interactions between neoplastic cells and their non-neoplastic 
microenvironment.  The stroma entity plays a pivotal role in many stages of 
carcinogenesis including proliferation, invasion, angiogenesis, metastasis and also 
drug resistance.  The importance of the stroma has been demonstrated within this 
study and therefore further tumour/stroma phenotyping was achieved.   
 
A Genieª algorithm was established to determine the distribution and coverage of 
stroma compared to that of the tumour (Figure 4.51). 
 
 
 
Helen Angell   239 
 
Figure 4.51 Example Images of α-SMA Staining and Genieª Analysis  
 
A) Example image of liver metastatic CRC tissue stained α-smooth muscle actin (α-SMA) 
used to aid in the identification of stroma.  Sections were stained immunohistochemically 
(anti-human α-SMA IgG2a, 2 µg/ml).  B) Digital images were acquired (at x 20 original 
magnification) and Genieª Classifiers were used to distinguish tumour (T, red) stroma (S, 
yellow) and glass (blue). 
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A Genieª algorithm was constructed to analyse the percentage coverage of stroma, 
tumour and glass (Figure 4.51).  The algorithm utilised α-SMA as a stromal marker.  
Regions of glass (blue) were excluded, except for any regions of white within the 
tumour cells.  Primary and metastatic CRC has a very globular tumour phenotype 
where the tumour cells often grow in circular structures, encapsulating areas of white 
space.  The entirety of these structures was used to depict the area of tumour 
coverage, not just the surrounding tumour cells.   
 
The algorithm was then run across different CRC samples and the percentage 
coverage compared (Figure 4.52). 
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Figure 4.52 Percentage Area of Tumour and Stroma 
 
Liver metastatic tissue was examined immunohistochemically for α-smooth muscle actin (α-
SMA) to aid in the identification of stroma (anti-human α-SMA IgG2a, 2 µg/ml).  Digital 
images were acquired and Genieª Classifiers were used to distinguish areas of tumour or 
non-neoplastic tissue (pink), stroma (green) and glass (blue) and expressed as a percentage 
of area covered.  A) A comparison between primary CRC and matched liver metastatic 
tissue.  B) Primary CRC with no affiliated metastatic disease (MET-) and primary CRC that 
has since developed liver metastasis (MET+) were compared.  C) Primary and metastatic 
tumours were combined and compared to distant non-neoplastic (Non Neo) tissue. 
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The percentage coverage of tumour (pink) and stroma (green) was compared between 
primary and metastatic CRC samples (Figure 4.52A).  The metastatic tissue had 
larger percentage coverage of stroma compared to the primary tissue.  No difference 
was observed between primary tissue with a MET+ or MET- phenotype (Figure 
4.52B).  Additionally, when comparing tumour samples to adjacent non-neoplastic 
tissue, the tumour samples had elevated levels of stroma to that seen in a non-
neoplastic sample (Figure 4.52C). 
 
Given the extensive amount of tumour-promoting, stroma-derived factors that 
facilitate tumour initiation, progression and metastasis, the stroma is likely to 
influence therapeutic outcome.  A large repertoire of molecules and receptors 
orchestrate the interactions between tumour cells and their microenvironment.  These 
include: cellular adhesion molecules, such as L1CAM and CD44; chemokines, for 
example CXCL12; and also various integrins and ECM receptors.  It has been suggest 
that these could provide suitable targets to overcome drug- and chemoresistance 
(Sebens and Schafer, 2011). 
 
The interactions orchestrated between stromal cells and tumour cells have been well 
studied; however, the author would like to suggest a focus on investigating the cross-
talk between tumour-associated stroma and immune infiltrates.  It has been shown 
that CAFs are pro-inflammatory during early stages of tumour progression and 
promote macrophage infiltration, angiogenesis and tumour growth (Erez et al., 2010).  
In addition, it is thought that CAFs can polarise different immune cells and modify 
their infiltration (Grum-Schwensen et al., 2010; Liao et al., 2009). 
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4.3. CONCLUSIONS AND FUTURE WORK 
The frequency of a selection of immune cells was assessed immunohistochemically 
in CRC primary and liver metastatic patients.  In addition, aspects of the tumour 
microenvironment were also studied and correlations with immune cells were 
subsequently made. 
 
4.3.1. Immunohistochemistry Optimisation 
Staining protocol optimisation was a fundamental requirement of this chapter, 
ensuring correct antibody specificity and that results were representative of the 
clinical setting.  Careful marker selection, immune cell isolation, FACS analysis, 
positive and negative cell pellets, method development and key tissue selection all 
contributed to successful staining optimisation.   
 
Automated IHC staining procedures combined with novel developments in image 
analysis facilitated rigorous and systematic quantification of immune cell infiltrates.  
Advancement in these areas has enabled a refined pathological approach to accurately 
determine immune cell densities and their distribution throughout tumour and stroma. 
 
4.3.2. Adaptive Immunity 
When investigating the prevalence of CD8 cells, a significant link between tumour 
and stroma tissue was apparent.  An example of this relationship is shown in Figure 
4.53A, showing the linear trend between the frequency of CD8 cells within primary 
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tumour and primary stroma (p = 0.000243, r = 0.76, r
2
 = 0.58).  This reiterates the 
importance of the tumour microenvironment and the impact of the stroma.  Elevated 
levels of CD8 CTLs within the stroma may facilitate the infiltration of CD8 cells into 
the tumour and result in a better prognosis.  In addition, the frequency of CD31 
staining in the tumour stroma was also strongly correlated with the number of CD8 
cells observed in both the primary tumour (Figure 4.53B, p = 0.0112, r = 0.58, r
2
 = 
0.34) and in the primary tumour stroma (Figure 4.53C, p = 0.0178, r = 0.55, r
2
 = 0.3).  
Perhaps the increase of vasculature results in increased infiltration of CD8 cells. 
 
When evaluating CRC tissue, there was a significant increase in the number of CTLs 
at the tumour edge compared to the number infiltrating the tumour and tumour-
associated stroma, perhaps indicating the inability of CD8 cells to penetrate into the 
CT.  Previous studies have shown that high levels of CD8 infiltrates are associated 
with survival in CRC (Mlecnik et al., 2010a).  Further analysis of metastatic tissue 
showed a linear relationship between the numbers of CD8 cells found at the tumour-
adjacent non-neoplastic tissue and those seen infiltrating the tumour stroma (Figure 
4.53D, p = 0.00005.78, r = 0.37, r
2
 = 06).  Are we observing a slow moving Ôtraffic 
jamÕ of CD8 cells trying to infiltrate the tumour?  
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Figure 4.53 Concluding Statistical Correlations Observed for CD8 Cells 
 
Primary CRC with no affiliated metastatic disease (MET-, AÐC) and liver metastatic CRC (D) 
samples were evaluated immunohistochemically as previously described.  Spotfire statistical 
analysis was then used to compare A) CD8 cells between primary tumour and primary 
tumour-associated stroma (p = 0.000243, r = 0.76, r
2
 = 0.58).  B) CD31 stained vasculature 
within primary stroma compared to CD8 cell frequency in primary tumour (p = 0.0112, r = 
0.58, r
2
 = 0.34) or with C) tumour-associated stroma (p = 0.0178, r = 0.55, r
2
 = 0.3).  D) A 
comparison in liver metastatic CRC samples between CD8 cells within the tumour-associated 
stroma and those seen in the tumour-adjacent non-neoplastic tissue (p = 0.00005.78, r = 
0.37, r
2
 = 06). 
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Tregs showed similar trends to CD8 cells in that they were significantly elevated 
within the stromal areas compared to infiltrating the tumour itself.  This was true for 
both primary and secondary disease.  Interestingly, the highest level of infiltrating 
Tregs was observed in the tumour-adjacent non-neoplastic tissue, compared to those 
that had infiltrated the tumour, which is very similar to that seen for CD8 cells.  
Further analysis revealed a linear relationship between the number of CD8 cells 
found at the tumour edge and the number of Tregs within the tumour tissue (Figure 
4.54A, p = 0.0487, r = 0.33, r
2
 = 0.11).  Are Tregs and the cytokines they produce, in 
combination with the tumour microenvironment, contributing to trafficking of CD8 
cells to the tumour edge?  Tregs present at the IM were also strongly associated with 
increases of Tregs infiltrating the tumour-associated stroma (Figure 4.54B, 
p = 0.000000000989, r = 0.80, r
2
 = 0.64).  Further to this, elevations of Tregs within 
the tumour and tumour-associated stroma, correlated with reduced levels of tumour 
cell killing (Figure 4.54C, p = 0.0117, r = Ð0.40, r
2
 = 0.16 and Figure 4.54D, 
p = 0.0272, r = Ð0.35, r
2
 = 0.13).  This demonstrates the impact of elevated Tregs 
within the tumour on the anti-tumour response.  Previous studies have shown 
elevated Tregs in HCC compared to non-tumour tissue or healthy liver samples, 
where low-Treg groups showed improved OS and DFS compared to high-Treg 
groups (Kobayashi et al., 2007).  In addition, the prevalence of Tregs was higher in 
primary than metastatic tumours (Kobayashi et al., 2007). 
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Figure 4.54 Concluding Statistical Correlations Observed for Tregs 
 
Liver metastatic CRC samples were evaluated immunohistochemically as previously 
described.  Spotfire statistical analysis was then used to compare A) Tregs within the tumour 
and CD8 cells at the tumour-adjacent non-neoplastic tissue (p = 0.0487, r = 0.33, r
2
 = 0.11).  
B) Tregs between the tumour-associated stroma and tumour-adjacent non-neoplastic tissue 
(p = 0.000000000989, r = 0.80, r
2
 = 0.64).  C) The level of CC-3 positive tumour-associated 
stroma cell death was compared to the frequency of Tregs within the tumour (p = 0.0117, r = 
-0.40, r
2
 = 0.16) or D) between the frequency of Tregs within the tumour-associated stroma (p 
= 0.0272, r = -0.35, r
2
 = 0.13). 
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Further analysis was achieved to conclude the overall relationship between 
infiltrating CD8 cells and Tregs, in combination with tumour cell proliferation 
(Figure 4.55).  The ratio of CD8 to Treg cells was calculated and compared between 
the tumour and stroma of primary CRC and liver metastatic samples.  A significant 
relationship was observed, highlighting the link between the ratio of CD8:Tregs in 
the tumour and stroma (p = 0.00000204).  Low infiltration of CD8 and Tregs in the 
stroma was associated with low numbers seen in the tumour.  In addition, the 
CD8:Treg ratio was associated with the proliferation of the tumour cells.  Ki67 was 
used as a marker for proliferation, where a spectrum of colour depicted the 
proliferation state from high (bright red), medium (purple) to low (blue).  A low ratio 
of CD8:Treg cells was associated with higher levels of tumour proliferation. 
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Figure 4.55 Statistical Correlation Between CD8/Treg Cell Ratio in the Tumour and 
Stroma, Linked with Tumour Proliferation 
 
Primary CRC and liver metastatic CRC samples were evaluated immunohistochemically for 
CD8 and Foxp3 cell infiltrates as previously described.  Spotfire statistical analysis was then 
used to compare the ratio of CD8:Tregs in the tumour (x axis) and the stroma (y axis).  This 
was also correlated to the degree of tumour proliferation, within the same samples, measured 
by the proliferation marker Ki67 using IHC techniques.  The range of Ki67 staining was 
coloured from blue (low proliferation) to red (high proliferation).  (p = 0.00000204, r
2
 = 0.469). 
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4.3.3. Innate Immunity 
When evaluating CD68, similar trends were observed for macrophages as those seen 
for CTLs and, to some extent, Tregs.  Macrophage infiltration within tumour-
associated stroma correlated with the numbers seen within tumour tissue (Figure 
4.56A, p = 0.00000351, r = 0.88, r
2
 = 0.77).  In addition, the increase in numbers of 
macrophages found at the tumour edge correlated with an increase in numbers 
infiltrating the tumour-associated stroma (Figure 4.56B, p = 0.00149, r = 0.53, r
2
 = 
0.28).   
 
A linear relationship was observed between increases in TAMs within the stroma and 
increased levels of tumour cell death (Figure 4.56C, p = 0.0273, r = 0.53, r
2
 = 0.29).  
This could be a result of IL-2- and IL-12-mediated tumour cell death.  In agreement 
with this anti-tumour macrophage activity, increased TAM frequency was linked to a 
decrease in tumour cell proliferation (Figure 4.56D, p = 0.0112, r = -0.60, r
2
 = 0.36). 
 
Results appear to demonstrate the anti-tumour properties of TAMs; however, the 
importance of pro-tumour activities of TAMs is also recognised.  Future research 
within this area could distinguish the M1/M2 phenotype of the macrophages present 
at the tumour microenvironment, thus providing further understanding of their 
prognostic significance. 
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Figure 4.56 Concluding Statistical Correlations Observed for Macrophages 
 
Primary CRC with no affiliated metastatic disease (MET-, A, C, D) and liver metastatic CRC 
(B) samples were evaluated immunohistochemically as previously described.  Spotfire 
statistical analysis was then used to compare A) CD68 positive macrophages within the 
tumour and tumour-associated stroma (p = 0.00000351, r = 0.88, r
2
 = 0.77).  B) The 
frequency of CD68 cells in metastatic tumour-adjacent non-neoplastic tissue was compared 
with matched tumour-associated stroma (p = 0.00149, r = 0.53, r
2
 = 0.28).  C) Macrophages 
in tumour-associated stroma were compared with the level of CC-3-positive tumour-
associated stroma cell death (p = 0.0273, r = 0.53, r
2
 = 0.29).  D) The number of 
macrophages in the tumour were compared with CC-3-positive tumour cell death (p = 0.0112, 
r = -0.60, r
2
 = 0.36). 
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As with previous immune infiltrates, the highest occurrence of NK cells was 
observed within the stroma of both primary and metastatic disease.  However, 
although similar trends were observed for the location of NK cells, the percentage of 
positive CD56 cells was significantly lower than that of other immune infiltrates, 
such as CD8s, Tregs and macrophages.  The existence of fewer NK cells would 
suggest a reduced level of tumour cell cytotoxicity and therefore favour disease 
progression and metastasis.  These counterintuitive clinical results were surprising 
and would have significant influence on the development of a tumour 
microenvironment model (Chapter 6).  Future work should aim to understand the 
chemokines, cytokines and cellular interactions that orchestrate the limited numbers 
of NK cells in and around CRC tumours. 
 
A tumour cell-centric view of cancer progression fails to include the importance of 
the tumour microenvironment and the immune infiltrates within it.  Research has 
alluded to the importance of the stroma.  During tumour progression, the surrounding 
microenvironment co-evolves into an activated state that facilitates tumour growth.  
Further understanding of this dynamic situation is empirical to address remaining 
questions and discover potential targeting opportunities.   
 
The question of the prognostic role of Tregs in human CRC appears to be complex 
and ambiguous.  The overall significant findings of this chapter, along with possible 
positive and negative contributing prognostic factors, are summarised 
diagrammatically in Figure 4.57. 
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Figure 4.57 Diagrammatic Summary of Current Findings and Prognostic Factors within 
Literature.   
 
A) An example image of the invasive margin (IM) of liver metastatic CRC tissue stained using 
IHC techniques, with representative cartoon immune cells demonstrating research findings.  
(CT, centre of tumour, NNLV, non-neoplastic liver).  B) Differentiation of the positive and 
negative prognostic factors in CRC.  (NK, natural killer; CTLs, cytotoxic T lymphocytes; DCs, 
dendritic cells; MDSCs, myeloid-derived suppressor cells; IRF1, interferon regulatory factor 1; 
IL-12R 2, interleukin-12 receptor 2; STAT4, signal transducer and activator of transcription 4 
gene; Tbet, T cell-associated transcription factor; CRT, Calreticulin; IL-17A, interleukin-17A; 
RORC, retinoic acid-related orphan receptor C; HMGB1, high-mobility group protein B1). 
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An understanding of the underlying mechanisms responsible for immune cell 
infiltration is an important area of research and could add to a positive or negative 
prognostic impact.  The expression of genes associated with pro-inflammatory cells, 
such as IL-17A and the Th17-specific transcription factor ROR.C have a negative 
prognostic impact in CRC.  In addition, the high-mobility group protein B1 
(HMGB1), a chromatin-binding protein released during cell stress, predicts poor 
survival.  Calreticulin (CRT), required for loading of class I MHC proteins, is 
translocated to the cell surface during stress.  An absence of CRT expression has a 
negative prognostic impact.  In contrast, CRT cell-surface expression and the 
expression of IRF1, IL-12R.2, STAT4 and Tbet genes, are all associated with a 
positive prognosis (Fridman et al., 2011). 
 
Additional future work could include looking at the changes in immune cell infiltrate 
pre and post chemotherapy treatment.  A post-chemotherapy phenotype of CD8
+
 high 
and Foxp3
+
 low was associated with improved RFS and OS (Ladoire et al., 2011b). 
Perhaps a post-chemotherapy induced anticancer immune response is the deciding 
factor in DFS and OS. 
 
Summary: Access to state-of-the-art imaging platforms and methodologies has 
enabled a refined pathological approach to accurately determine immune cell 
densities and their distribution throughout tumour- and stroma-rich regions.  A 
significant increase in the prevalence of CD8 CTLS, Foxp3 Tregs, CD68 
macrophages and CD56 NK cells was observed in the stroma of primary and 
metastatic CRC, compared to infiltration of the tumour.  A direct comparison 
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between non-metastatic primary CRC (MET-) and primary CRC that resulted in 
metastasis (MET+) was conducted.  Elevated Tregs and reduced numbers of CD8 
cells were observed in MET+ compared to MET- samples.  Within MET+ tissue, 
immune infiltrates were elevated in adjacent non-neoplastic tissue, compared to 
distant non-neoplastic samples.  This study adds to the ongoing discussion on the role 
of immune cells in metastatic development.  A metastatic phenotype has been alluded 
to, where elevation of Tregs and low density CTLs, within primary tumour, is 
associated with metastasis.  Accumulating evidence points to a critical role of 
immune infiltrates in allowing metastatic development, where Tregs may support 
tumour growth by suppressing the host anti-tumour immune response. 
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CHAPTER 5 Ð A LINK BETWEEN IN SITU AND CIRCULATING 
TREGS 
 
 
Helen Angell   257 
Chronological Framework of Thesis Progression  
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The comparison of Treg accumulation between cancer patients and healthy 
volunteers was a fundamental requirement of this PhD to begin to understand the 
involvement of Tregs in actively suppressing the anti-tumour immune response and 
influencing survival rates and disease progression.  Immunological mechanisms have 
been intensely studied in CRC.  However, the prognostic significance of infiltrating 
Foxp3
+
 regulatory T cells, CD56
+
 NK cells, and CD8
+
 cytotoxic lymphocyte cells in 
primary and liver-metastatic colon tumour tissue remains unclear. 
 
The aim of this chapter was to analyse the level of regulatory T cells in peripheral 
blood of primary and liver-metastatic patients and to investigate whether any 
correlation existed between this and infiltrating Foxp3
+
 regulatory T cells Ôin situÕ.   
 
5.1. METHODOLOGY 
5.1.1. Patient Treg Suppression Assay 
Tregs were isolated and a suppression assay set up as described in section 3.1.1.  
[Methyl-
3
H]-thymidine (TRA120 aqueous solutions 37 mBq, 1 mCi, B499 185 
Gbq/mmol 5 Ci/mmol, Amersham) at 0.5 µCi per well was added for the final 18 
hours of a day 5 assay.  Plates were harvested on day 5 and, following the addition of 
scintillation fluid (MicroscintTM PerkinElmer, Cat 6013611), were left to dry at 37 ¡C 
in a humidified atmosphere containing 5 % v/v CO2 for 2 hours prior to being read on 
a Microplate Scintillation & Luminuscence Counter (TopCount NXTTM, Packard). 
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5.1.2. Whole Blood FACS Analysis 
Approximately 1Ð4 ml of whole blood (WB) was either provided as anonymous 
blood samples from patients undergoing liver resection or taken from healthy 
volunteers as previously described.  100 µl of WB was transferred to a FACS tube 
and incubated with anti-human CD25-PE, anti-human CD4-Pcy5, and anti-human 
CD3-ECD for 30 minutes.  Red blood cells were then lysed using 500 µl of OptiLyse 
C (Beckman Coulter, A11895) and incubated for 10 minutes.  Cells were then 
centrifuged for 5 minutes at 250 ! g and the supernatant removed.  Cells were then 
fixed by adding 2.5 % v/v formaldehyde in PBS incubated for 15 minutes at room 
temperature.  Cells were centrifuged for 5 minutes at 250 ! g and the supernatant 
removed.  If intracellular staining was required, the samples were permeabilised in 
500 µl of permeabilising buffer (0.1 % w/v saponin in PBS) and then anti-human 
Foxp3-FITC antibody added for 30 minutes.  Cells were washed in 1 ml PBS, and 
centrifugated at 250 ! g for 5 minutes prior to the addition of 100 µl FLOW-
COUNT
TM
 Fluorospheres (Beckman Coulter, 7547053) and 500 µl of PBS to allow 
cell counting.  Cells were analysed on a Beckman Coulter FC 500 flow cytometer 
using the ÔAbsolute CountÕ algorithm to provide a read out of cells/µl of WB. 
 
5.1.3. In vitro Immunohistochemistry Antibody Staining Assay 
Sections were dewaxed and rehydrated using a Leica Autostainer XL.  Following 
this, where appropriate, antigen retrieval was performed using a pressure vessel in a 
RHS2 Microwave Rapid Histoprocessor (Milestone).  The appropriate target retrieval 
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solution was added, pH6 (Dako, S1699), pH8 EDTA or pH9 (Dako, S2367).  Slides 
were heated to 110 ¡C for 5 minutes and then cooled under running water for 15 
minutes.  The Autostainer 720 (Lab Vision) was then used to perform all antibody 
stains, washes and block steps, where antibodies were made up in PBS-0.05% Tween.  
Once the pre-treatment had been completed, the section was marked with an upper 
and lower boundary, using a waterproof pen (Dako, S2002) and pre-rinsed in TBS-T.  
3% H2O2 was applied for 10 minutes at room temperature to block endogenous 
peroxidase activity.  Slides were washed twice in TBS-T.  Avidin block (Vector Labs, 
SP-2001) was applied for 20 minutes followed by a TBS-T wash.  Biotin Block 
(Vector Labs, SP-2001) was applied for 20 minutes followed by an additional TBS-T 
wash.  Slides were incubated for 20 minutes with serum-free protein block (Dako, 
X0909), which was then blown off the slides (a wash step was not performed at this 
stage).  Sections were incubated with primary antibody for 60 minutes.  The current 
study used the following antibodies at the corresponding optimised concentrations: 
mouse anti-human Foxp3 IgG1 (5 µg/ml, Clone 236A/E7, Abcam 20034,), mouse 
anti-human CD8 IgG2b (0.5 µg/ml, Clone 4B11, Leica NCL-CD8-4B11), mouse 
anti-human CD56 IgG1 (0.5 µg/ml, Clone 1B6, Leica NCL-L-CD56-1B6), mouse 
anti-human Ki67 IgG1 (0.35 µg/ml, Clone MIB-1, Dako M7240), mouse anti-human 
CD68 IgG1 (0.2 µg/ml, Clone PG-M1, Dako M0876), rabbit anti-human CD31 (0.27 
µg/ml, CHG-CD31-PI, AstraZeneca in house), rabbit anti-human cleaved caspase-3 
(5 µg/ml, Clone D175, Cell Signalling Technology 9661), mouse anti-human α-SMA 
IgG2a (2 µg/ml, Clone 1A4, Sigma A2547) and mouse anti-human  HIF-1α, IgG1 (5 
µg/ml, Clone 54, Becton Dickinson 610950).  Following primary antibody 
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incubation, slides were washed twice in TBS-T.  Slides were incubated with 
corresponding secondary antibody; Vector Elite ABC kit (PK6101) or Mouse 
Envision HRP-linked polymer (Dako, K4001) for 30 minutes.  Slides were washed 
twice in TBS-T and then incubated with avidin-biotinylated antibody (Vector Elite 
ABC kit) for 30 minutes.  Slides were washed twice in TBS-T and then incubated in 
DAB (D/K3468) solution for 10 minutes.  Slides were rinsed twice in distilled water 
and removed from the autostainer.  Sections were counterstained with CarazziÕs 
Haematoxylin Gill III (Surgipath, 01540BBE) then dehydrated in ethanol and cleared 
using xylene on the Leica Autostainer XL.  Slides were then mounted using Premier 
Cover Glass slips (24 mm ! 50 mm, Surgipath
¨
) with Histomountª (National 
Diagnostics, HS-103) on a Leica CV5030 and left to dry before viewing on a Leica 
DM4000B microscope.   
 
5.1.4. Image Analysis 
Analysis of IHC images was achieved using a ScanScope digital scanner (Aperios 
Technologies Ltd.) and images were taken at x 20 original magnification.  Images 
were viewed and organised using ImageScope viewer and Spectrum operating 
system.  Each scanned image was annotated for analysis to exclude areas of glass, 
dark background staining or poor sample quality.  Genieª pattern recognition 
software was used for the automated quantitative assessment of immune infiltrates 
within specific regions of tissue.  Genieª classifiers were generated for the 
separation of areas of tumour, stroma, lymphatic aggregates, non-neoplastic tissue 
and glass (as previously described in section 4.2.3).  
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5.1.5. Tissue Samples and Ethics 
Samples were supplied by the GIMARK study tissue holdings (Division of Pre-
Clinical Oncology, University of Nottingham) and given ethical approval by 
Nottingham Research Ethics Committee 1, REC reference 08/H0403/37, first granted 
in 2008.  The SCS tissue bank supplies all tissues for the GIMARK study and this is 
also a University of Nottingham tissue bank operating under current ethical approval 
REC ref 10/H0405/6.  All samples were acquired with ethical approval and written 
informed consent, patient information is summarised in Table 5.1. 
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Table 5.1 A Summary of the Tissue Used 
 
 
(QMC; Queens Medical Centre Hospital, Nottingham) 
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5.1.6. Method of Statistical Analysis 
Data were collated into certain groups and graphically expressed as the mean, where 
error bars depicted SD.  Further analysis was then carried out to quantify any trends 
in the data, using Prism® 5 software and Spotfire® programmes.  Paired data 
underwent a t-test to determine any significant differences.  If the data assumed a 
normal distribution pattern, a paired or unpaired t-test was carried out.  If the data did 
not assume a normal distribution pattern, a ranked method was selected.  For paired 
rank testing a Wilcoxon test was carried out.  For unpaired rank testing a Mann-
Whitney analysis was used. 
 
5.2. RESULTS AND DISCUSSION 
5.2.1. Examining Tregs in CRC Liver Metastatic Patients 
There is accumulating evidence showing an increase in the prevalence of Tregs in 
cancer patients.  Elevated levels of Tregs are seen in the PB of pancreas cancer 
patients (Liyanage et al., 2002).  Research has also shown significant increases in the 
proportions of CD4
+
CD25
+ 
T cells in PB of patients with epithelial malignancies 
(Wolf et al., 2003), gastrointestinal cancers (Sasada et al., 2003) and patients with 
NSCLC and late-stage OVC (Woo et al., 2001). 
 
Further investigation into the pervasiveness of Tregs and other immune cells in CRC 
patients was required to solidify the hypothesis that inflammation is an influencing 
factor in tumour progression, and to explore links between circulating immune cells 
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and those found at the tumour site.  The current research was carried out on 
anonymous blood samples from patients undergoing liver resection.   
 
Isolation of Tregs from patients was problematic due to restrictions on the availability 
of the blood from surgery (late afternoon) and subsequent length of the isolation 
procedure.  It was therefore necessary to store the whole blood overnight prior to 
Treg isolation.  In addition to this, it was only possible to collect a maximum of 18 ml 
of blood per patient, which was subject to change on a patient-to-patient basis.  
Despite these difficulties, a proliferation suppression assay was set up with Tregs 
isolated from patient blood as previously described, to investigate the suppressive 
ability of Tregs from liver metastatic patients against PHA stimulated effector cells 
(Figure 5.1). 
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Figure 5.1 Metastatic Liver Patient Treg Suppression of PHA Stimulated Effector Cells, 
via 3H-Thymidine Incorporation 
 
CD4
+
CD25
+
 Tregs and CD4
+
CD25
-
 effector cells were isolated from 18 ml blood from a 
consenting metastatic liver patient.  CD4
+
CD25
-
 cells, stimulated with 10 µg/ml PHA were 
plated at 5 x 10
4
 cells per well.  CD4
+
CD25
+
 cells were then added at 0:2, 0:1, 1:0, 1:5, 1:10 
and 1:20 Treg:effector cell ratios.  Cells were cultured at 37 ¡C in a humidified atmosphere 
containing 5 % v/v CO2 for 96 hours.  0.5 µCi of [Methyl-3H]-thymidine was added per well 
and incubated for the final 18 hours of the assay before harvesting.  Scintillation fluid was 
added prior to reading on a Microplate Scintillation Counter.  Data are a mean of triplicates 
from a single plate (± SD) and is representative of n = 3 experiments.  A) Patient sample 
compared to B) healthy donor.  Results were evaluated using Prism 5 and statistically 
analysed using a one way ANOVA and Tukey's multiple comparison post-test (** p < 0.001, 
* p < 0.05). 
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The effect of Tregs from the liver metastatic patient was compared to that of a 
healthy donors.  However, due to time restrictions the patient blood was left 
overnight and the healthy donor blood was used immediately.  The proliferative 
response of T cells from the liver metastatic patient was much reduced.  Although the 
response of effector cells in the presence of Treg cells was reduced, it was not 
significant.  It is possible that reduced proliferation, observed across the entire 
experiment, was due to leaving the blood overnight prior to use.  Further work 
looking at healthy donor blood left overnight would help to identify the reason for 
this drop in proliferation. 
 
Due to the aforementioned problems of limited volumes of patient blood and the 
timings of receiving the samples, it was necessary to develop a more efficient assay 
to determine true Treg numbers in a shorter amount of time.  A technique was 
developed to determine Treg numbers using whole blood (WB) FACS analysis 
staining for CD4, CD3, CD25 and Foxp3.  Assay optimisation was crucial as WB 
FACS staining is problematic.  Previous groups have developed WB FACS surface 
staining techniques (Qiu et al., 2009); however, WB FACS analysis of internal 
markers, such as Foxp3, have not been published.   
 
WB FACS analysis requires lysis of the red blood cells.  This is a very destructive 
step and has a huge impact on the robustness of the cells of interest. Protocol 
optimisation is illustrated in Figure 5.2, where the destructive nature of this reagent is 
demonstrated in the ÔsprayÕ of cells in the FSC/SSC plots (Figure 5.2A).  To 
minimise these effects and improve the protocol, additional fixative steps were 
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subsequently introduced.  This was successful and resulted in little, if any, disruption 
to the cells of interest.  It was therefore possible to gate accurately on the lymphocyte 
population.  The results of assay optimisation can be seen in Figure 5.2, where the 
final assay method (Figure 5.2C) results in approximately 11 % CD4
+
CD25
+
Foxp3
+
 
Tregs, which correlates with previous research (Rudge et al., 2006).  The final stage 
of assay optimisation was to incorporate a cell counting element.  Fluorescent beads 
at a known concentration were introduced into the system, which allowed specific 
calculations to be carried out for cell populations (Figure 5.2C).  The final read out 
for this assay was cells/µl WB. 
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Figure 5.2 Optimisation of Whole Blood FACS Analysis Protocol 
 
100 µl of whole blood (WB) was incubated with 5 µl PeCy5 anti-CD4, ECD anti-CD3 and PE 
anti-CD25 for 10 minutes.  Various conditions were then tried to attain clear populations and 
good intracellular staining.  A) FACSlyse was added for 10 minutes before washing twice in 
PBS (1 % FCS).  B) Cells were fixed in 4 % formaldehyde prior to FACSlyse for 10 minutes.  
C) Optilyse was added for 10 minutes followed by fixation in 4 % formaldehyde.  Cells were 
then permeabilised followed by intracellular staining using 5 µl Alexa 488 anti-human FOXP3 
for 30 minutes.  Fluorescent cell counting beads were also added once the protocol was 
optimised to allow cell count per µl of WB.  Data were acquired on a Beckman Coulter FC 
500 flow cytometer and analysed using Weasel software. 
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Following successful assay optimisation, a screen of Tregs/µl of WB was carried out 
in 19 liver metastatic cancer patients and was compared to healthy volunteers (Figure 
5.3). 
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Figure 5.3 Whole Blood FACS Analysis of Foxp3
+
 Tregs in CRC Metastatic Patients 
Compared to Healthy Volunteers  
 
100 µl of whole blood (WB) was incubated with 5 µl PeCy5 anti-CD4, ECD anti-CD3 and PE 
anti-CD25 for 10 minutes.  Optilyse was added for 10 minutes followed by fixation in 4 % 
formaldehyde.  Cells were then permeabilised and intracellular stained with 5 µl Alexa 488 
anti-human Foxp3 for 30 minutes.  Fluorescent cell counting beads were added (960/µl) to 
allow Treg count per µl of WB analysis and a direct comparison between CRC hepatic 
metastatic (patient) and healthy aged-matched volunteers (healthy).  Data were acquired on 
a Beckman Coulter FC 500 flow cytometer and analysed using Weasel software.  Statistical 
analysis was achieved using the unpaired t-test where *** p < 0.0001 and error bars depict ± 
SD. 
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A significant (p < 0.0001) elevation in the number of circulating Tregs in CRC liver 
metastatic patients was observed when compared to healthy volunteers (Figure 5.3).  
This is in agreement with previous accumulating evidence showing significant 
increases in the proportions of CD4
+
CD25
+ 
T cells in the PB of patients with NSCLC, 
OVC (Woo et al., 2001), and gastric and oesophageal cancer patients (Mizukami et 
al., 2008a). 
 
Additional research has shown that spontaneous T cell responses against a variety of 
TAAs have been detected in the peripheral blood of CRC patients; however, no 
survival benefit was observed (Nagorsen et al., 2005).  This lack of effect may be the 
immunosuppressive effect of elevated peripheral blood (PB) and tumour-infiltrating 
Tregs.  Tumour cells use Tregs to suppress desired anti-tumour immune responses 
and protect themselves from immune attack (Wang, 2006). 
 
5.2.2. Additional Immune Cells in CRC Liver Metastatic Patients 
The inverse relationship and prognostic significance of Tregs and CD8
+
 CTLs is 
becoming increasingly documented within the literature.  The current study 
subsequently examined the same patient cohort for levels of CD3
+
CD8
+
 CTLs 
(Figure 5.4). 
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Figure 5.4 Whole Blood FACS Analysis of CD8
+
 Cells in CRC Metastatic Patients 
Compared to Healthy Volunteers  
 
100 µl of whole blood (WB) was incubated with 5 µl PE anti-CD4, ECD anti-CD3 and FITC 
anti-CD8 for 10 minutes.  Optilyse was added for 10 minutes followed by fixation in 4 % 
formaldehyde.  Fluorescent cell counting beads were added (960/µl) to allow CD8 cell count 
per µl of WB analysis and a direct comparison between CRC hepatic metastatic (patient) and 
healthy aged-matched volunteers (healthy).  Data were acquired on a Beckman Coulter FC 
500 flow cytometer and analysed using Weasel software.  Statistical analysis was achieved 
using the unpaired t-test where * p < 0.05 and error bars depict ± SD. 
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A significant (p < 0.05) difference between healthy volunteers and CRC liver 
metastatic patients was observed.  Patients suffering from CRC had reduced levels of 
CD8
+
 CTLs compared to healthy individuals.   
 
This is in agreement with recently published data that demonstrated that CD8
low
 cell 
density resulted a pro-tumour phenotype, associated with reduced OS and RFS 
(DeNardo et al., 2011). 
 
Previous research evaluated the prognostic significance of the numbers of CD8 cells 
in the peripheral blood of patients with CRC.  Peripheral CD8 counts were a 
significant (p < 0.05) independent prognostic indicator of OS; patients with higher 
CD8 levels had longer OS than those with lower CD8 frequencies (Qiu et al., 2009).   
 
The prevalence of NK and NKT cells was then scrutinised to explore any additional 
trends in circulating immune cells within CRC patients (Figure 5.5). 
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Figure 5.5 Whole Blood FACS Analysis of CD56
+
CD3
-
 NK Cells and CD56
+
CD3
+
 NKT 
Cells in CRC Metastatic Patients Compared to Healthy Volunteers  
 
100 µl of whole blood (WB) was incubated with 5 µl PeCy5 anti-CD56 and ECD anti-CD3 PE 
for 10 minutes.  Optilyse was added for 10 minutes followed by fixation in 4 % formaldehyde.  
Fluorescent cell counting beads were added (960/µl) to cell count per µl of WB analysis and a 
direct comparison between CRC hepatic metastatic (patient) and healthy aged-matched 
volunteers (healthy).  A) CD56
+
CD3
-
 cells were gated to determine NK cells/µl WB or B) 
gated on CD56
+
CD3
+
 to establish NKT cells/µl WB.  Data were acquired on a Beckman 
Coulter FC 500 flow cytometer and analysed using Weasel software (unpaired t-test, 
* p < 0.05).  
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The frequency of CD56
+
CD3
-
 NK cells (Figure 5.5A) and CD56
+
CD3
+
 NKT cells 
(Figure 5.5B) was assessed in both patient and healthy volunteer groups.  Reduced 
numbers of circulating NK cells was observed within the patient population 
compared to volunteers (p < 0.05).  Circulating NKT cells showed no significant 
difference between the two groups.  This lack of significance with NKT cells 
conflicts with previous research on diffuse large B-cell lymphoma, which reported 
elevated NKT cell numbers.  In addition, research suggested a link between decreased 
NKT numbers with tumour burden and a more aggressive disease (Hus et al., 2011).  
 
The current study has shown significant differences in circulating immune cells 
within the peripheral blood of CRC patients versus healthy volunteers.  However, 
questions remained unanswered such as: are these trends mimicked at the local 
tumour site?   
 
To determine whether these trends in circulating immune cells resulted in any 
differences in situ, matched patient tumour tissue was examined 
immunohistochemically.  A similar study to that of chapter 4 was carried out; 
however, limited tissue availability meant that it was only possible to successfully 
stain for two markers; Foxp3 and CD8 were chosen.  
 
Matched patient tumour tissue was examined for Tregs by Foxp3 IHC staining and 
subsequently compared to corresponding levels of circulating Tregs (Figure 5.6). 
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Figure 5.6 IHC Study of Tumour and Stromal Tregs in CRC Metastatic Patients, linked 
to Matched Whole Blood FACS Analysis 
 
A) Liver metastatic CRC tissue was examined for Treg infiltration into the tumour and stroma 
using IHC techniques, stained with anti-human Foxp3 IgG1 (5 µg/ml).  Digital images were 
acquired and Genieª Classifiers were combined with a nuclear algorithm to quantify the 
number of Foxp3-positive Tregs in tumour and stroma (unpaired t-test, ** p < 0.01).  These 
IHC results from B) tumour or C) stroma were directly compared to patient matched 
circulating Treg numbers.  Here, 100 µl of whole blood (WB) was incubated with 5 µl PeCy5 
anti-CD4, ECD anti-CD3 and PE anti-CD25 for 10 minutes.  Optilyse was added for 10 
minutes followed by fixation in 4 % formaldehyde.  Cells were then permeabilised and 
intracellular stained with 5 µl Alexa 488 anti-human Foxp3 for 30 minutes.  Fluorescent cell 
counting beads were added (960/µl) to allow Treg count per µl of WB analysis.    
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A similar trend was observed to that seen in previous IHC studies: the number of 
Tregs was significantly elevated in the stroma of CRC liver metastatic patients 
compared to the numbers seen within the tumour itself (Figure 5.6A).  The frequency 
of Tregs/µl of blood evaluated in Figure 5.3 was then linked to the number of Tregs 
seen at the tumour microenvironment of matched patient samples.  Specifically, 
Tregs/µl WB were contrasted with Tregs in the tumour (Figure 5.6B) and those found 
in the stroma (Figure 5.6B).  A direct relationship was noticed between elevation of 
Tregs in the blood and the numbers of Tregs found at the tumour site.  Data were 
expressed linearly to further evaluate this association (Figure 5.7). 
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Figure 5.7 The Relationship Between Circulating Tregs and their Prevalence at the 
Tumour Site. 
 
The correlation between IHC Treg analysis and peripheral blood work was evaluated using 
linear regression.  The number of percentage positive Tregs within the A) tumour or B) 
stroma, evaluated by IHC, were expressed against the number of Tregs/µl whole blood (WB) 
from matched CRC liver metastatic patient samples.  A trend line was calculated from the line 
of best fit.  
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Linear regression was used to evaluate the relationship between circulating Tregs and 
those observed within the tumour (Figure 5.7A).  A distinct correlation was seen, 
where increased levels of Tregs within the PB was associated with increased levels of 
Tregs seen within the tumour (r
2
 = 0.1424).  A similar trend was also observed when 
comparing Tregs/µl WB to those present within the stroma (Figure 5.7B, r
2
 = 
0.3338).   
 
Previously published research has presented evidence to suggest a relationship 
between improved OS and a reduction in circulating Tregs in patients with metastatic 
castration-resistant prostate cancer (Vergati et al., 2011).  
 
To determine whether similar trends were seen with CTLs, further IHC was carried 
out within the same cohort of patients and the number of percentage positive CD8 
cells within the tumour and stroma was established (Figure 5.8). 
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Figure 5.8 IHC Study of Tumour and Stromal CTLs in CRC Metastatic Patients, linked 
to Matched Whole Blood FACS Analysis 
 
A) Liver metastatic CRC tissue was examined for CD8 CTL infiltration into the tumour and 
stroma using IHC techniques, stained with anti-human CD8 IgG2b (0.5 µg/ml).  Digital 
images were acquired and Genieª Classifiers were combined with a nuclear algorithm to 
quantify the number of CD8-positive CTLs in tumour and stroma (unpaired t-test, ** p < 0.01).  
These IHC results from B) tumour or C) stroma were directly compared to patient matched 
circulating CD8 cell numbers.  Here, 100 µl of whole blood (WB) was incubated with 5 µl PE 
anti-CD4, ECD anti-CD3 and FITC anti-CD8 for 10 minutes.  Optilyse was added for 10 
minutes followed by fixation in 4 % formaldehyde.  Fluorescent cell counting beads were 
added (960/µl) to allow CD8 cell count per µl of WB analysis. 
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The prevalence of CD8 cells within the tumour and stroma was evaluated and 
significantly higher frequencies of CTLs were detected in the stroma (Figure 5.8A).  
The number of percentage positive CD8 cells in the tumour or stroma was then 
compared to the frequency in matched patient PB (Figure 5.8B and C).  The 
relationships were further analysed using linear regression (Figure 5.9).  
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Figure 5.9 The Relationship Between Circulating CTLs and their Prevalence at the 
Tumour Site 
 
The correlation between IHC CD8 analysis and peripheral blood work was evaluated using 
linear regression.  The number of percentage positive CD8 CTLs within the tumour, 
evaluated by IHC, were expressed against the number of CD8s/µl whole blood (WB) from 
matched CRC liver metastatic patient samples.  A trend line was calculated from the line of 
best fit. 
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A direct correlation was observed between the number of CD8 cells within the PB 
and the frequency within the tumour of matched patient tissue (Figure 5.9A, 
r
2
 = 0.5775).  No significant correlation was observed when evaluating the tumour-
associated stroma. 
 
5.3. CONCLUSION AND FUTURE WORK 
5.3.1. Examining Tregs in CRC Liver Metastatic Patients 
Accumulating evidence shows an increase in the prevalence of Tregs in pancreas 
cancer patients (Liyanage et al., 2002), epithelial malignancies (Wolf et al., 2003), 
gastrointestinal cancers (Sasada et al., 2003) and patients with NSCLC and late-stage 
OVC (Woo et al., 2001).  Further investigation into the pervasiveness of Tregs and 
other immune cells in CRC patients was required to solidify the hypothesis that 
inflammation is an influencing factor in tumour progression, and to explore links 
between circulating immune cells and those found at the tumour site.  
 
Due to the aforementioned problems with patient blood samples, a more efficient WB 
FACS analysis method was successfully developed to determine true Treg numbers. 
Assay optimisation, built on previously published techniques (Qiu et al., 2009), 
allowed development of WB FACS analysis of internal markers, such as Foxp3.  
Following successful assay optimisation, a screen of Tregs/µl of WB was carried out 
in 19 liver metastatic cancer patients and compared to healthy volunteers.  A 
significant elevation in the number of circulating Tregs in CRC liver metastatic 
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patients was observed, compared to healthy volunteers.  Tumour cells use Tregs to 
suppress the anti-tumour immune response and protect themselves from immune 
attack (Wang, 2006), perhaps facilitated by elevated circulating PB Tregs.   
 
5.3.2. Additional Immune Cells in CRC Liver Metastatic Patients 
The same patient cohort was examined for levels of CD3
+
CD8
+
 cells and patients 
suffering from CRC were found to have reduced levels of CD8
+
 CTLs compared to 
healthy individuals.  This inverse relationship of Tregs and CD8
+
 CTLs is becoming 
increasingly documented within the literature, where CD8
low
 cell density was 
associated with a pro-tumour phenotype, reduced OS and lower RFS (DeNardo et al., 
2011).  Numbers of PB CD8 cells in CRC was an independent prognostic indicator of 
OS; patients with higher CD8 levels had longer OS than those with lower CD8 
frequencies (Qiu et al., 2009).   
 
The frequency of CD56
+
CD3
-
 NK cells and CD56
+
CD3
+
 NKT cells was then 
scrutinised to explore any additional trends in circulating immune cells within CRC 
patients.  The frequency of circulating NK cells was lower within the patient 
population than in volunteers.  However, in contradiction to recent publications, NKT 
cells showed no significant difference between the two groups (Hus et al., 2011).  
 
To determine whether these trends in circulating immune cells resulted in any 
differences in situ, matched patient tumour tissue was examined 
immunohistochemically for Foxp3 and CD8.  The number of Tregs/µl WB was 
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evaluated against the frequency of Tregs in the tumour and tumour-associated stroma.  
A direct linear relationship was observed; increased levels of Tregs within the PB 
were associated with increased levels of Tregs seen within the tumour and stroma.  In 
addition, a direct correlation was observed between the number of CD8 cells within 
the PB and the frequency within the tumour of matched patient tissue.  
 
Results have shown a significant difference in the prevalence of immune cells in the 
peripheral blood of CRC liver metastatic and healthy volunteers.  Within the blood, 
CRC patients exhibited a Treg
high
CD8
low
NK
low
 phenotype when compared to age-
matched healthy controls.  Previous studies have evaluated the prognostic importance 
of immune infiltrates at the tumour microenvironment.  The link between circulating 
immune cells and those found in situ could provide a valuable prognostic tool. 
 
The current study, however, fails to answer the Ôchicken or the eggÕ-like question.  
Which came first, amplified numbers of circulating immune cells or elevated tumour 
infiltrates?  In addition, the question still remains: can tumours traffic these immune 
cells into its local microenvironment, from such distant locations?  Also, would you 
see the same association between in situ and circulating immune cells in patients not 
presenting metastatic disease?  Additional research is therefore greatly warranted.   
 
It appears that most tumours are associated with tumour-promoting innate immune 
response, involving macrophages, while B and T cells are involved in a less efficient 
anti-tumour immune response.  Tumour cells exploit infiltrating immune cells for 
their own benefit. 
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Summary:  The comparison of Treg accumulation between cancer patients and 
healthy volunteers was a fundamental requirement of this PhD.  The aim of this 
chapter was to analyse the level of Tregs in peripheral blood of primary and liver-
metastatic patients and to investigate whether any correlation existed between this 
and infiltrating Foxp3
+
 regulatory T cells Ôin situÕ.  Within peripheral blood, CRC 
patients exhibited a Treg
high
CD8
low
NK
low
 phenotype when compared to age matched 
healthy volunteers.   
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CHAPTER 6 Ð BUILDING AN IN VITRO MODEL AND 
INTERROGATING THE SYSTEM 
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Chronological Framework of Thesis Progression 
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This PhD study has established that Tregs could be key players in CRC tumour 
progression.  Previous chapters have demonstrated the prevalence of Tregs in and 
around the tumour.  In addition, the study determined a correlation between Tregs 
and patients with a MET+ phenotype.  Key to these data were the finding that Tregs 
co-localised to various effector cells.  Although research into Treg biology is 
intensifying, many questions remain unanswered.  In order to progress the study 
further and understand tumour-Treg-immune cell interactions, it was necessary to 
construct a realistic Ôex vivoÕ model.  The rationale for this model was to gain an 
insight into the role of Tregs within the tumour microenvironment and suppression of 
anti-tumour immunity.  Due to the time constraints of a PhD, this work was 
undertaken in parallel with chapters 4 and 5.  Chapter 6 aimed to investigate 
research interactions between CD4
+
CD25
+
 Tregs and a candidate for Treg mediated 
suppression.  The original contender selected was CD3
-
CD56
+
 NK cells.  In addition, 
the model encompassed further levels of complexity, incorporating tumour cells.  
Despite several mechanisms of suppression being suggested, the effects of regulatory 
T cells on tumour-killing cells, such as natural killer cells, remain ambiguous.  It is 
becoming widely acknowledged that inhibiting Treg function in cancer patients may 
contribute to the success of new immunotherapies.  This in vitro model would 
therefore be employed to screen for Treg targets.  This compilation of assays could 
provide a platform on which to validate lead antibodies produced against the selected 
Treg target. 
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6.1. METHODOLOGY 
6.1.1 K562 Cell Killing Assay 
K562 tumour cells were re-suspended at 2 × 10
7
 cells per ml in PBS and 5(6)-
Carboxyfluorescein diacetate N-succinidyl ester (CFSE, Sigma, Cat 2188) was added 
at a final concentration of 2.5 µM.  Cells were incubated for 8 minutes with vortexing 
every 2 minutes.  Cells were then centrifuged for 4 minutes at 300 × g and the 
supernatant removed.  Cells were re-suspended in 10% v/v FBS RPMI and 
transferred to a new tube.  This step was repeated three times.  Stained cells were 
recounted using Trypan blue exclusion.  CFSE stained K562 cells were seeded at 1 × 
10
4
 cells per well in a 96-well round bottom Nunc Tissue Culture Plate (Nuclon
TM
 
Surface, Cat 163320).  Isolated PBMCs from a healthy donor (as previously 
described) were then added (100 µl) at 1:0, 1:3, 1:10 and 1:30 K562:PBMC cell 
ratios.  Cells were cultured at 37 ¡C in a humidified atmosphere containing 5 % v/v 
CO2 for 6 hours.  Cells were then stained with 100 µl 1:10 v/v propidium iodide (PI) 
for 15 minutes, to assess cell viability before being analysed using FACS. 
 
6.1.2 NKG2D and TGF-β RII FACS Analysis 
PBMCs were isolated as previously described.  1 × 10
6
 cells were transferred to 
FACS tubes and washed in 1 ml PBS by centrifugation at 250 × g for 5 minutes.  5 µl 
of anti-human TGF-β RII primary antibody (R&D Systems, AF-241-NA) was 
incubated for 20 minutes followed by two PBS wash steps.  Additional antibodies, 
such as anti-human CD8-FITC, anti-human CD3-Alexa 647, anti-human CD3-ECD, 
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anti-human CD4-ECD, anti-human CD56-PC5, and anti-human NKG2D-PE 
(Beckman Coulter, A08934), were also used in different required combinations.  
Cells were washed twice in PBS before incubating, where appropriate, with TGF-β 
RII secondary donkey anti-goat IgG-PE (R&D Systems, F0107) for 20 minutes at 
room temperature, protected from light.  Cells were then fixed by adding 1 ml of 2.5 
% v/v formaldehyde in PBS and incubated for 15 minutes.  A final wash step in PBS 
preceded analysis on a Beckman Coulter FC 500 flow cytometer and data were 
analysed using Weasel software. 
 
6.1.3 ULBP-2 and MICA FACS Analysis 
Various tumour cell lines were re-suspended at 1 × 106 cells per ml in PBS.  200 µl of 
this cell suspension was centrifuged for 5 minutes at 300 × g and the supernatant 
removed. Cells were re-suspended in 1% v/v BSA PBS and left on ice to block for 
30 minutes.  10 µl of monoclonal anti-human MICA (R&D Systems, MAB1300) and 
ULBP-2 (R&D Systems, MAB1298) primary antibodies at 25 µg/ml were incubated 
for 30 minutes on ice.  Cells were then washed twice in BSA-PBS before incubating 
with 10 µl of secondary goat F(abÕ)2 anti-mouse IgG (Fcγ)-FITC antibody (Beckman 
Coulter, PN IM1619) at 25 µg/ml, kept on ice and in the dark.  Two final wash steps 
in BSA-PBS preceded analysis on a Beckman Coulter FC 500 flow cytometer and 
data were analysed using Weasel software. 
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6.1.4 NK Cell Isolation 
NK cell isolation was achieved using an EasySep® Human CD56 selection kit 
(EasySep®, 18055) and carried out according to the manufacturerÕs instructions.  In 
brief, PBMCs were isolated as previously described (Section 2.1.2) and re-suspended 
at 1 × 10
8
 cells per ml in isolation buffer (PBS w/o Ca/Mg, 0.1 % BSA, 2 mM 
EDTA). EasySep® Positive Selection Cocktail was added at 100 µl/ml of cells, mixed 
and incubated at room temperature for 15 minutes.  This cocktail contained a 
combination of mAbs, bound in bispecific tetrameric antibody complexes (TACs), 
directed against CD56 and dextran.  EasySep® Magnetic Nanoparticles were then 
added at 50 µl/ml of cells, mixed and incubated for 10 minutes.  These nanoparticles 
were a suspension of magnetic dextran iron particles in water.  The cell suspension 
was increased to 2.5 ml by adding isolation buffer and then placed into the Purple 
EasySep® Magnet and incubated for 5 minutes.  Following this, the magnet and tube 
were inverted together, in one continuous motion, pouring of the supernatant fraction.  
The magnetically labelled NK cells remain inside the tube, held by the magnetic 
field.  The tube was removed from the magnet and the separation process repeated a 
further two times by adding an additional 2.5 ml of isolation buffer.  Following this 
the tube was removed from the magnet to elute the NK cells, which were then re-
suspended in the appropriate media, ready for use. 
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6.1.5 Soluble TGF-β Human FlowCytomix Kit 
The levels of TGF-β were quantified using a FlowCytomixª bead-based Multiple 
Analyte Detection Kit (eBioscience
¨
, BMS8420FF, 58729005).  This is a fluorescent 
bead immunoassay, utilising similar science as the ELISA technique.  Samples were 
first diluted 1:10 with Assay Buffer and acidified by adding 20 µl of 1N HCl and 
incubated at room temperature for 1 hour, followed by the addition of 20 µl 1N 
NaOH.  Similar to an ELISA, a standard curve was prepared using 3 µl of standard 
mixture provided, with 57 µl of assay buffer, titrated into seven standard dilutions at 
1:3.  Beads coated with TGF-β-specific antibodies were then prepared (1:20 reagent 
dilution buffer) and 10 µl added to 10 µl of sample per tube.  20 µl of a biotin-
conjugated secondary antibody was added to bind to the TGF-β captured by the first 
antibodies (1:20 reagent dilution buffer), mixed and incubated at room temperature 
for 2 hours in the dark.  400 µl of assay buffer was added to each tube, centrifuged for 
5 minutes at 200 × g and the supernatant removed.  This wash step was repeated, 
followed by addition of Streptavidin-PE, which emits a signal when bound to the 
biotin conjugate.  0.7 µl of Streptavidin-PE mixture and 19.3 µl of assay buffer were 
added per tube, mixed and incubated at room temperature for 1 hour, in the dark.  
Following this, 400 µl of assay buffer was added to each tube, centrifuged for 5 
minutes at 200 × g and the supernatant removed.  This wash step was repeated prior 
to analysis on a Beckman Coulter FC 500 flow cytometer and data were analysed 
using FlowCytomix Pro 2.3 Software. 
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6.1.6. Method of Statistical Analysis 
Data points were in triplicate and graphically expressed as the mean, where error bars 
depicted SD.  Further analysis was then carried out to quantify any trends in the data, 
using Prism® 5 software.  To analyse the repeat measured data within this chapter a 
one way ANOVA was firstly implemented to determine any significant differences.  
A TukeyÕs multiple comparison post-test was then implemented to further distinguish 
p values between data groups. 
 
6.2. RESULTS AND DISCUSSION 
NK cells play an important role in the innate immune system, as they are cytotoxic 
towards tumour cells via the granule exocytosis and the Fas-Fas-L pathway.  Granule 
exocytosis utilises perforin to traffic granzyme A and B to the cytosol of appropriate 
targets, where they induce cell death by cleavage of critical substrates (Figure 6.1).  
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Figure 6.1 Diagrammatic Representation of Natural Killer Cell and Tumour Interaction 
 
Natural Killer (NK) cells are cytotoxic towards tumour cells via release of Interferon-γ (IFN-γ) 
and tumour necrosis factor-α (TNF-α).  A network of cell surface receptors, including 
members of the NK Groups 2 (NKG2) family, killer cell immunoglobulin-like receptors (KIRs) 
and natural cytotoxicity receptors (NCRs) including NKp46, NKp30 and NKp44, orchestrate 
tumour cell target recognition.  This initiates a cascade of intracellular events in the target 
tumour cell involving rapid induction of reactive oxygen species, caspase activation, loss of 
mitochondrial membrane potential and DNA fragmentation, leading to target cell death.  
(GZB, granzyme B; TGF-β RII, transforming growth factor-β receptor II). 
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Following target recognition, NK cells rapidly secrete large amounts of IFN-γ, TNF-
α, CCL3, CCL4 and CCL5 that influence innate and adaptive immune responses 
(Ghiringhelli et al., 2006; Zimmer et al., 2008).  Tumour cell recognition by NK cells 
is dictated by a balance between inhibitory signals mediated by MHC class I 
molecules and activating signals triggered by specific ligands.  The MIC-NKG2D 
system is an example of an activating signal that participates in the control of 
epithelial tumours.  However, in cancer patients, tumour-mediated shedding of MICs 
can occur resulting in reduced NK cell activation (Ghiringhelli et al., 2005). 
 
Multiple checkpoints exist to prevent inappropriate activation of damaging 
mechanisms, including TGF-β, which down-regulates cell-surface expression of 
activating NK receptors and so limits their killing activities (Moretta et al., 2005).  
Cell surface expression of TGF-β receptors on NK cells makes them vulnerable to 
control by soluble TGF-β.  Therefore, under certain pathological conditions that 
increase exposure to TGF-β, NK cells may under-express activating receptors.  
Signals from soluble or cell-associated TGF-β within a tumour microenvironment can 
therefore suppress NK cell killing, enabling tumour escape (Moretta et al., 2005).  
Within a tumour site, the cytokine profile is typically immunosuppressive and the 
level of TGF-β is likely to be elevated.  Sources of TGF-β within the tumour 
microenvironment include tumour cells, stromal cells, migratory hematopoietic cells 
and Tregs.  In addition, macrophages have been incriminated in tumour progression 
and one contributory factor might be the release and activation of latent TGF-β (Wahl 
et al., 2006).   
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Therefore, it is suggested that NK cell surface expression of TGF-β receptors may 
facilitate Treg-mediated, cell-contact dependent, down regulation of the NK cell-
activating receptor NKG2D (Ghiringhelli et al., 2005; Moretta et al., 2005; Zimmer et 
al., 2008).  Figure 6.2 illustrates this hypothesis and highlights the basic components 
for the proposed in vitro model.   
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Figure 6.2 Diagrammatic Representation of Treg Suppression of Natural Killer Cells 
and Tumour Interaction 
 
Cell surface expression of transforming growth factor-β receptor II (TGF-β RII) on natural 
killer (NK) cells makes them vulnerable to control by soluble TGF-β.  Signals from soluble or 
cell-associated TGF-β within a tumour microenvironment cause under-expression of 
activating NK receptors, therefore suppress NK cell killing, enabling tumour escape.  It is 
suggested that NK cell surface expression of TGF-β receptors functions to facilitate Treg-
mediated cell-contact dependent down regulation of the NK cell-activating receptor NKG2D.  
Thus, Tregs are able to inhibit NK cell effector functions and resting NK cell proliferation, 
resulting in reduced cytotoxicity towards tumour targets.  (TCR, T cell receptor; NKG2D, NK 
Group 2 member D; KIR, killer cell immunoglobulin-like receptor; NCR, natural cytotoxicity 
receptor). 
Helen Angell   300 
It is speculated that Tregs are able to inhibit NK cell effector functions and resting 
NK cell proliferation, resulting in reduced cytotoxicity towards tumour targets 
(Zimmer et al., 2008).  Studies have shown that Tregs impair NK cell activation in 
cancer patients (Ghiringhelli et al., 2005).  Both human and murine in vitro and in 
vivo systems have shown Tregs potently suppress NK cell responses, including the 
NK cell-mediated control of tumour expansion (Ghiringhelli et al., 2005). 
 
NK cells have been shown to kill MHC class I-deficient (MHC I-) tumour cell lines 
(Smyth et al., 2000).  In vivo studies have demonstrated that NK-deficient mice have 
problems clearing MHC I- tumour cells and chemically induced tumours are more 
susceptible in mice depleted of NK cells (Kim et al., 2000).   
 
An in vitro model, investigating the suppressive ability of Tregs on NK cell killing 
activity and interactions with effector cells will improve understanding of the role of 
Tregs within the tumour microenvironment and suppression of anti-tumour immunity.   
 
6.2.1. K562 Cell Killing Assay with PBMCs 
The first step in constructing a Treg:effector:NK cell suppression model is the 
development of a reliable cell killing assay.  Preliminary studies involved looking at 
the K562 cell line, derived from a chronic myelogenous leukaemia (CML) patient in 
blast crisis (Klein et al., 1976).  K562 cells are subject to NK cell killing as they lack 
the MHC complex required to inhibit NK cell activity.  This cell line was used 
initially to develop this work looking at cell killing by PBMCs. 
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CFSE labelling was used to distinguish the K562 cells from co-cultured unlabelled 
PBMCs.  Cells were co-cultured for 6 hours and then counter-stained with PI to 
assess cell viability (Figure 6.3A). 
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Figure 6.3 FACS Analysis of K562 Cell Killing Assay with PBMCs 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE, 8 minutes.  Cells were then 
re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  CFSE 
stained K562 cells were seeded at 1 x 10
4
 cells per well with isolated PBMCs at 1:0, 1:3, 1:10 
and 1:30 (K562:PBMC cell ratios).  Cells were cultured at 37 ¡C in a humidified atmosphere 
containing 5 % v/v CO2 for 6 hours and then counter-stained with 100 µl propidium iodide (PI) 
for 15 minutes to assess cell viability.  A) Cells were analysed using FACS, gated to initially 
remove cell debris ('Population') and then to evaluate CFSE positive cells only.  B) Cell killing 
was expressed as a percentage of PI+ to PI- cells.  Data are a mean of triplicates from a 
single plate (± SD) and is representative of three different experiments, statistically analysed 
using a one way ANOVA and Tukey's multiple comparison post-test (*** p < 0.001). 
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The total cell population was first gated to remove debris and then subsequently 
further gated to remove CFSE-negative PBMC cells.  FACS analysis was then set to 
quantify a consistent number of events within the CFSE positive region (K562 cells), 
to prevent variations in PBMC events from influencing the results.  Cell walls of 
viable cells are impermeable to PI; however, necrotic cells lose their integrity and 
become permeable.  The incorporation of PI can therefore be used as a measure of 
cell viability.  This assay was repeated three times and cell-killing activity expressed 
as a percentage of CFSE
+
PI
+
 (dead K562s) cells to CFSE
+
PI
-
 (viable K562s) (Figure 
6.3B). 
 
Increasing numbers of PBMCs resulted in elevated levels of CFSE
+
PI
+
, dead K562 
cells.  A background of 24.04 % was observed with no PBMCs present, which 
significantly increased to 71.07 % with 1:30 K562:PBMC cell ratios (Figure 6.3B). 
 
This assay was repeated with varying K562:PBMC cell ratios to determine the 
optimum killing conditions (Figure 6.4). 
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Figure 6.4 Extended K562 Cell Killing Assay with PBMCs 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
CFSE stained K562 cells were seeded at 1 x 10
4
 cells per well with isolated PBMCs at 1:0, 
1:3, 1:10, 1:30, 1:60, 1:90 and 1:120 (K562:PBMC cell ratios).  Cells were cultured at 37 ¡C 
in a humidified atmosphere containing 5 % v/v CO2 for 6 hours and then counter-stained with 
100 µl propidium iodide (PI) for 15 minutes to assess cell viability.  A) Cells were analysed 
using FACS, gated to initially remove cell debris ('Population') and then to evaluate CFSE 
positive cells only.  B) Cell killing was expressed as a percentage of PI+ to PI- cells.  Data are 
a mean of triplicates from a single plate (± SD) and is representative of three different 
experiments, statistically analysed using a one way ANOVA and Tukey's multiple comparison 
post test (** p < 0.01; *** p < 0.001; ns, no significant difference). 
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This FACS data were then expressed as a percentage of K562 cell death (Figure 
6.4B).  As described previously, an increase in cell death was observed when the ratio 
of PBMCs was elevated to 1:30.  A plateau was then seen at higher ratios, where an 
increase in PBMC cell number did not influence the percentage of K562 cell death 
(Figure 6.4B). 
 
To allow time for Treg isolation during day 1, followed by an overnight cell-killing 
assay, it was essential to extend the killing assay.  A time course was therefore 
prepared to determine the effect of extended incubation times (Figure 6.5). 
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Figure 6.5 Extended K562 Cell Killing Assay with PBMCs 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
CFSE-stained K562 cells were seeded at 1 x 10
4
 cells per well with isolated PBMCs at 1:0, 
1:3, 1:10, 1:30, 1:60, 1:90 and 1:120 (K562:PBMC cell ratios).  Cells were cultured at 37 ¡C 
in a humidified atmosphere containing 5 % v/v CO2 for 12, 18 or 20 hours and then counter-
stained with 100 µl propidium iodide (PI) for 15 minutes to assess cell viability.  A) Cells were 
analysed using FACS, gated to initially remove cell debris ('Population') and then to evaluate 
CFSE positive cells only.  B) Cell killing was expressed as a percentage of PI+ to PI- cells.  
Data are a mean of triplicates from a single plate (± SD) and is representative of three 
different experiments, statistically analysed using a one way ANOVA and Tukey's multiple 
comparison post test  (* p < 0.05; *** p < 0.001; ns, no significant difference). 
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Prolonging the cell killing assay at the required 1:30 K562:PBMC ratio made very 
little difference to the percentage of cell death (Figure 6.5).  Assay optimisation was 
therefore complete and a reliable cell-killing assay established (future work will now 
not include the detailed FACS analysis figures).  This assay was then used to 
determine the effect on cell killing when a Treg population was introduced into the 
system.   
 
Isolated Tregs and PBMCs from the same donor were co-cultured with CFSE stained 
K562s and incubated for 16 hours prior to determining the K562 percentage cell 
death via PI staining (Figure 6.6).  No significant suppression of cell killing was 
observed.  It was speculated that this was due to skewed Treg:PBMC cell ratios with 
the presence of the K562 cells.   
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Figure 6.6 Failure of Treg Mediated Suppression of K562 Cell Killing Assay with 
PBMCs 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
Expanded Tregs and donor matched isolated PBMCs were incubated at the indicated ratios 
with CFSE-stained K562 cells and cultured at 37 ¡C in a humidified atmosphere containing 5 
% v/v CO2 for 16 hours.  Cells were counter-stained with 100 µl propidium iodide (PI) for 15 
minutes to assess cell viability and analysed using FACS, gated on CFSE positive cells, then 
cell killing expressed as a percentage of PI+ to PI- cells.  Data are a mean of triplicates from 
a single plate (± SD). 
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A 4 hour pre-incubation step for the Tregs and PBMCs was then introduced, prior to 
adding the K562 target cells (Figure 6.7). 
 
A significant reduction in the percentage of K562 cell killing was observed when 
Tregs were introduced at a 1:30:60 K562:PBMC:Treg cell ratio (Figure 6.7).  This 
significant suppression was not observed when the Tregs were replaced with the same 
number of CD25
-
 effector control cells.  This confirmed that Tregs were having a 
suppressive effect on a population of cells within PBMCs that would normally cause 
the cell killing activity.  At this stage it was speculated that this was against NK cells.   
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Figure 6.7 Treg Mediated Suppression of K562 Cell Killing Assay with PBMCs 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
Isolated Tregs and PBMCs were pre-incubated at the indicated ratios for 4 hrs.  Isolated 
effector cells (Eff) from the same donor replaced Tregs as a control.  CFSE-stained K562 
cells were then introduced and cultured at 37 ¡C in a humidified atmosphere containing 5 % 
v/v CO2 for 12 hours.  Cells were counter-stained with 100 µl propidium iodide (PI) for 15 
minutes to assess cell viability and analysed using FACS, gated on CFSE-positive cells, then 
cell killing expressed as a percentage of PI+ to PI- cells.  Data are a mean of triplicates from 
a single plate (± SD) and is representative of three different experiments, statistically 
analysed using a one way ANOVA and Tukey's multiple comparison post-test (* p < 0.05). 
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6.2.2. FACS Investigation of Model Markers on PBMCs 
To confirm the details of the proposed model, it was essential to investigate the key 
components using specific cell markers to determine the expression on single cell 
populations.  This enabled a more complex understanding of the functional role of 
each cell population and how it contributed to the suppression of tumour cell killing.   
 
A network of cell surface receptors, including members of the NKG2 family, KIR 
family and NCRs, orchestrate tumour target cell recognition.  These receptors 
collaborate with cytokine receptors to coordinate the recognition and disposal of 
dangerous cells, whilst avoiding normal autologous cells.  Specifically, the cell 
surface receptor NKG2D plays a key role in coordinating the recognition and disposal 
of tumour cells and so an understanding of its distribution on different cell 
populations was important (Figure 6.8). 
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Figure 6.8 Investigation of NKG2D Expression   
 
1 x 10
6
 isolated PBMCs were washed in PBS and incubated with A) 5 µl FITC anti-CD8, PE 
anti-NKG2D, Alexa647 anti-CD3 and ECD anti-CD4 or B) pC5 anti-CD56, PE anti-NKG2D, 
and ECD anti-CD3 for 20 minutes.  Cells were washed and fixed for 15 minutes.  Data were 
acquired immediately on a Beckman Coulter FC 500 flow cytometer and analysed using 
Weasel software. 
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NKG2D was seen to be expressed on CD3 and CD8 cells, and to a lesser extent on 
CD4 cells (Figure 6.8A).  More detailed FACS analysis was required to distinguish 
the different subdivisions of cells expressing NKG2D. 
 
CD56 is a known marker for NK and NKT cell populations (Whiteside and 
Herberman, 1990).  CD56 was used against NKG2D after gating positively or 
negatively for CD3 cell populations.  Data highlighted that NKG2D is expressed on 
CD56
+
CD3
-
 NK cells and also CD56
+
CD3
+
 NKT cells (Figure 6.8B).   
 
It is hypothesised that NK cell surface expression of TGF-β receptors may function to 
facilitate Treg-mediated, down-regulation of NKG2D.  The expression TGF-β RII 
was therefore investigated (Figure 6.9). 
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Figure 6.9 Investigation of TGF-β  RII Expression   
 
1 x 10
6
 isolated PBMCs were washed in PBS and incubated with primary TGF-β RII antibody 
for 20 minutes.  Cells were then washed twice in PBS and incubated with 5 µl A) ECD anti-
CD4, Alexa 647 anti-CD3 and FITC anti-CD8 or B) ECD anti-CD3 and PeCy5 anti-CD56 for 
20 minutes.  Following two further wash steps, cells were incubated with secondary TGF-β 
RII antibody for 20 minutes and fixed for 15 minutes.  Data were acquired immediately on a 
Beckman Coulter FC 500 flow cytometer and analysed using Weasel software. 
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FACS analysis revealed co-staining of TGF-β RII with CD3+ cells, CD4+ cells and 
also CD8
+
 cells.  To further distinguish these cell populations, the NK cell marker 
CD56 was then introduced (Figure 6.9B). 
 
TGF-β RII was seen on cells that express CD56, confirming that NK cells have TGF-
β RII.  Gating the cell population on CD3 enabled segregation of NK and NKT cells, 
where both were seen to express TGF-β RII.  The cell surface expression of TGF-β 
receptors on NK cells could render them vulnerable to control by soluble TGF-β.  
Therefore, under certain pathological conditions known to increase exposure to TGF-
β, NK cells may under-express activating receptors, such as NKG2D.  Signals from 
soluble or cell-associated TGF-β within a tumour microenvironment may therefore 
suppress NK cell killing, enabling tumour escape.  Within a tumour site, the cytokine 
profile is typically immunosuppressive and the level of TGF-β is likely to be 
elevated.  Sources of TGF-β within the tumour microenvironment include tumour 
cells, stromal cells, migratory haematopoietic cells and Tregs. 
 
6.2.3. K562 Cell Killing Assay with NK Cells 
NK cells were isolated from 50 ml of healthy blood as described in section 6.1.4.  
The EasySep® human CD56 positive selection kit is designed to isolate CD56
+
 NK 
and NKT cells from PBMCs.  The kit utilises tetrameric antibody complexes and 
dextran-coated magnetic particles combined with a human fc receptor antibody to 
minimise non-specific binding.  The process is summarised in Figure 6.10. 
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Figure 6.10 Diagrammatic Representation of the EasySep® Human NK Isolation 
Procedure 
 
Step 1 involves adding EasySep® antibody selection cocktail to peripheral blood mononuclear 
cells (PBMCs), isolated from 50 ml human blood.  Magnetic nanoparticles are then added, 
mixed and incubated in step 2.  This cell suspension is then placed into the purple EasySep® 
magnet and incubated for 5 minutes.  The magnet and tube are inverted together, in one 
continuous motion, pouring off the supernatant (Step 4).  The magnetically labelled NK cells 
remain inside the tube, held by the magnetic field.  To elute the NK cells, the tube is simply 
removed form the magnet (step 5). 
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Isolated NK cells were co-cultured with CFSE-stained K562 cells at increasing ratios 
to establish their cytotoxic function (Figure 6.11).  A significant increase in the 
percentage of K562 cell death was observed when NK cell ratios were elevated to 1:3 
(64.0 %), 1:10 (83.4 %) and 1:30 (89.8 %) K562:NK cell ratios.  In this assay, NK 
cells were isolated based on a CD56-positive selection only.  Due to this, the 
population would therefore also include CD56
+
CD3
-
 NK, CD56
+
CD3
+
 NKT, 
CD56
+
CD8
+
 cell types.  A CD56
-
 control was included and showed elevated levels 
(36.9 %) of cytotoxic activity compared to effector cells (data not shown) and 
background levels of K562 cell death (1:0 ratio, 4.5 %).  This demonstrates other 
cytotoxic T cells that would perhaps contribute to tumour-cell killing; however, those 
populations were outside the scope of the current study. 
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Figure 6.11 K562 Cell Killing Assay with Isolated NK Cells 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
CFSE stained K562 cells were seeded at 1 x 10
4
 cells per well with isolated CD56+ natural 
killer (NK) cells at 1:0, 1:3, 1:10 and 1:30 (K562:NK cell ratios).  Isolated CD56- cells were 
included as a control.  Cells were cultured at 37 ¡C in a humidified atmosphere containing 5 
% v/v CO2 for 16 hours and then counter-stained with 100 µl propidium iodide (PI) for 15 
minutes to assess cell viability.  Cells were analysed using FACS, gated on CFSE positive 
cells, then cell killing expressed as a percentage of PI+ to PI- cells.  Data are a mean of 
triplicates from a single plate (± SD) and is representative of three different experiments, 
statistically analysed using a one way ANOVA and Tukey's multiple comparison post-test 
(*** p < 0.001). 
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As NK cells were isolated based on CD56-positive selection, further FACS analysis 
was achieved to determine the percentage breakdown of various other cell 
populations included (Figure 6.12).   
 
FACS analysis revealed a relatively high percentage of CD8 cells within the 
population.  Also, by gating on CD3 positive or CD3 negative it was possible to 
determine the amount of NK versus NKT cells present (Figure 6.12). 
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Figure 6.12 FACS Analysis of Isolated NK Cells 
 
NK cells were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  A pre-titrated volume of surface antibodies was added: ECD anti-CD3, FITC 
anti-CD8, PeCy5 anti-CD56 with A) PE anti-TGF-β RII or B) PE anti-NKG2D.  Cells were then 
fixed and permeabilised.  Data were acquired on a Beckman Coulter FC 500 flow cytometer 
and analysed using Weasel software.  NK and NKT analysis was carried out on CD3+/- 
gating. 
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Flow cytometer data confirmed the expression of NKG2D receptor on CD3
-
 NK and 
CD3
+
 NKT cell populations (Figure 6.12).  In addition, cell surface expression of the 
TGF-β receptor II (TGF-β RII) on CD56
+ 
NK cells was observed, which potentially 
makes them vulnerable to control by soluble TGF-β.  
 
The effect of introducing Tregs into the system was then determined.  This was 
established by isolating both NK cells and Tregs on the same day, from the same 
donor.  Tregs and NK cells were then pre-incubated at various ratios before adding 
K562 tumour cells and observing the cytotoxicity of the NK cells (Figure 6.13).  
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Figure 6.13 Treg Mediated Suppression of K562 Cell Killing Assay with NK Cells 
Isolated from the same Donor 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
Isolated Tregs and CD56+ natural killer (NK) cells were pre-incubated at the indicated ratios 
for 4 hours.  Isolated effector (Eff) and CD56- cells were also included as controls.  CFSE 
stained K562 cells were then introduced and cultured at 37 ¡C in a humidified atmosphere 
containing 5 % v/v CO2 for 12 hours.  Cells were counter-stained with 100 µl propidium iodide 
(PI) for 15 minutes to assess cell viability and analysed using FACS, gated on CFSE positive 
cells, then cell killing expressed as a percentage of PI+ to PI- cells.  Data are a mean of 
triplicates from a single plate (± SD) and is representative of three different experiments, 
statistically analysed using a one way ANOVA and Tukey's multiple comparison post-test 
(*** p < 0.001). 
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Tregs significantly reduced the tumour cell killing activity of the NK cells (Figure 
6.13).  At the highest ratio of NK cells to K562 cells (1:10), the percentage cell 
killing was 83.4 %.  This was significantly reduced to 70 % when Tregs were 
introduced into the system at a 1:10:20 cell ratio (p < 0.001).  To determine whether 
the NK cells were orchestrating target cell killing of K562 cells via the NKG2D 
receptor, a neutralising NKG2D antibody was studied (Figure 6.14).  
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Figure 6.14 The Effect of a Neutralising anti-NKG2D Antibody on NK Cell Killing of 
K562 Cells 
 
K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
Isolated NK cells were pre-incubated with various concentrations of a neutralising NKG2D 
antibody for 30 minutes.  CFSE stained K562 cells were seeded at 1 x 10
4
 cells per well with 
NK cells at 1:0, 1:3, 1:10 and 1:30 (K562:NK cell ratios).  Cells were cultured at 37 ¡C in a 
humidified atmosphere containing 5 % v/v CO2 for 6 hours and then counter-stained with 100 
µl propidium iodide (PI) for 15 minutes to assess cell viability.  Cells were analysed using 
FACS, gated on CFSE-positive cells, then cell killing expressed as a percentage of PI+ to PI- 
cells.  Data are a mean of triplicates from a single plate (± SD) and is representative of three 
different experiments, statistically analysed using a one way ANOVA and Tukey's multiple 
comparison post-test (* p < 0.05).  
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Here isolated NK cells were pre-incubated with a titration of neutralising NKG2D 
antibody (nNKG2D) prior to co-culture with K562 cells.  A significant reduction in 
NK cell killing capability was observed with 25 µg/ml of nNKG2D antibody.  The 
titration of nNKG2D was introduced into the 1:10 K562:NK cell ratio and resulted in 
a reduction from 83.0 % to 73.7 % at the top concentration of 25 µg/ml.  This 
window of suppression resulting from blocking the NKG2D pathway is relatively 
small.  To ensure the antibody was fully functional, FACS analysis of NKG2D 
expression was carried out on isolated NK cells incubated with varying amounts of 
nNKG2D (Figure 6.15). 
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Figure 6.15 FACS Analysis of Isolated NK Cells with Neutralising anti-NKG2D Antibody 
NK cells were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  Cells were pre-incubated with a titration of neutralising anti-NKG2D antibody 
for 30 minutes.  PE anti-NKG2D surface antibody was added before cells were fixed.  Data 
were acquired on a Beckman Coulter FC 500 flow cytometer and analysed using Weasel 
software. 
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Results show a dose-dependent level of expression of NKG2D.  NKG2D expression 
drops to 9.96 % when NK cells are incubated with 25 µg/ml of antibody compared to 
a normal level of approximately 52.6 %.  This FACS analysis confirmed the 
neutralising antibody was working well.  The small window of effect is therefore 
interesting and could be due to a number of reasons.  It is known that various other 
recognition receptors and ligands contribute to the cell killing activity of NK cells, for 
example, NKp46, NKp30 and NKp44. 
 
To further understand the mechanisms of cell killing in this system and to test the 
TGF-β-focused hypothesis, an additional antibody was also investigated to neutralise 
the TGF-β receptor II (nTGF-β RII).  Again, this was introduced into the 
K562:NK:Treg assay system (Figure 6.16). 
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Figure 6.16 Treg Mediated Suppression of K562 NK Cell Killing is Abrogated by 
Neutralising TGF-β  RII Antibody 
 
A) K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells 
were then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell 
counting.  Neutralising TGF-β RII antibody (nTGF-β RII, 50 µg/ml) was pre-incubated with 
isolated CD56+ natural killer (NK) cells (1 hour) before adding Tregs isolated from the same 
donor (4 hours).  CFSE stained K562 cells were then introduced and cultured at 37 ¡C in a 
humidified atmosphere containing 5 % v/v CO2 for a further 16 hours.  Cells were counter-
stained with 100 µl propidium iodide (PI) for 15 minutes to assess cell viability and analysed 
using FACS, gated on CFSE positive cells, then cell killing expressed as a percentage of PI+ 
to PI- cells.  Data are a mean of triplicates from a single plate (± SD) and is representative of 
three different experiments, statistically analysed using a one way ANOVA and Tukey's 
multiple comparison post-test (* p < 0.05, *** p < 0.001).  B) Diagrammatic representation of 
the rationale behind the assay. 
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At a 1:10 K562:NK cell ratio, 67.5 % of K562 cell killing was achieved, which was 
reduced to 41.6 % when Tregs were introduced into the assay.  This suppressive 
ability of Tregs was significantly abrogated by pre-incubating the NK cells with 
nTGF-β RII, returning the percentage of K562 cell death to 57.9 % (Figure 6.16).  
Data are in agreement with literature suggesting a link between membrane-tethered 
TGF-β and cell-to-cell contact dependent Treg suppression mechanisms (Nakamura 
et al., 2004; Nakamura et al., 2001). 
 
Many components within the tumour microenvironment have been shown to 
contribute to the elevated levels of soluble TGF-β.  Sources of TGF-β within the 
tumour microenvironment include tumour cells, stromal cells and migratory 
haematopoietic cells (Liu et al., 2007). 
 
It remains unclear whether Tregs are capable of directly producing TGF-β 
themselves, or if they induce bystander cells to do so (Nakamura et al., 2004; 
Nakamura et al., 2001).  The ability of Tregs to produce soluble TGF-β was therefore 
studied by evaluating the concentration of TGF-β present in the supernatants of ex 
vivo isolated Tregs (Figure 6.17). 
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Figure 6.17 Treg Production of Soluble TGF-β  
 
CD4
+
CD25
+
 Tregs were isolated from 50 ml blood from a consenting healthy volunteer.  Cells 
were cultured in 0 % FCS Media at 37 ¡C in a humidified atmosphere containing 5 % v/v CO2 
for 72 hours.  The levels of TGF-β were quantified using FlowCytomixª.  Samples were 
firstly acidified prior to adding TGF-β specific beads.  20 µl of biotin-conjugated secondary 
antibody was added, mixed and incubated for 2 hours.  Samples were washed twice followed 
by addition of Streptavidin-PE, mixed and incubated for 1 hour.  Finally samples were 
washed prior to analysis on a Beckman Coulter FC 500 flow cytometer and data were 
analysed using FlowCytomix Pro 2.3 Software.  Samples were compared against a standard 
curve (1:3) and results evaluated using Prism
¨
 5.  Data are a mean of triplicates from a single 
plate (± SD), statistically analysed using a one way ANOVA and Tukey's multiple comparison 
post-test (*** p < 0.001). 
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The level of TGF-β was determined using FlowCytomixª detection kit.  Originally, 
supernatants were analysed from suppression experiments (Figure 3.3); however, 
preliminary experiments revealed that media containing FCS affected the results.  To 
overcome this problem, Tregs were isolated as previously described and incubated for 
72 hours in serum free media (Figure 6.17).  Wells containing 1 × 104 Tregs per ml 
resulted in an increased concentration of TGF-β (889.6 ρg/ml), which was 
significantly higher than wells with 5 × 103 Tregs (544.3 ρg/ml) and 2.5 × 103 Tregs 
(426.4 ρg/ml).  Data suggest that the soluble TGF-β analysed is being produced by 
the Tregs present. 
 
Given the reported ability of TGF-β to inhibit lymphocyte cytotoxicity, the 
production of TGF-β by Tregs when co-cultured with NK cells was investigated.  An 
understanding of whether TGF-β was responsible for the suppression of NKG2D-
mediated NK cell cytotoxicity of ligand-expressing tumour targets was required. 
 
To further determine the implications of elevated levels of TGF-β within the tumour 
microenvironment and to clarify that TGF-β is a key player in the suppression 
mechanisms of NK-mediated tumour cell killing, Tregs were removed from the assay and 
replaced with a known concentration (10 ng/ml) of soluble TGF-β (sTGF-β) (Figure 
6.18).   
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Figure 6.18 TGF-β  1 Mediated Suppression of K562 NK Cell Killing is Abrogated by 
Neutralising TGF-β  RII Antibody 
 
A) K562 cells at 2 x 10
7
 cells per ml were stained with 2.5 µM CFSE for 8 minutes.  Cells were 
then re-suspended in 10 % v/v FBS RPMI and washed three times prior to cell counting.  
Neutralising TGF-β RII antibody (nTGF-β RII, 20 or 50 µg/ml) was pre-incubated with isolated 
CD56
+
 natural killer (NK) cells for 1 hour.  Soluble TGF-β 1 was then introduced at a final 
concentration of 10 ng/ml and incubated for 4 hours.  CFSE-stained K562 cells were introduced 
and cultured at 37 ¡C in a humidified atmosphere containing 5 % v/v CO2 for a further 16 hours.  
Cells were counter-stained with 100 µl propidium iodide (PI) for 15 minutes to assess cell viability 
and analysed using FACS, gated on CFSE-positive cells, then cell killing expressed as a 
percentage of PI+ to PI- cells.  Data are a mean of triplicates from a single plate (± SD) and is 
representative of three different experiments, statistically analysed using a one way ANOVA and 
Tukey's multiple comparison post-test (* p < 0.05).  B) Diagrammatic representation of the 
rationale behind the assay. 
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A similar trend to introducing Tregs was observed, where sTGF-β significantly 
suppressed NK cell killing from 67.5 % to 53.4 % (p < 0.05).  nTGF-β RII antibody at 
50 µg/ml returns K562 cell killing to 68.5 % (p < 0.05).  TGF-β specific antibodies have 
been shown to prevent suppression in vitro and CD25
+
 Treg are not able to suppress 
CD8
+
 cells lacking the TGF-β receptor (Chen et al., 2005).  However the data presented 
here is inconsistent with previous studies that have suggested that only surface bound 
TGF-β is functional during attempts to transfer suppression on NK cell cytotoxicity by 
using the supernatants of activated Tregs (Smyth et al., 2006).  The author would like to 
suggest that both membrane-tethered and close proximity sTGF-β are having a 
significant impact.  Research suggests that Tregs are functioning in a TGF-β-dependent 
manner.  Data are in agreement with research showing TGF-β1 causes a strong down-
regulation of the surface expression of NKp30 and inhibition of NK-mediated 
recognition and killing of DCs (Castriconi et al., 2003).    
 
To specifically examine the effects of TGF-β on NKG2D expression, isolated CD56
+
 
NK cells were cultured with a titration of sTGF-β and the NKG2D expression 
determined using FACS analysis (Figure 6.19).  
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Figure 6.19 FACS Analysis of NKG2D Expression on Isolated NK Cells with increasing 
amounts of Soluble TGF-β  
 
NK cells were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for 
FACS analysis.  Cells were pre-incubated with a titration of soluble TGF-β overnight.  PE 
anti-NKG2D surface antibody was added before cells were fixed.  Data were acquired on a 
Beckman Coulter FC 500 flow cytometer and analysed using Weasel software. 
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A reduction in NKG2D expression levels can be seen when NK cells were cultured 
with increasing amounts of sTGF-β (Figure 6.19).  In comparison to previous 
research, the drop in NKG2D expression is relatively small.  This could be due to 
differences in incubation times as previous studies have incubated isolated NK cells 
with sTGF-β for 7 days compared to the 4 or 16 hours investigated during this study 
(Castriconi et al., 2003).   
 
Internal analysis of all the aforementioned cytokines would also be very interesting, 
and would provide an insight into their origin within the suppressive environment. 
 
6.2.4. Evaluating TGF-β in CRC Liver Metastatic Patients 
Previous studies have demonstrated an inverse linear relationship between plasma 
TGF-β1 and the level of NKG2D on NK cells in lung cancer patients (Lee et al., 
2004a). 
 
Studies demonstrate that TGF-β-specific antibodies prevent suppression in vitro and 
Tregs are not able to suppress CD8
+
 cells that lack the TGF-β receptor (Chen et al., 
2005).  Due to the TGF-β-focused hypothesis within this study, it was decided to 
investigate the level of TGF-β in CRC liver metastatic patient blood (Figure 6.20). 
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Figure 6.20 Concentration of Soluble TGF-β  in Blood of CRC Liver Metastatic Patients 
Compared to Healthy Volunteers  
 
The plasma from previous blood donors was analysed for the concentration of TGF-β using 
FlowCytomixª.  Samples were firstly acidified prior to adding TGF-β specific beads.  20 µl of 
biotin-conjugated secondary antibody was added, mixed and incubated for 2 hours.  Samples 
were washed twice followed by addition of Streptavidin-PE, mixed and incubated for 1 hour.  
Finally, samples were washed prior to analysis on a Beckman Coulter FC 500 flow cytometer 
and data were analysed using FlowCytomix Pro 2.3 Software.  Samples were compared 
against a standard curve (1:3) and were results evaluated using Prism
¨
 5.  Data were 
statistically analysed using an unpaired t test (± SD, * p < 0.05). 
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29 CRC liver metastatic patients had a mean sTGF-β concentration of 17.1 µg/ml 
compared to a mean of 9.1 µg/ml in healthy volunteers.  Results suggest that CRC 
metastatic liver patients have higher levels of sTGF-β in their PB.  Further analysis 
comparing the sTGF-β concentration to matched patient Tregs/µl WB showed no 
significant correlation.  The elevated levels of sTGF-β within the patient cohort can 
therefore not be explained by elevated numbers of circulating Tregs at this time; 
however, within a tumour site the cytokine profile is typically immunosuppressive 
and the level of TGF-β is likely to be elevated. 
 
6.2.5. FACS Investigation of Tumour Markers 
Engagement of NKG2D by its ligand (NKG2DL) results in activation of NK cell 
killing and cytokine secretion or co-stimulation of CTLs.  NKG2D is a receptor for 
the stress-inducible and tumour-associated MHC class I chain-related proteins A 
(MICA) and B (MICB); and members of the cytomegalovirus UL16 binding proteins 
(ULBP) family ULBP1-4 and REAT1G.  NKG2DL are up-regulated in tumours 
which should render the tumour cells sensitive to NKG2D-dependent cell killing.  
MIC molecules are expressed in association with cell stress, infection or malignant 
transformation.  In vitro, cell stress-inducible MIC molecules are expressed by many 
tumour cell lines and up-regulated upon infection with human Escherichia coli (Groh 
et al., 1999).   
 
Here, nine cancer cell lines were analysed for their expression of MICA and ULBP-2 
(Figure 6.21). 
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Figure 6.21 FACS Analysis Investigating the Expression of MICA and ULBP-2 on a 
Selection of Tumour Cell Lines 
 
A suspension of 1 x 10
6
 cells/ml was washed and blocked in PBS-BSA and then incubated 
with anti-MICA or anti-ULBP-2 at 25 µg/ml for 30 minutes.  Cells were washed twice before 
incubating for 30 minutes with secondary FITC antibody.  MICA (blue) and ULPB-2 (red) 
expression was compared against a control of unstained cells for each cell line.  Data were 
acquired on a Beckman Coulter FC 500 flow cytometer and analysed using Weasel software. 
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Data showed high levels of expression on SW-620 cells for both MICA and ULBP-2.  
PAN-1, MCF-7, DMS 114 and LNCaP also showed expression of these ligands to a 
lesser extent.  It is interesting to observe that most cell lines have a mixed expressing 
population, perhaps indicative of ligand up/down-regulation at differing stages of the 
cell cycle.   
 
Expression of NKG2DL on NK-resistant tumour lines has been shown to mediate 
tumour elimination (Cerwenka et al., 2000), and ectopic expression of NKG2D 
ligands causes rejection of tumour cells by NK and CTLs in syngeneic mice 
(Maccalli et al., 2009).  This illustrates the relevance of NKG2D signalling in 
immunosurveillance against tumours.  However, tumours have developed multiple 
ways to evade the NKG2D-mediated immune response.  Literature illustrates that 
tumour cells release soluble MIC molecules to adjust to the NKG2D-mediated 
tumour immune surveillance (Groh et al., 1999).  Tumour cells shed NKG2DL, 
resulting in increased levels in the peripheral blood of cancer patients. 
 
6.3. CONCLUSIONS AND FUTURE WORK 
6.3.1. Cell Killing Assay 
The development of a reliable cell killing assay was an essential starting point for this 
chapter to provide the foundations for constructing a Treg:effector:NK cell 
suppression model.  The K562 cell line provided a dependable tumour cell line, easily 
subjective to NK cell-mediated killing as they lacked the MHC complex required to 
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inhibit NK cell activity.  This was in agreement with previous research demonstrating 
the ability of NK cells to kill MHC I-deficient tumour cell lines (Smyth et al., 2000).  
The replacement of PBMCs in preliminary studies with isolated NK cells and further 
introduction of Tregs was a fundamental requirement to begin to understand the 
interactions between Tregs and NK cells in the tumour environment.  Tregs 
suppressed the cell killing ability of NK cells in agreement with in vivo studies 
showing Treg impairment of NK cell activation in cancer patients (Ghiringhelli et al., 
2005).  Both human and murine in vitro and in vivo systems have shown Tregs 
potently suppress NK cell responses, including the NK cell-mediated control of 
tumour expansion (Ghiringhelli et al., 2005). 
 
6.3.2. Investigation of Model Key Players  
Flow cytometer data confirmed the expression of NKG2D receptor on CD3
-
 NK and 
CD3
+
 NKT cell populations.  The involvement of NKG2D in orchestrating NK cell-
mediated tumour killing was tested in vitro using an nNKG2D antibody.  High 
concentrations of the nNKG2D antibody significantly reduced NK cytotoxicity.  In 
addition, cell surface expression of TGF-β RII on CD56
+ 
NK cells was observed, 
which potentially makes them vulnerable to control by sTGF-β.  This hypothesis was 
tested by introducing a nTGF-β RII antibody into a K562:NK:Treg cell killing assay 
to block TGF-β signalling. The suppressive ability of Tregs was abrogated with the 
addition of nTGF-β RII antibody.  It was demonstrated that Tregs produce a small 
quantity of sTGF-β.  Also, sTGF-β was shown to suppress NK cell-mediated killing 
of K562 cells, which was also recovered by nTGF-β RII antibody.  Data illustrates 
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that under certain pathological conditions known to increase exposure to TGF-β, NK 
cells may under-express NKG2D.  Signals from soluble or cell-associated TGF-β 
within a tumour microenvironment may result in suppression of NK cell-mediated 
killing, enabling tumour escape.   
 
Results have contributed to further developments regarding the Treg-NK interactions 
at the tumour microenvironment (Figure 6.22). 
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Figure 6.22 Further Developed Diagrammatic Representation of Treg Suppression of 
Natural Killer Cells and Tumour Interaction 
 
Cell surface expression of tumour growth factor-β (TGF-β) on NK cells makes them 
vulnerable to control by soluble TGF-β.  NK cell surface expression of TGF-β receptor II 
(TGF-β RII) functions to facilitate Treg mediated cell-contact dependent down-regulation of 
the NK cell-activating receptor NKG2D.  Thus, Tregs are able to inhibit NK cell interaction 
with tumour ligands such as MHC class I chain-related proteins A (MICA) and B (MICB) and 
also members of the cytomegalovirus UL16 binding proteins (ULBP) family such as ULBP1-4 
and REAT1G, reducing cytotoxicity towards tumour targets. 
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6.3.3. Refined Hypothesis 
The low frequency of NK cells found within the tumour, at the tumour IM and also 
within the tumour microenvironment illustrated in chapter 4, raised concerns with 
regards to developing a NK cell-mediated tumour-killing model.  NK cells are an 
efficient tumour cell killing entity, therefore the work described in chapter 6 remains 
to be of significant value and could possibly contribute to further research, 
developing ways to increase NK cell presence at the tumour microenvironment and 
improve tumour cell death.  However, the prevalence of CD8 CTLs within the 
tumour microenvironment did not go unnoticed.  Without the time constraints of the 
current study, the author would refine the tumour model and begin to investigate the 
role and contribution of CD8 cells, in parallel to further developing NK cell directed 
research.  Preliminary data have been accomplished, developing CD8 isolation 
techniques and investigating the expression of NKG2D (Figure 6.23). 
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Figure 6.23 NKG2D FACS Analysis of Isolated CD8 Cells  
 
CD8 cell isolation was achieved using an EasySep® Human CD8 Positive Selection Kit 
(EasySep®, 18053) and carried out according to the manufacturerÕs instructions.  CD8 cells 
were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for FACS 
analysis.  Cells were incubated with a pre-titrated volume of surface antibodies; PeCy5 anti-
CD4, FITC anti-CD8 and PE anti-NKG2D.  Cells were then fixed and data were acquired on a 
Beckman Coulter FC 500 flow cytometer and analysed using Weasel software. 
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CD8 cell isolation was successfully achieved from 50 ml of healthy blood as 
described in section 7.1.1.  The EasySep® human CD8 positive selection kit is 
designed to isolated CD8
+
 cells and utilises tetrameric antibody complexes and 
dextran-coated magnetic particles combined with a human fc receptor blocker to 
minimise non-specific binding.  CD8
+
 cells were isolated to a 98.2 % purity, as 
evaluated using FACS analysis (Figure 6.23).  Isolated CD8 cells were then assessed 
for the expression of NKG2D.  Approximately 90.7 % of CD8
+
 cells were also 
positive for NKG2D receptor expression.  These results are in agreement with 
previous FACS analysis of NKG2D expression on PBMCs showing a CD8
+
NKG2D
+
 
cell population (Figure 6.8). 
 
Further work investigated the effects of incubating isolated CD8 cells with a titration 
of sTGF-β (Figure 6.24). 
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Figure 6.24 FACS Analysis of NKG2D Expression on Isolated CD8 Cells with 
increasing amounts of Soluble TGF-β  
 
CD8 cell isolation was achieved using an EasySep® Human CD8 Positive Selection Kit 
(EasySep®, 18053) and carried out according to the manufacturerÕs instructions.  CD8 cells 
were isolated from 50 ml healthy human blood and 1 x 10
6
 cells were removed for FACS 
analysis.  Cells were pre-incubated with a titration of soluble TGF-β overnight.  PE anti-
NKG2D surface antibody was added before cells were fixed.  Data were acquired on a 
Beckman Coulter FC 500 flow cytometer and analysed using Weasel softaware. 
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As shown in Figure 6.24, isolated CD8 cells expressed lower levels of NKG2D 
receptor when pre-incubated with sTGF-β.  In the absence of sTGF-β, approximately 
94.7 % of CD8 cells expressed detectable levels of NKG2D.  This value decreased 
when cells were incubated with a titration of sTGF-β, dropping to approximately 
86.6 % at top concentrations of 0.5 µg/ml.  Results were similar to those seen when 
NK cells were incubated with sTGF-β (Figure 6.19). 
 
Preliminary results demonstrate that CD8 cells express NKG2D and that this 
expression is susceptible to sTGF-β mediated down-regulation.  Data are in 
agreement with previous literature demonstrating that NKRs can also be expressed by 
T cells (Correia et al., 2011).  Studies have shown that CD8 cells can express both 
activating and inhibiting NKRs, including KIR members, NKG2D and NKp46.  
Thus, modifying T cell function could be possible by altering the TCR threshold by 
changing the expression of activating or inhibitory NKRs.  Whilst little is known 
about the environmental signals that trigger NKR acquisition by CD8 cells, recent 
studies have suggested that IL-15 is a key player (Correia et al., 2011).  CD8+CD56+ 
T cells cultured with IL-15 resulted in NK-like cytotoxicity.  Meresse et al 
demonstrated that, in the presence of IL-15, CD8 cells acquired the ability to kill 
NKG2DL-bearing target cells (Meresse et al., 2004). 
 
Is it possible that the presence of NKG2D receptor on effector cells of innate (NKs) 
and adaptive (CD8s) immune systems could link innate and adaptive immune 
responses?  Over-expression of NKG2DL on tumour cells results in tumour 
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regression, perhaps by NK cell activation combined with a potent co-stimulatory 
signal to NKG2D expressing CD8 cells. 
 
6.3.4. Future Work 
Future work could involve working with a cytokine-induced killing (CIK) population.  
This involves culturing PBMCs with IL-1a, anti-CD3, IFN-γ and IL-2 to push the 
cells towards a phenotypically cell killing population (Li et al., 2007).  In addition, a 
variety of agents, generally referred to as biologic response modifiers, are known to 
increase the activation, proliferation, or cytotoxicity of NK cells, including IL-2, IL-
12 and IFN-α.  Cytokine-induced NK cell activation may be responsible for anti-
tumour effectiveness of cytokine-based immunotherapy, possibly an area of future 
interest. 
 
Expansion of a human-NK-92 cell line could also be investigated (Tam et al., 2003), 
with the idea to possibly replace freshly isolated NK cells and thus allow more 
elaborate assays, not restricted by limited cell numbers. 
 
Additional research could include the use of cortisol, an adrenocortical hormone that 
suppresses the immune system and directly inhibits NK cell activity.  Further to this, 
prolactin is an immunostimulatory hormone that has been shown to directly increase 
NK cell cytotoxicity (Mavoungou et al., 2005).  It has been suggested that the 
increase in NK cell cytolytic activity observed after prolactin treatment correlates 
with an increase in surface expression of NCRs, including NKp30, NKp44 and 
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NKp46 (Mavoungou et al., 2005).  Indoleamine 2,3-dioxygenase (IDO) is a powerful 
enzyme with suggested immunomodulatory effects.  IDO-generated tryptophan-
derived catabolites such as L-kynurenine have been reported to prevent up-regulation 
of NKp46 and NKG2D and therefore as a consequence impair NK cell killing activity 
(Della Chiesa et al., 2006).  Further development and knowledge of the 
aforementioned hormones and enzymes could result in advances in NK cell-mediated 
anti-tumour therapies. 
 
Literature suggests that tumour cells release soluble MIC molecules and shed 
NKG2D ligands in order to modulate and evade NKG2D-mediated tumour immune 
surveillance (Groh et al., 1999).  As with the elevated levels of sTGF-β in CRC liver 
metastatic patients, it would be interesting to investigate whether a difference is 
observed in the concentration of MICA or ULBP2 present in circulating peripheral 
blood. 
 
Summary:  The development of an in vitro human Treg suppression model, 
investigating NK cell tumour killing, could be used to improve knowledge of tumour 
microenvironment and suppression of anti-tumour immunity.  Preliminary studies 
have developed a cell-killing assay and shown that K562 cells are susceptible to cell 
killing by NK and possibly CD8 cells. 
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CHAPTER 7 Ð FINAL CONCLUSIONS 
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Chronological Framework of Thesis Progression 
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Construction of a realistic ex vivo model was achieved in chapter 6, where research 
was carried out in parallel with chapters 4 and 5.  The current chapter aims to draw 
final conclusions and closing remarks. 
7.1. FINAL CONCLUSIONS 
During the preparation of this thesis, Hanahan and Weinberg published an updated 
version of their iconic ÔHallmarks of CancerÕ (Hanahan and Weinberg, 2011).  The 
next generation and emerging hallmarks include Ôavoiding immune destructionÕ and 
Ôtumour-promoting inflammationÕ.  The importance of the immune system in perhaps 
all cancers is becoming readily acknowledged.  The ability of the immune system to 
inadvertently support other cancer-promoting hallmarks, resulting in tumour-
promoting consequences of inflammatory responses, is becoming widely appreciated 
(Cavallo et al., 2011). 
 
Compelling evidence suggests that inflammation can have a counterintuitive effect on 
all phases of carcinogenesis.  For example: inducing DNA instability and mutation in 
tumour-initiating cells; supplying growth factors to sustain tumour proliferation; 
releasing survival factors that limit tumour cell death; proangiogenic factors; ECM-
modifying molecules to facilitate angiogenesis, invasion and metastasis; and 
inductive signals that initiate EMT.  In addition to the infiltrating pro-inflammatory 
immune cells, other cell types, including epithelial cells, endothelial cells, fibroblasts, 
and stromal cells, may play a role in contributing to the inflammation by secreting 
and responding to pro-inflammatory factors such as the aforementioned cytokines, 
chemokines, growth factors, and proteases. 
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The concept that inflammation is associated with neoplasia was first proposed by 
Rudolff Virchow in 1863.  Centuries later, a wealth of evidence has accumulated to 
support the hypothesis that organs subjected to chronic inflammation can provide the 
perfect milieu in which tumours thrive.  There is now a general consensus that 
inflammation and immune cells play a critical role in tumorigenesis.  Reprogramming 
of the immune microenvironment in tumours is a promising strategy for improving 
the efficacy of standard anticancer treatments. 
 
It is now widely acknowledged that inhibiting Treg function in cancer patients may 
contribute to the success of new therapies, specifically immunotherapies (Colombo 
and Piconese, 2007).  Evidence suggests that depleting Tregs leads to rejection of 
transplanted tumours in mouse models (Shimizu et al., 1999). 
 
The current study has investigated ways to work with Tregs, looking at their isolation 
procedure, mechanisms of suppression and possible methods for expansion.  The 
involvement of Tregs at the tumour microenvironment was studied within clinical 
colorectal cancer samples.  Data have confirmed the importance of immune infiltrates 
in and around the tumour.  A novel method of image analysis was implemented and 
facilitated quick and objective immune cell quantification in precise tumour- and 
stroma-rich regions.  This detailed analysis has alluded to a CD8-low Treg-high liver 
metastatic phenotype within primary CRC tissue.  Such a powerful image analysis 
platform could potentially revolutionise traditional pathological techniques, whereby 
the TNM staging system could be replaced with an immune score as a more accurate 
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indicator of patient prognosis.  In addition, correlations have been made between 
circulating immune cells in peripheral blood and those seen in situ. 
 
Finally, the mechanism by which NK (and CD8) cells are prevented from 
orchestrating tumour cell killing has been proposed.  The importance of TGF-β has 
been highlighted where Tregs can suppress NK cell-mediated tumour cell killing via 
down regulation of NKG2D receptor expression.  An understanding of this 
mechanism could provide potential therapeutic targets in an immunotherapy directed 
strategy. 
 
A final diagrammatic summary of the current study is depicted in Figure 7.1. 
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Figure 7.1 Concluding Diagrammatic Representation of Immune Cell Interactions 
within the Tumour Microenvironment 
 
Cell-surface expression of tumour growth factor-β receptor II (TGF-β RII) on natural killer 
(NK), natural killer T (NKT) and CD8 cells, makes them vulnerable to control by soluble TGF-
β (sTGF-β).  In addition, this could facilitate Treg-mediated cell-contact dependent down-
regulation of NKG2D receptor.  Thus, Tregs are able to inhibit NK cell and CD8 cell 
interactions with tumour ligands such as MHC class I chain-related proteins A (MICA) and B 
(MICB) and also members of the cytomegalovirus UL16 binding proteins (ULBP) family such 
as ULBP1-4 and REAT1G, reducing cytotoxicity towards tumour targets.  (TCR, T cell 
receptor; KIR, killer cell immunoglobulin-like receptor; NCR, natural cytotoxicity receptor; 
mTGF-β RII, membrane-tethered transforming growth factor-β receptor II). 
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Overall a detailed understanding of the host immune system and tumour cells has 
been achieved, which will facilitate the advancement of future anti-cancer focused 
research.  The development of this current model could therefore provide a platform 
to screen possible Treg targets.  Initial studies could use siRNA and then progress to 
an antibody-directed therapeutic approach.  This compilation of assays would provide 
a platform to validate lead antibodies produced against the selected Treg target. 
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CHAPTER 8 Ð APPENDIX 
8.1. ACHIEVMENTS 
8.1.1. Papers In Preparation 
Title TBC, similar to: Elevated stromal Foxp3+ regulatory T cells combined with low density 
CD8+ cytotoxic T cells are associated with colorectal metastatic tumour progression.  H.K. 
Angell, X. Huan, S. Mistry, M. Cumberbatch, N. Gray, C. Womack, S.A. Watson, R.W. 
Wilkinson, D.I. Pritchard.  To be submitted to: TBC
 
 
Title TBC.  H.K. Angell, X. Huan, S. Mistry, M. Cumberbatch, N. Gray, C. Womack, S.A. 
Watson, R.W. Wilkinson, D.I. Pritchard.  To be submitted to: TBC.
 
 
Title TBC, similar to: Foxp3+ regulatory T cells suppress CD56+ natural killer cell-mediated 
tumour killing in a transforming growth factor-β dependent manner.  H.K. Angell, S.A. 
Watson, R.W. Wilkinson, D.I. Pritchard.  To be submitted to: TBC. 
 
8.1.2. Published Abstracts 
Blood Sweat and Tregs.  Angell H, Blount DG, Watson SA, Wilkinson RW, Pritchard DI.  
Journal of Pharmacy and Pharmacology 62(10): 1491-1492. 
 
Immunological Regulation in the Tumour Microenvironment.  Angell H, Blount DG, Watson 
SA, Wilkinson RW, Pritchard DI. Journal of Pharmacy and Pharmacology 62(10): 1221-1222. 
 
Blood Sweat and Tregs: Immunological regulation in the tumour microenvironment.  Angell H, 
Blount D, Watson S, Wilkinson R, Pritchard D.  Immunology 131(suppl. 1):58. 
 
8.1.3. Oral Presentations 
Accepted at NCRI Cancer Conference, 2011, Liverpool 
Elevated stromal Foxp3+ regulatory T cells combined with low density CD8+ cytotoxic T cells 
are associated with colorectal metastatic tumour progression.  H.K. Angell, X. Huan, S. Mistry 
M. Cumberbatch, N. Gray, C. Womack, S.A. Watson, D.I. Pritchard, R.W. Wilkinson.
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UKPharmSci Conference, Nottingham 
Immunological Regulation in the Tumour Microenvironment.  Angell H, Blount DG, Watson 
SA, Wilkinson RW, Pritchard DI.    
 
UKPharmSci Conference, Nottingham 
Blood Sweat and Tregs.  Angell H, Blount DG, Watson SA, Wilkinson RW, Pritchard DI.   
 
8.1.4. Awards 
! Richard Hambro Award, NCRI 2011 
! AstraZeneca Scientific Innovations Award 2011 
! NCRI Cancer conference, Liverpool; National Cancer Research Institute ÔPassport 
and NetworkingÕ prize 2010. 
 
8.1.5. Posters 
British Association of Cancer Research/ The Royal Society of Medicine, London 
Immunological Regulation in the Tumour Environment.  Angell H, Blount DG, Watson SA, 
Grabowska AM, Wilkinson RW, Pritchard DI.  
 
Bioengineering and Synthetic Biology, Oxford 
Injectable hyperbranched materials with thermal-responsive and photocrosslinkable 
properties for tissue engineering applications.  Tai H, Wang W, Birkin N, Howard D, Angell H, 
Heath F, Endruweit A, Rose F, Alexander C, Shakessheff K, Howdle S. 
 
The EACR Special Conference; Inflammation and Cancer, Berlin 
Immunological Regulation in the Tumour Environment.  Angell HK, Blount DG, Watson SA, 
Grabowska AM, Wilkinson RW, Pritchard DI.  
 
UKPharmSci Conference, Nottingham 
Blood Sweat and Tregs: Immunological Regulation in the Tumour Microenvironment II.  
Angell H, Blount DG, Watson SA, Wilkinson RW, Pritchard DI. 
 
 
 
UKPharmSci Conference, Nottingham 
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Immunological Regulation in the Tumour Microenvironment.  Angell H, Blount DG, Watson 
SA, Wilkinson RW, Pritchard DI. 
 
NCRI Cancer Conference, Liverpool 
Blood Sweat and Tregs: Immunological Regulation in the Tumour Microenvironment II.  
Angell H, Blount DG, Watson SA, Wilkinson RW Pritchard DI. 
 
BSI Annual C 
ongress, Liverpool  
Blood Sweat and Tregs: Immunological Regulation in the Tumour Microenvironment II.  
Angell H, Blount DG, Watson SA, Wilkinson RW Pritchard DI. 
 
Accepted at NCRI Cancer Conference, 2011, Liverpool 
Elevated stromal Foxp3+ regulatory T cells combined with low density CD8+ cytotoxic T cells 
are associated with colorectal metastatic tumour progression.  H.K. Angell, X. Huan, S. 
Mistry, M. Cumberbatch, N. Gray, C. Womack, S.A. Watson, D.I. Pritchard, R.W. Wilkinson.
 
 
Accepted at NCRI Cancer Conference, 2011, Liverpool 
Foxp3+ regulatory T cells suppress CD56+ natural killer cell-mediated tumour killing in a 
transforming growth factor-β dependent manner.  H.K. Angell, S.A. Watson, R.W. Wilkinson, 
D.I. Pritchard. 
 
Accepted at NCRI Cancer Conference, 2011, Liverpool 
Quantitative assessment of tumour infiltrating lymphocytes using Genie
TM
 pattern recognition 
software for the separate analysis of tumour versus stroma in head and neck squamous cell 
carcinoma (HNSCC) improves biomarker reproducibility.  X. H. Yap, H. K. Angell, N. Gray, C. 
Womack, R. W. Wilkinson, M. Cumberbatch. 
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